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Chapter 1 
1.1. Control of breathing 
The main purpose of the respiratory control system is to achieve and maintain arterial blood 
gas homeostasis, so that the oxygen demands of the organs are met and the metabolic 
end-product, carbon dioxide, is produced and exhaled. 
Two major groups of ventilatory stimuli can be distinguished: 
1 the feedback stimuli, as part of the ventilatory control system, which can be divided into: 
• chemical feedback / metabolic control which consists of the arterial and 
cerebrospinal fluid pH (pHa, pHcsp), arterial and cerebrospinal fluid carbon dioxide 
tension (PaCC^, PCSFC02) and arterial oxygen tension (Pa02), detected by 
chemoreceptors. 
• non chemical feedback stimuli, in which mechanical (e.g. airway resistance (Raw); 
compliance of the thoracic wall (C,h) and compliance of lung parenchyma (CJ) and 
neuronal (e g. pulmonary stretch receptors, hypothalamus, cortex and motor 
neurones) stimuli are involved. 
2 the non feedback stimuli, such as physiological, hormonal (e g. adrenalin, thyroxin, 
progesterone), physical (e.g temperature and pain) and iatrogenic (e.g. intrinsic muscle 
training, drug therapy) stimuli. 
Both types of stimuli may interact with each other. 
Figure 1 1. shows a diagram of the ventilatory control system. It can be divided into two sub-
systems: the controlling system and the controlled system. 
The controlling system is the sub-system with blood gas values as input parameter and 
minute ventilation or the neuronal equivalent as output parameter. The controlled system 
has the ventilation as input and blood gas values as output. This occurs in ventilated 
patients The output parameter of the controlling system is the input parameter of the 
controlled system and vice versa [1-3] 
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Figure 1.1. The ventilatory chemical control system (simplified). 
CSF = cerebrospinal fluid; central ehemor. = central chemoreceptors; peripheral 
ehemor.= peripheral chemoreceptors; motorneurons = spinal motor neurons of the 
inspiratory muscles; IC = intercostal inspiratory muscles; DIA = the diaphragm; FTP 
= transpulmonary pressure; R.w= airway resistance; Cih = compliance of the 
thoracic wall; CL * compliance of lung parenchyma; V E = minute ventilation ;VD = 
anatomical dead space; V A = alveolar ventilation; P a 0 2 = arterial oxygen tension; 
P a C 0 2 = arterial carbon dioxide tension; pHa = arterial pH; pHcsF=cerebrospinal 
fluid pH. Above dashed line: controlling system, below: controlled system. 
1.1.1. Feedback stimuli 
1.1.1.1. Chemical feedback stimuli 
The 'respiratory centers' are located in the medulla oblongata and pons [4] Gas exchange 
in the lungs will result in certain levels of PaC02, Pa02 and pHa. The peripheral 
chemoreceptors, located at the carotid bifurcations (the carotid bodies) and in the aortic 
arch (the aortic bodies), sense the level of Pa02, pHa and PaCOj, convert them into 
neuronal signals, which are transmitted to the respiratory centers via carotid sinus nerves, 
glossopharyngeal nerves (Nix) and via vagal nerves (Nx). The central chemoreceptors are 
located at the ventral medullary surface, including the retrotrapezoid nucleus, the region of 
the nucleus tractus solitarius, the region of the locus ceruleus, the rostral aspect of the 
ventral respiratory group and the medullary raphe [5, 6]. They are sensitive to local changes 
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in pH and PCO2 in the extracellular fluid of the brain [4, 5, 7-9] In the respiratory regulation 
mechanism, the blood brain barrier (BBB) and the cerebral blood flow play an important role 
in modulating artenal blood gas stimuli for the central chemoreceptors Cerebral blood flow 
vanes with artenal blood gas tension The BBB has a high permeability to lipid-soluble 
molecules (such as COj), whereas the ionic bicarbonate and hydrogen ions are probably 
impeded to pass this bamer [10] When arterial hydrogen ion (hT-concentration) is elevated, 
ventilation is increased by (peripheral) chemoreceptor stimulation which leads to a fall in 
artenal PCO2 As a consequence the Ι-Γ-concentration within the brain's extracellular fluid 
will fall 
Apart from this 'chemical dnve', the respiratory centers receive many other specific and non­
specific input signals, such as input from hypothalamus, cortex and pulmonary stretch 
receptors via the vagal nerve (see below) The output of the medullary respiratory centers is 
transmitted to the motor neurons of the respiratory muscles (diaphragm and intercostal 
muscles) which are located in the spinal cord The changes in activity of these muscles will 
change the configuration of the thoracic wall and pressure in the thorax, resulting in a 
change in minute ventilation, the input stimuli of the controlled system 
The performance of the ventilatory control system can be studied by measurements on the 
intact system, the so-called closed loop and in the open loop situation 
In the closed loop situation, the controlled and the controlling system are functionally 
connected The effects of external disturbances, such as drugs, can be investigated In the 
open loop situation, the controlled system gives no input to the controlling system The 
chemical feedback stimuli can be manipulated in order to measure the ventilatory responses 
to changes in arterial carbon dioxide (C02), and oxygen (02), the so-called hypercapnic 
ventilatory response and hypoxic ventilatory response, respectively The level of ventilation, 
manipulated by the percentages of C0 2 and 0 2 in the inspiratory air is measured as an 
output parameter of the controlling system 
Graphically, the functioning of the ventilatory control system can be descnbed by two 
curves (a) the hypercapnic ventilatory response that represents the controlling system The 
slope of the curve reflects the CO2 sensitivity of the penpheral and central chemoreflex 
loops, whereas the (extrapolated) intercept with the x-axis is the apnoeic threshold and (b) 
the metabolic hyperbola that represents the charactenstics of the controlled system, since 
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during mechanical ventilation, such as in paralysed patients, minute ventilation is imposed 
and arterial blood gases are the dependent variables Its shape is determined by the 
metabolic rate and C0 2 production These charactenstics of the two subsystems together 
will inform us about the total control system The intersection of the ventilatory response to 
CO2 and the metabolic hypertola is the 'working point' of the total control system Any 
change in one of these subsystems will change the working point (figure 1 2 ) 
20i 
15-
m 
metabolic hyperbola 
ventilatory response to CO, 
— ι 1 1 -
4 6 8 
PaC02 (kPa) 
(V'CO,: χ Lmln ) 
10 
Figure 1 2 Charactenstics of the ventilatory chemical control system 
The controlled system is represented by the metabolic hyperbola, whose position is influenced by the 
metabolic rate and C 0 2 -production The controlled system is represented by the ventilatory C0 2 
response curve 
1.1.1.2. Non-chemical feedback stimuli 
The control of breathing can be influenced by several non-chemical feed back stimuli 
Neuronal stimuli influence the ventilatory control Afferent vagal activity generates non 
chemical feedback information to the controlling part of the ventilatory control system It also 
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1.1.2. Non-feedback stimuli 
An important stimulus to the respiratory control system is psychological influence, mediated 
via the cortex, the 'emotional brain' (limbic system) and sympathetic fibers A high activity of 
the emotional brain, psychological stress, together with a high sympathetic-adrenergic tone, 
all may contnbute to the hyperventilation syndrome In this syndrome the metabolic 
feedback control is modified by psychological factors 
Neurological syndromes such as cerebrovascular accidents, cerebral tumours, brain stem 
lesions etc , may result in dysregulation of ventilatory control [2, 29, 30] 
The withdrawal of the 'wakefulness dnve' results in unstable, penodic breathing in stage I 
sleep [27, 31] Dunng the stages II, III and IV of slow wave sleep the wakefulness dnve of 
breathing is diminished even more, resulting in a decreased ventilation and in a reduction in 
chemoresponsiveness The hypoventilation in non-REM sleep is associated with a small 
increase in PaC02 and a fall in Pa02 Dunng rapid eye movement (REM) sleep, the 
behavioural control system probably affects ventilatory control Furthermore, dunng REM 
sleep hypoventilation occurs due to the inactivity of the intercostal and accessory 
respiratory muscles In COPD patients hypoventilation may occur more prominently 
Hormones and neurotransmitters affect the ventilatory control system Ventilation is 
increased by progesterone, resulting in a decrease in PaC02 probably by interaction with 
penpheral chemoreception and central hypothalamic interaction [11] Estrogens may 
facilitate this action [12] Hypothyroidism is accompanied by a ventilatory depression, 
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whereas hyperthyroidism increases ventilation mainly by an increase in tidal volume The 
thyroid hormone does not affect the slope of the ventilatory CO2 curve, but induces a shift to 
the left of the curve [11, 13, 14] Examples of neurotransmitters affecting ventilation are 
acetylcholine, ammo acids (GABA), aromatic monoamines (epmephnne, norepinephrine, 
dopamine) and peptides (substance-P, ß-endorphmes) [11, 15-24] 
Physical stimuli such as pain, temperature and movement may change ventilation Pain, for 
example increases breathing probably without modifying the central and peripheral 
chemoreflex loop and the central modulation of the hypoxia-related output of the penpheral 
chemoreflex loop [32] 
Iatrogenic stimuli such as drugs affect ventilatory control They can be divided into 
depressants and stimulants and may act on the chemoreception This will result in a 
decrease or an increase in slope and in shifts of the ventilatory C02 response curve and 
some are centrally acting drugs Anaesthetics, sedatives, alcohol and opoids are examples 
of depressants, acetazolamide, progesterone, almitnne bismyselate, theophylline and 
caffeine are stimulants (paragraph 1 5 ) 
1.2. Measurements on ventilatory control 
1.2.1. Input parameters - Blood gas values 
The input parameters for the controlling system, / e PO2 and PC02/pH (input parameters of 
the peripheral chemoreceptors) can be measured directly via an artenal blood gas sample, 
whereas the input for the central chemoreceptors, PCSFCC^, can be obtained by sampling 
CSF fluid by suboccipital or lumbar puncture However, less invasive techniques or even 
non-invasive techniques are desired The use of artenahzed blood samples from the 
earlobe or fingertip (capillary samples) are accepted for estimating pH and PaC02, yet Pa02 
is not estimated correctly [33-35] End-tidal measurements of PCOj (PETC02) and P02 
(PET02) can be used to approximate arterial values in healthy subjects However, in COPD 
patients end-tidal values of PC02 and P02 do not adequately reflect artenal values because 
of substantial artenal-to-end-tidal PC02 and P02 gradients Non-invasive techniques of 
measunng PCSFC02 in humans are not descnbed in the literature 
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1.2.2. Output parameters - Minute ventilation and mouth occlusion 
pressure 
In healthy subjects, minute ventilation can be used as an output parameter of the controlling 
system. However, in COPD patients increased airway resistance, reduced compliance of 
the hyperinflated thorax and impaired function of respiratory muscles may modify the 
ventilation (figure 1 1.) In this situation, the ventilatory responses to chemical stimuli may be 
reduced, while more direct central output parameters such as Poi or electromyogram 
(EMG) of respiratory muscles may not be affected [36, 37]. Therefore, the use of the 
ventilation as output parameter in COPD patients of the central respiratory control is limited. 
A more direct output parameter of the controlling system in COPD patients is the mouth 
occlusion pressure. The mouth pressure 100 ms after onset of inspiration from an occluded 
mouthpiece (Poi) has been proposed as a more accurate index of respiratory center output. 
The Po -ι is not influenced by airway resistance since there is no airflow during the occluded 
period [38-43]. Poi is independent from changes in chemical drive during the occlusion, 
because there is not enough time for arterial gas tensions to change. Furthermore it is 
unlikely that conscious reactions will interfere with Poi [38]. This method is only valid if the 
patient' s nervous system, spinal cord, penpheral nerves and respiratory muscles are not 
diseased, weakened or fatigued. Consequently, the difficulty in interpretation of the Poi 
measurements in these patients will also depend on the function of the respiratory muscles 
and on the shape of the chest wall. Although these factors are often impaired in COPD 
patients, Poi is a closer approximation of the respiratory centre output activity than minute 
ventilation [2, 38]. 
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1.2.3. Ventilatory responses 
1.2.3.1. Hypercapnic ventilatory response (HCVR) 
The ventilatory response to C02 can be assessed by several methods At least three 
techniques are available 
The Read rebreathing method 
This method is based on rebreathing a 7% carbon dioxide mixture in oxygen from a small 
bag (4-6 litres) [44-47] With this design the open loop situation can be assessed the input 
parameter of the controlling system, PFTCC^, will increase in time while rebreathing, 
resulting in a change in VE, the output parameter of the controlling system The validity of 
Read's rebreathing method depends on the rapid equilibrium between alveolar gas, blood, 
brain and cerebrospinal fluid PC02 This means that a constant relationship is established 
between artenal PC02 and PCSFC02 IS not influenced by the level of ventilation [44, 48] In 
hypercapnic patients with chronic obstructive pulmonary disease (COPD) this method is 
less suitable, since no equihbnum will occur between PaC02 and PETC02 due to both a 
large dead space ventilation and an already high PaC02 Furthermore, it has been shown 
by Linton et al [48] and Berkenbosch et al [49] that applying the Read method in 
conditions of metabolic acidosis (e g during acetazolamide therapy) may result in a 
considerable overestimation of the slope of the C02 response curve The difference was 
explained by the rate of change in cerebral blood flow upon increasing carbon dioxide 
tension during the rebreathing and with the steady state method (see chapter 2) 
The dynamic end-tidal forcing technique 
The technique of dynamic end-tidal forcing (DEF) was introduced by Swanson and Bellville 
[50] The relative contnbutions of the penpheral and central chemoreceptors can be 
separated by a two-compartment analysis of dynamics of the ventilatory responses, using 
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the differences in time constants and in delay times Penpheral chemoreceptors are fast 
responding in contrast to the slow responding central chemoreceptors With this technique it 
is possible to force the end-tidal PC0 2 (PETC0 2 ) and P0 2 (PETOJ) to follow any desired 
pattern, e g step-changes, by manipulating the inspired C 0 2 and 0 2 concentrations with a 
computer on a breath by breath basis The P E T C 0 2 and PET0 2 can be, separately from each 
other, maintained at any desired level, independent of the ventilatory response and the gas 
tensions in the mixed venous return [51] (see chapter 2, 3 and 4) A two-compartment 
analysis of the ventilatory response to step changes in P E T C 0 2 allows the separation of a 
fast (penpheral chemoreceptors), and slow (central chemoreceptors) component [50, 52] 
(figure 1 3 ) 
This technique has been validated by Berkenbosch et al [53], who artificially perfused the 
vertebral artenes and the ponto-medullary region in cats In this way, the contnbution of the 
central and penpheral chemoreceptors to the total ventilation and their interaction was 
validated 
3.&1 
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Figure 1 3 DEF-run 
Example of a representative DEF run in a cat The upper part of the panel shows the PETC02 (scale 
right upper comer) The dots in the second trace represent breath by breath ventilation (V'i) The 
curve through these data points is the model fit, the sum of the central component V'c (third trace) 
and the penpheral component V'p (lower trace) 
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The steady state method 
This method is based on an elevation of alveolar PCO2 (PAC02) by breathing a gas mixture 
with elevated COj concentrations The measurement of ventilation is made when a steady 
state is reached, 1 e after -5-7 minutes in equilibration of alveolar and end-tidal PC02l and 
equilibrium of COj between the artenal and CSF compartments With this technique no 
separation can be made between the sensitivities of the central and penpheral chemoreflex 
loops The steady state method can be used in COPD patients to obtain reliable data about 
the C02 sensitivity of the ventilatory control system (see chapter 5 and 6) [2, 48, 54, 55] 
1.2.3.2. Hypoxic ventilatory response (HVR) 
Assessment of ventilatory responses to hypoxia may be camed out using a vanety of 
procedures When applying a step change into hypoxia, the HVR shows a biphasic 
response e g [56-58] There is an initial stimulating component ansmg from the peripheral 
chemoreceptors (acute response) followed by a centrally mediated hypoxic ventilatory 
depression The latter component probably arises from central neuronal structures, 
although changes in cerebral blood flow may also be involved, eg [59-61] It is important 
that HVR-responses are camed out under conditions of constant PETCC^, since different 
levels of C02 influence this response at the penpheral chemoreceptor (interaction) (figure 
1 4 ) The steady state relation between Vi and Pa02 is nonlinear and can be described by 
either hyperbolic or exponential functions, whereas a linear function can be used to 
describe the relation between Vi and Sa02 [61, 62] There is no physiologic reason to 
select one over the other However, with the linear response, the sensitivity S simplifies this 
method as only a limited number of data points is required [63] 
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Figure 1.4. The hypoxic ventilatory response 
An example of three hypoxic ventilatory responses at different levels of PC02 
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1.3. Sleep and control of breathing 
One of the non-feedback inputs for the ventilatory control system is the so-called 
'wakefulness dnve' Most probably this is reflected by the neural activity in the reticular 
activating system (RAS) combined with input from the cortex and thalamus During sleep 
the activity within this RAS-system is diminished, consequently the control of breathing will 
change (for references see Longobardo et a l , 2002 [64]) 
The ventilatory charactenstics of Non Rapid Eye Movement (NREM) sleep and Rapid Eye 
Movement (REM) sleep are shown in table 1 1 NREM sleep can be subdivided into (light) 
NREM 1 and 2 stages and the (deep) stages NREM 3 and 4 In REM sleep a 'tonic' and 
'phasic' part can be discerned During NREM sleep 'metabolic' control of breathing is intact 
This means that the ventilation is mainly dnven by the C02 production and the stimulation of 
the chemoreceptors by PaC02 Ventilatory responses to hypoxia and hypercapma are 
lowered Dunng NREM 1, which is short in duration, penodic breathing may occur 
Breathing becomes regular during NREM 2, 3 and 4 and dunng tonic REM sleep During 
phasic REM sleep, ventilation becomes irregular again and is probably somewhat 
influenced by 'behavioural mechanisms' which occur dunng dreaming [8, 65-70] 
Dunng REM sleep, the gamma motoneuron innervation of all muscles (except facial 
muscles) is virtually non-existent This gives nse to a 'gamma paralysis' of the muscles, 
including the intercostal and accessory muscles As the diaphragm has few muscle 
spindles, this muscle is hardly affected by the gamma paralysis The diaphragm is virtually 
the sole respiratory muscle in REM sleep 
In COPD patients several studies have shown that dunng REM sleep hypoventilation is 
more prominent as compared to healthy subjects, which leads to a nocturnal deterioration of 
hypoxia and hypercapma in these patients [66, 71] This increased hypoventilation is mainly 
caused by the inability of a flattened diaphragm to compensate the diminished intercostal 
and accessory respiratory muscle function and, in some patients, by a diminution of the 
already low hypoxic and hypercapmc ventilatory response 
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Sleep stages 
Regulation 
Breathing 
Ventilatory Response 
to C02 and 0 2 
Upper airway 
resistance 
Rib cage movement 
Abdominal 
movement 
minute ventilation 
PaC02 
Pa02 
NREMU2 
metabolic 
control 
penodic, regular 
apnoeas 
possible 
NREMa^ 
metabolic 
control 
regular 
1 
! 
1 
1 
11 
11 
11 
REM (tonic) 
behavioural and 
metabolic 
control 
mostly regular 
1 
1 ! 
1 
1 
11 
1 1 
11 
REM (phasic) 
behavioural 
control 
irregular 
11 
variable 
11 
11 
variable 
variable 
variable 
Table 1 1 Charactenslics of the NREM and REM sleep stages (Adapted from Vos PJE with 
permission [122]) 
1.4. COPD 
COPD is a disease state charactenzed by airflow limitation that is not fully reversible The 
airflow limitation is usually both progressive and associated with an abnormal inflammatory 
response of the lungs to noxious particles or gases [72] 
A subgroup of patients with severe COPD is unable to maintain their normal blood gas 
values, the hallmark of respiratory failure Two major types of respiratory failure can be 
distinguished gas exchange and ventilatory pump failure, manifested primarily by 
hypoxaemia and hypercapnia, respectively Generally, hypoxia can be the result of 
ventilation-perfusion (V7Q') mismatch, nght-left shunting, low Fi02 or impaired diffusion 
Hypercapnia results from ventilatory pump failure, which was the selection cntenon in the 
studied group of COPD patients in the current thesis 
There are several causes of ventilatory pump failure inadequate ventilatory dnve, 
excessive respiratory workload and inadequate inspiratory muscle function (Fig 1 5 ) [73-
75] 
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Figure 1 5 Ventilatory pump failure contributing factors (Adapted from Karpel J and Aldnch Τ , with 
permission [73]) 
Inadequate ventilatory dnve will lead to CO2 retention In hypercapmc COPD, an adaptation 
of chemoreceptors to chronic hypercapma is postulated [76, 77] 
Excessive respiratory workload due to expiratory flow limitation in patients with severe 
COPD can also lead to ventilatory pump failure Hypennflation of the chest wall and airway 
obstruction play a major role in this situation [78, 79] 
Inadequate inspiratory muscle function due to a flattening of the diaphragm is a major 
problem in COPD patients Furthermore, respiratory muscle function can be impaired by 
malnutntion and corticosteroid therapy Hypennflation of the lungs may contnbute to the 
excessive shortening during precontraction of the diaphragm, putting it in a unfavourable 
position on the length-tension curve [80] 
The goals of treatment for COPD patients are to prevent symptoms of the disease and 
recurrent exacerbations, and to preserve optimal lung function and gas exchange In the 
light of the above mentioned factors that may contribute to ventilatory pump failure, 
treatment may aim at the correction of impaired ventilatory dnve, reducing and/or 
overcoming the respiratory load and improve respiratory muscle strength and endurance 
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The ventilatory dnve can be increased by respiratory stimulants This is described in 
paragraph 1.5. 
The respiratory load can be decreased by drugs such as ß2-agonists, anticholinergic drugs, 
methylxanthines, corticosteroids, anti-oxidative agents and antibiotics and by non-invasive 
ventilation e.g.[81]. Respiratory muscle strength and endurance can be increased by 
inspiratory muscle training (TF-IMT) [82-85]. 
The prognosis of COPD patients is influenced adversely by hypoxia, malnutrition, 
lungfunction and most probably by hypercapnia. Treatment of hypoxia by long term oxygen 
supplementation improves survival [86-92]. However, some of the patients treated with 
oxygen supplementation will develop hypercapnia or existing hypercapnia may worsen [75, 
93]. Some studies suggest that hypercapnia is an independent factor in determining the 
prognosis of COPD patients [89, 90, 92, 94]. However this is still under debate [88, 91, 95]. 
This validates the investigation into means of diminishing this hypercapnia. 
1.5. Respiratory stimulants 
1.5.1. Carbonic anhydrase inhibitors 
Acetazolamide (ACET) and other carbonic anhydrase inhibitors (CAI) are potent respiratory 
stimulants e.g. [96-99]. In humans ACET inhibits hydrogen-ion ([H*]) secretion by the renal 
tubuli resulting in a metabolic acidosis. Due to the metabolic acidosis arterial [H+] rises 
which is a stimulus (via peripheral chemoreceptors) to increase ventilation This will in turn 
cause a decrease in PaC02 and eventually an increase in cerebrospinal fluid [H*][1, 100, 
101] The enzyme carbonic anhydrase is present in many tissues. Current literature has 
suggested that CAI will reduce cerebral blood flow, and thus contribute to C02 retention in 
the CSF and increase the central chemoreceptor stimulus Table 1.2 shows a list of organs 
and tissues involved in the ventilatory control that contain carbonic anhydrase. In chapter 2 
and 3 the mechanism by which ACET stimulates ventilation and improves arterial blood 
gases will be further discussed 
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ORGAN/TISSUE references 
Brain 
astroglia 
choroid plexus 
dorsal medullary neurons 
hypothalamus 
Rostro ventrolateral medullary superficial neurons 
cerebral vessels 
Peripheral nervous system 
carotid bodies 
aortic bodies 
Lungs 
capillary endothelium 
alveolar epithelium 
Blood 
erythrocytes 
Muscle 
Type 1, 2a and 2b (cytosolic) 
extracellular, sarcolemmar 
bound to Sarcoplasmatic Reticulum (SR) 
capillary endothelium 
Kidneys 
proximal tubuli 
Table 1 2 Location and indications of physiological / functional activity of carbonic anhydrase in 
vanous tissues playing a role m the control of breathing 
1.5.2. Progesterone 
During the progestational phase of the menstrual cycle and during pregnancy the 
progesterone level is increased, which results in an alveolar hyperventilation and a fall in 
PC0 2 of about 1 kPa [102] Progesterone, the synthetic progesterone medroxyprogestone 
acetate (MPA) and its metabolites, act mainly via hypothalamic stimulating effects [11, 12, 
68, 101, 103-107] Some studies report that MPA acts also via penpheral and/or central 
chemoreceptor pathways [11, 108] In chapter 4 the mechanism by which MPA influences 
the control of breathing will be discussed further 
eg [100, 123-128] 
e g [97,129-132] 
eg [133] 
e g [100,134] 
e g [135,136] 
e g [100] 
-25-
Chapter 1 
1.5.3. Other respiratory stimulants 
Almitnne bismesylate causes a substantial and long-lasting increase of pulmonary 
ventilation by an action on the peripheral chemoreceptors In this way almitnne improves 
oxygen tension to a similar degree as does oxygen supplementation [109-112] Side 
effects, such as peripheral neuropathy, are descnbed when higher doses are given [113] 
Almitnne is not registered in most European countnes, including the Netherlands 
Ammonium Chlonde induces a metabolic acidosis [114-116] Minute ventilation is increased 
due to an increase in breathing frequency, suggesting that ammonium chlonde acts via 
chemoreceptors 
Doxapram is a central nervous system respiratory stimulant In low doses respiratory 
stimulation is mainly mediated through an effect on the penpheral chemoreceptors and on 
the brain stem respiratory neurons [101, 110, 117] 
Methylxanthmes are potent central nervous system stimulants and they have a direct effect 
on brainstem respiratory centers Theophylline and caffeine are used for children in the 
management of idiopathic apnea of prematunty [68, 11Θ] 
The rationale for prescnbing theophyllines to COPD patients is pnmanly for their 
bronchodilator action [68] 
Finally, Prethcamid is used as a respiratory stimulant Prethcamid (ι ν ) lowers the stimulus 
threshold of the respiratory centers, which results in increase in tidal volume and frequency 
[119, 120] Brewis et al [121] reported no long-term effects of the drug and doubted 
whether the short term response is large enough to be clinically useful 
-26-
Introduction 
1.6. General aims of the thesis 
A subgroup of patients with severe chronic obstructive pulmonary disease (COPD) is 
hypercapnic and hypoxic It has been shown that long-term treatment with supplemental 
oxygen improves survival [86, 87] However, in some of the COPD patients hypercapnia 
may worsen with oxygen supplementation There are indications in current literature that 
hypercapnia itself may adversely influence the prognosis [89, 90, 92, 94] However, the 
role of hypercapnia and moreover, the effect of treatment of hypercapnia is still under 
debate [88, 91, 95] Nevertheless, it seems important to investigate means of diminishing 
hypercapnia In this thesis the effect of two respiratory stimulants, acetazolamide (ACET) 
and medroxyprogesterone acetate (MPA) are studied 
This thesis can be divided into two parts 
Part I consists of three animal studies 
In chapter 2 we descnbe the effects of ACET on the ventilatory C02 response curve in 
normoxic cats using the DEF technique The aims of this study were firstly, to find a dose 
sufficient to cause ventilatory stimulation and not causing a complete inhibition of 
erythrocytic carbonic anhydrase Secondly, we studied the effects of the drug on the 
peripheral and central chemoreflex loops 
In chapter 3 the results of administration of ACET in hypoxic cats are presented 
In chapter 4 the effects of MPA in combination with ACET in cats are presented In this 
study we hypothesized that a combination therapy with ACET and MPA could possibly 
result in a more than additive effect on the control of breathing, via both the chemoreceptor 
and a hormonal route 
Part II consists of two human studies 
In chapter 5 the results of a double blind cross over placebo controlled study in a group of 
hypercapnic and hypoxic COPD patients are presented The aim of this study was to 
evaluate the effects of ACET and MPA as monotherapy on ventilation and gas exchanges 
during day and night-time 
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Finally, in chapter 6 we investigated the effect of combined treatment with ACET and MPA 
in order to answer the question, whether there is an interaction between chemoreceptor and 
hormonal ventilatory dnves in this group of COPD-patients 
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2.1. SUMMARY 
1 The effect of 4 mg kg 1 acetazolamide (ι ν ) on the slope (S) and intercept on the 
PaC02 axis (B) of the ventilatory C0 2 response curve of anaesthetized cats with intact or 
denervated carotid bodies was studied using the technique of dynamic end-tidal forcing 
(DEF) 
2 This dose did not induce an artenal-to-end-tidal PC02 (P(a-ET)C02) gradient, indicating 
that erythrocytic carbonic anhydrase was not completely inhibited Within the first 2 h after 
administration, the small dose caused only a slight decrease in mean standard bicarbonate 
of 1 8 and 1 7 mmol L1 in intact (n=7) and denervated animals (n=7), respectively Doses of 
acetazolamide larger than 4 mg kg 1 (up to 32 mg kg1) caused a significant increase in P(a-
ET)C02 gradient 
3 In carotid body denervated cats, 4 mg kg 1 acetazolamide caused a decrease in the 
C0 2 sensitivity of the central chemoreflex loop (Sc) from 1 52 ± 0 42 to 0 96 ± 0 32 L mm1 
kPa1(mean ± S D ), while the intercept on the PaC02 axis (B) decreased from 4 5 ± 0 5 to 
4 2 ± 0 7 kPa 
4 In carotid body intact animals, 4 mg kg 1 acetazolamide caused a decrease in the C02 
sensitivity of the penpheral chemoreflex loop (Sp) from 0 2 8 ± 0 1 8 t o 0 1 9 ± 0 1 2 L mm1 
kPa 1 Sc and Β decreased from 1 52 ± 0 55 to 0 84 ± 0 21 L mm1 kPa1 and from 4 0 ± 0 5 
to 3 0 ± 0 6 kPa, respectively, not significantly different from changes encountered in the 
denervated animals 
7 It is argued that the effects of acetazolamide on the C0 2 sensitivity of the penpheral 
chemoreflex loop m intact cats may be caused by a direct effect on the carotid bodies Both 
m the intact and denervated animals the effect of the drug on Sc and Β may not be due to a 
direct action on the central nervous system, but rather to an effect on cerebral vessels 
resulting m an altered relationship between brain blood flow and brain tissue PC02 
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2.2. INTRODUCTION 
Carbonic anhydrase is present in several tissues directly or indirectly involved in the control 
of breathing, for example in renal tubular cells, erythrocytes, lung and brain capillary 
endothelium, in penpheral and possibly also central chemoreceptors [1-6] The most widely 
used inhibitor of the enzyme is acetazolamide [4] At doses sufficient to cause more than 
99% inhibition of erythrocytic carbonic anhydrase, this drug effects a large gradient between 
arterial PC02 (determined from in vitro samples) and end-tidal PC02, and an increase in 
ventilation e g [7-9] 
Clinically, acetazolamide is mostly used in too small a dose to inhibit erythrocytic carbonic 
anhydrase completely Usually, however, ventilation increases at these low doses, which is 
probably caused by an ensuing metabolic acidosis e g [10-13] 
Several authors have studied the effect of acetazolamide on the ventilatory response curve 
to C02 by applying the Read rebreathmg technique e g [11, 12] It has been shown, 
however, that applying this rebreathmg technique in conditions of metabolic acidosis may 
result in a considerable overestimation of the C02 response slope [14, 15] Furthermore, 
neither the Read technique nor conventional steady state techniques are able to assess 
possible effects of drugs on the sensitivities of the peripheral and central chemoreflex loops 
separately from each other 
In this study in anaesthetized cats we investigated the effect on the penpheral and central 
chemoreflex loop of a low dose of acetazolamide (4 mg kg1) not causing complete inhibition 
of erythrocytic carbonic anhydrase, indicated by the absence of an artenal-to-end-tidal 
PC02 (P(a-ET)C02) gradient To this aim, we applied the dynamic end-tidal forcing (DEF) 
technique in animals with intact carotid bodies, to assess the C02 sensitivity of the 
penpheral and central chemoreflex loops, as well as the intercept on the PaC02 axis of C02 
response curve [16] In this study we also determined the effect of acetazolamide on the 
C02 response curve in carotid body-denervated cats The aim was to see whether applying 
the data thus obtained on a steady-state C02 mass balance of the brain [15, 17] could give 
us more insight into a possible mechanism of action of this drug on the central chemoreflex 
loop 
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2.3. METHODS 
Animals and surgery 
Fourteen adult cats (weight 4.0-5.6 kg) were sedated with 15 mg.kg1 ketamine 
hydrochloride (i.m.). Atropine sulphate (0.5 mg s.c ) was given. The animals were anaesthe-
tized by inhalation of a gas mixture containing 0.5-1% halothane and 30% 0 2 in N2 while the 
femoral arteries and veins were cannulated Subsequently a dose of 20 mg kg"1 a-
chloralose and 100 mg.kg1 urethane was slowly infused intravenously and the addition of 
halothane to the inspirate was discontinued. Anaesthesia was maintained with a continuous 
infusion of 1 mg.kg1.h1 a-chloralose and 5 mg.kg"1.h"1 urethane. Rectal temperature was 
monitored with a thermistor and maintained within 0.5°C in the range from 36.3 to 39.3°C 
by a heating blanket and an infrared lamp. 
The trachea was cannulated at midcervical level and connected to a respiratory circuit. In 
seven cats both carotid sinus nerves were identified at their junctions with the 
glossopharyngeal nerves and were cut. To check the effectiveness of carotid nerve section, 
these animals were exposed to a short hypoxic challenge. All seven cats responded with a 
decrease in ventilation, indicating that the peripheral chemoreceptors were functionally 
eliminated. 
The animals were connected to an extracorporeal circuit (ECC) for continuous blood gas 
measurement Using the ECC, blood from the left femoral artery was pumped back via the 
right femoral vein with a flow of 6 ml.min'1 
Measurements 
Respiratory airflow was measured with a Fleisch No 0 flow transducer (Fleisch, Lausanne, 
Switzerland) connected to a differential pressure transducer (Statham PM197, Los Angeles, 
California, USA), and was electncally integrated to yield tidal volume. The CO2 and 02 
concentrations in the tracheal gas were measured with an infrared analyser (Gould Godart 
MK2 Capnograph, Bilthoven, The Netherlands) and a fast-responding zirconium oxide cell 
(Jaeger 02-test, Würzburg, Germany), respectively. The inspiratory gas concentrations were 
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made with mass flow controllers (type AFC 260, Advanced Semiconductor Materials, De 
Bilt, The Netherlands) Artenal pH and PC02 in the blood passing the extracorporeal circuit 
were measured continuously with a pH electrode (Radiometer E-5037-0, Copenhagen, 
Denmark), calibrated with phosphate buffers and a C0 2 electrode (General Electric 
A312AB, Milwaukee, Wisonscm, USA), calibrated with water equilibrated with C02-02-N2 
gas mixtures delivered by a gas mixing pump (Wosthoff, Bochum, Germany) The transport 
delay from the lungs to this C0 2 electrode was approximately 50 seconds The C0 2 elec­
trode was recalibrated about every 2 hours and corrections were made for drift when 
necessary Arterial blood pressure was measured using a Statham pressure transducer 
(P23ac, Los Angeles, California, USA) 
All signals were recorded on polygraphs, digitized (sample frequency 100 Hz), processed by 
a PDP 11/23 computer (Digital Equipment Corp, Maynard, Massachusetts, USA) and 
stored on disc Steady-state values of ventilation, blood pressure, end-tidal and artenal 
blood gas tensions were averaged over twenty breaths 
Expenmental protocol 
Each DEF-run started with a steady-state penod of ventilation of about 2 mm Thereafter 
the PETC0 2 was elevated by about 1-1 5 kPa within one or two breaths, maintained at a 
constant level for a penod of about 7 mm and then lowered stepwise to the previous value 
and kept constant for a further 7 mm (see Fig 3) The PET02 was held constant at about 15 
kPa throughout all runs In this way three to five control DEF-runs were performed in each 
cat Subsequently m ten animals (five of seven intact and five of seven carotid body 
denervated cats) the effects on the P(a-ET)C02 gradient of low cumulative doses of 
acetazolamide (Diamox, Lederle) up to 4 mg kg 1 (ι ν ) were determined The drug was dis­
solved in saline The doses, which were infused at constant end-tidal PC02, were 0 5, 0 5, 
1 and 2 mg kg 1 respectively (ι e 4 mg kg 1 in total) There was at least a 20 mm pause after 
each dose m order to let all parameters stabilize Four animals (two of seven intact cats and 
two of seven carotid body denervated cats) received a bolus infusion of 4 mg kg 1 About 
45-60 mm after the animals had received 4 mg kg 1 of the agent, another 3-5 DEF runs 
(acetazolamide runs) were performed Thereafter, to three of the (seven) carotid body 
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denervated animals a single subsequent intravenous dose of respectively Θ, 17 and 34 mg 
of bovine carbonic anhydrase C (Sigma, dialysed and lyophihzed from bovine erythrocytes, 
approx 5500 Wilbur-Anderson units mg1) in saline was administered and again 3 DEF-runs 
were performed After completion of the acetazolamide DEF-runs the respiratory effects of 
additional doses (respectively 2, 2, 8, 16 and 16 mg kg1) acetazolamide were studied In 
five intact cats and in three animals with denervated carotid bodies we determined minute 
ventilation at three different steady state levels of end-tidal PC02 after they had received a 
total dose of 32 mg kg 1 
Dafa analysis 
The steady state relation of ventilation (V,) to PETCOJ at constant PETC^ in the cat is linear 
down to the PETC02 axis as well described by DeGoede et al [18] 
V', = (SP+SC)(PETC02 - Β) (1) 
The parameters Sc and Sp are the central and peripheral ventilatory C0 2 sensitivities and 
the offset Β represents the apnoeic threshold or extrapolated PETC02 of the steady-state 
ventilatory response to C0 2 at zero ventilation 
For the analysis of the breath-to-breath data obtained in the DEF-runs we used a two-
compartment model [16] 
TcVJàt + V'c = Sc(PCTC02 (t-TJ-Bc) (2) 
TpV'p/dt + Vp = SP(PETC02 (t-Tp)-Bp) (3) 
το = τοηΧ
+(1-ΧΚ,(τ (4) 
V'.WsV'eW + VpW + C t (5) 
In the equations V'c and V'p denote the contributions of the central and penpheral 
chemoreceptors to the ventilation V', Be and Bp are the offsets of the central and penpheral 
ventilatory response The time constants of the central end penpheral ventilatory responses 
are denoted by TC and τρ Tc and Tp are the delay times needed to transport the C0 2 
disturbance from the lungs to the central and penpheral chemoreceptors, respectively To 
model the central time constant of the ventilatory on-transient to be different from that of the 
off-transient, TC IS wntten according to eqn (4) in which x=1 when PETC02 IS high and x=0 
when PETC02 IS low In some expenments a small dnft in ventilation was present Therefore 
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we included a dnft term C t in the model (eqn (5)) However, the trend was usually small and 
in multiple DEF studies in the same cat it was positive as well as negative 
We emphasize that the DEF technique can only separate the change in ventilation following 
a change in end-tidal C0 2 into parts belonging to the central and penpheral chemoreflex 
loops This is reflected in the fact that the offset parameters Be and Bp in eqns (2) and (3), 
respectively, cannot be estimated individually since they are not identifiable We therefore 
reduce the number of parameters in the model To this end it is customary to choose the 
same offset parameters for both loops, viz Bc=Bp=B [19] The offset Β is then equal to the 
extrapolated PETC02 of the steady state ventilatory response curve to zero ventilation 
(apnoeic threshold) As a consequence when a drug causes a change in apnoeic threshold 
it cannot be determined, using the DEF technique, whether the change has a central or 
peripheral origin Although it is not correct to call V'c and V'p the central and penpheral part 
of the ventilation due to the arbitrary choice of Bc=Bp, we usually do so for the sake of 
simplicity of the presentation For the steady state the two compartment model reduces to 
eqn (1) as it should 
All the parameters of the model were estimated simultaneously using the actual PETC02 as 
input and by fitting the data of each DEF study with a least-squares method To obtain 
optimal time delays a "grid search" was applied and all combinations of Tc and Tp with 
increments of 1 s and with T o Tp were tned until a minimum in the residual sum of squares 
was found The minimal time delays were somewhat arbitrarily chosen to be 1 s and τ
ρ
 was 
constrained to be at least 0 3 s [16] For the analysis of the response of the carotid body 
denervated cats Sp and τ
ρ
 were set at zero, since no fast component was present 
Statistical analysis 
To compare the values obtained from the analysis of the DEF runs in the control situation 
with those after acetazolamide infusion, a two-way analysis of vanance was performed, 
using a fixed model The level of significance was set at 0 05 Results are given as means ± 
SD 
The design of this study and the use of cats were approved by the Ethical Committee for 
Animal Expenments of the Leiden University 
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2.4. RESULTS 
In figure 1 cumulative dose-response curves of acetazolamide are shown for intact as well 
as denervated animals It appeared that, in a (total) dose smaller than or equal to 4 mg k g 1 , 
the drug did not induce a systematic P(a-ET)C02 gradient, indicating incomplete inhibition of 
erythrocytic carbonic anhydrase [4] Maximal widening of the artenal-to-end-tidal P C 0 2 
difference (approximately 2 5-3 kPa) was reached at a total dose of approximately 30 
mg k g 1 in intact cats, similar to the gradient reached after a bolus infusion of 50 mg k g 1 [9] 
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Figure 1 Dose response curve of acetazolamide 
The effect of acetazolamide on the artenal-to-end-tidal PC02 difference (Pia-ErJCOJ Mean values ± 
SD < intact cats, n=5 at 0 5, 1,2, 4, 6, 8,16, and 32 mg kg 1 , η =1 at 48 mg kg 1 Δ carotid body 
denervated cats, n=5 at 0 5, 1, 2, an 4 mg kg 1 , n=3 at 6, 8, 16, 32 and 48 mg kg1 * significantly 
different from control 
Figure 2 shows a recording of the respiratory effects of 4 mg k g 1 acetazolamide in one of 
the two carotid body intact animals to which a bolus infusion of this dose was given The 
infusion was performed at constant end-tidal P C 0 2 It shows that no artenal P(a-ET)C02 
gradient was induced since artenal P C 0 2 remained also virtually constant Shortly after the 
injection ventilation decreased and then slowly increased to a level above that existing 
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before drug administration. The second intact animal showed a similar response However, 
the two denervated animals receiving a bolus of 4 mg.kg1 did not show the slow ventilatory 
decrease 
7.40" 
7 · « . . 
• . ο " 
PaCO, (kPa) 
1 1 I I I 1 I 1 1 1 I 1 1 I I I I 1 I I I 1 I I 1 1 
ρ tlm· (min) 26 
Figure 2 Respiratory effects of 4 mg kg1 acetazolamide (i v.). 
Intravenous infusion of 4 mg.kg1 acetazolamide (arrow) at constant end-tidal PC02 in a cat with intact 
carotid bodies results in a rapid initial increase in ventilation V',. This initial increase is followed by a 
slow decrease, for which an effect of the dmg on the penpheral chemoreceptors may be responsible 
and a gradual increase in ventilation to a level above control. Note that the arterial PC02 (PaC02) 
remains virtually constant indicating ineffective inhibition of erythrocytic carbonic anhydrase P02 and 
PC02 denote gas tensions in tracheal gas; pHa is pH in arterial blood. 
In Fig 3 two examples of a computer analysis of DEF runs from an intact animal are shown, 
performed before and after infusion of 4 mg. kg'1 acetazolamide. It shows that after 
acetazolamide administration Sp, Sc and Β were decreased. A total of fifty-one DEF runs 
(31 control and 20 acetazolamide runs) were analysed 
10.0 
PO.IkP«) 
10.0 
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Figure 3 DEF runs before and after 4 mg kg1 acetazolamide 
Examples of two representative DEF runs in a carotid body intact animal before (left panel) and after 
(right panel) acetazolamide administration The upper part of each panel shows the PETC02 The dots 
represent breath-to-breath ventilation The curve through these data points is the model fit, the sum of 
the central component V'c and the peripheral component V'p and the drift (not shown separately) The 
values m the control run of the intercept on the PETC02 axis (B), the sensitivity of the central and 
penpheral chemoreflex loops Sc and Sp are 4 21 kPa, 1 24 and 0 43 L mm1 kPa1, respectively After 
acetazolamide these values decreased to levels of B, Sc and Sp of 2 27 kPa, 0 61 and 0 12 L mm1 
kPa1, respectively 
In table 1 the effects of 4 mg kg 1 acetazolamide on the DEF parameters in intact animals, 
together with those on standard bicarbonate and on the P(a-ET)C02 gradient are 
summarized The decrease in Sc, Sp and Β were highly significant A small but significant 
effect on Tc and τ ο η was found The significant but slight decrease in standard bicarbonate 
indicates that the acute renal effect of acetazolamide was mild An artenal-to-end-tidal 
PCO2 difference was not detectable, indicating incomplete inhibition of erythrocytic carbonic 
anhydrase at this dose [4] 
In table 2 the mean data obtained from twenty-six control and twenty-four acetazolamide 
runs of 4 mg kg 1 acetazolamide in the seven carotid body-denervated animals are summar­
ized In these animals we also found a decrease in Sc and Β As in the intact animals, no 
artenal-to-end-tidal PC02 gradient was found, and only a slight (insignificant) metabolic 
acidosis The change in mean Β in the denervated animals was not significantly different 
from the mean change found in those with intact carotid bodies (two-tailed t-test for 
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independent samples, p=0 06) The same was true for the effect of acetazolamide on mean 
Sc in both groups (p=0 5) Infusion of respectively Θ, 17 and 34 mg bovine carbonic 
anhydrase C (approximately 5500 Wilbur-Anderson units per mg) in three denervated 
animals did not change the values of Sc and Β obtained after 4 mg kg 1 acetazolamide 
From data reported by Travis et al [8] and Maren [4] we assume that about 2 h after the 
intravenous infusion of 4 mg kg 1 acetazolamide the concentration of free, unbound, 
acetazolamide in plasma will be too low to completely inhibit these large quantities of 
infused carbonic anhydrase 
Finally, in five of seven intact cats and three of seven carotid body denervated cats we 
determined ventilatory C0 2 sensitivity after a total dose of 32 mg kg 1 of the inhibitor In the 
denervated animals, the slope of the VVPaCOs response curve decreased further to a 
mean value of 20 ± 7% of the control value, ι e that existing before any acetazolamide 
infusion In the intact animals the slope decreased to a mean value of 32 ± 7% of the 
control value In all animals a large decrease in Β was seen, corresponding to that 
encountered dunng complete inhibition of erythrocytic carbonic anhydrase induced by an 
infusion of 70 mg kg 1 benzolamide [20] 
Sc (L mm1 kPa1) 
Sp (L mm1 kPa1) 
Β (kPa) 
P(a-ET)C02 (kPa) 
St bicarbonate (mmol L1) 
Tpis) 
tp(S) 
Tc(s) 
τ„„ (s) 
το„ (s) 
control 
1 52 ± 0 55 
0 28 ± 0 18 
4 0 ± 0 5 
0 04 ± 0 31 
20 6 ± 0 9 
5 ± 2 
4 ± 3 
8 ± 3 
89 ±11 
141 ±31 
acetazolamide 
0 84 ± 0 21 
0 1 9 ± 0 1 2 
3 0 ± 0 6 
0 17 ± 0 56 
1 8 8 ± 0 6 
5 ± 3 
6 ± 4 
1 0 ± 4 
107 ±28 
115±20 
Ρ 
0001 
0001 
0001 
45 
0003 
31 
11 
03 
24 
01 
Table 1 Effects of 4 mg k g 1 acetazolamide m cats with intact carotid bodies 
Sp and Sc are the C0 2 sensitivities of the penpheral and central chemoreflex loops, with delay times 
Tp and Tc τ ρ is the penpheral time constant and τ 0 Γ and τ ^ the central on and off-transient time 
constants and Β is the intercept on the PaC02 axis of the C 0 2 ventilatory response curve Values are 
presented as mean of the means per cat ± S D p-values are obtained from the ANOVA on the 
individual data 
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Sc (L mm1 kPa1) 
Β (kPa) 
P(a-ET)C02 (kPa) 
St bicarbonate (mmol L1 ) 
Te(s) 
Xon(S) 
to«(S) 
control 
152 ±0 42 
4 5 ± 0 5 
0 02 ± 0 20 
1 9 9 ± 2 1 
4 ± 1 
85 ±25 
132 ±31 
acetazolamide 
0 96 ± 0 32 
4 2 ± 0 7 
-0 02 ± 0 18 
1 8 2 ± 2 5 
6 ± 3 
116±83 
105 ±21 
Ρ 
0001 
0021 
60 
18 
06 
03 
005 
Table 2 Effects of 4 mg kg1 acetazolamide in carotid body denervated cats 
Sc is the sensitivity of the central chemoreflex loop with time constants τ0„ and τ,, and delay time Tc 
Β is the intercept on the PaC02 axis of the ventilatory C02 response curve Values are presented as 
mean of the means per cat ± S D p-values are obtained from the ANOVA on the individual data 
2.5. DISCUSSION 
This study shows that acetazolamide, at doses of 4 mg kg 1 and below, induced no 
significant P(a-ET)C02 gradient, indicating absence of effective inhibition of erythrocytic 
carbonic anhydrase In dogs, such a dose causes an appreciable gradient [21], and the 
maximal widening of the P(a-ET)C02 difference is reached at 20 mg kg 1 [4] We found that 
the maximal effect in the intact cat is reached at about 30 mg kg 1 Red cell enzyme activity 
in cat is about three times higher than in dog [22] This may explain the higher doses 
needed to achieve inhibition in the cat 
The mam findings of this study are that in carotid body intact cats Sp and Sc as well as Β 
decreased after 4 mg kg 1 acetazolamide In carotid body denervated cats Sc and Β were 
decreased to about the same extent 
For the interpretation of these results we start with the denervated cats in which we 
consider ventilation a function of brain tissue PC02 (PtC02) Since in these animals 4 mg kg 
1
 acetazolamide induced neither a significant decrease in standard bicarbonate nor a Ρ(3-ΕΤ) 
C0 2 gradient (table 2), we conclude that the observed changes in the slope and intercept of 
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the C0 2 response curve (relating ventilation to PaC02) were not due to renal or erythrocytic 
carbonic anhydrase inhibition of the drug The infused low dose of acetazolamide, if evenly 
distributed, would yield a brain concentration of 1 8 χ 105 M which is insufficient to give full 
inhibition of local carbonic anhydrase [4] Furthermore and importantly, acetazolamide is not 
evenly distributed at all, and is relatively excluded from the brain, even when administered 
in large doses [4, 23, 24] Consequently the brain concentration reached 1-2 hours after 
infusion of 4 mg kg 1 will be very much smaller than that needed to achieve effective 
inhibition of CNS carbonic anhydrase We therefore reason that the observed decreases in 
Sc and Β were not due to a direct effect on central chemoreceptors or other CNS nerve 
cells and ascribe these effects to a change in the relation between brain tissue PC02 and 
arterial PC02 To express this relationship we have previously used a steady-state mass 
balance equation for C0 2 for a brain compartment [20] which was originally proposed by 
Read & Leigh [17] and modified by Berkenbosch ef al [15] (see eqn (A1)) Our model yields 
a linear relationship between PtC02 and PaC02 (see also Fig 5) The slope and intercept of 
this relationship depend, among other factors, on brain metabolism, on the slope of the 
blood C02 dissociation curve and on the relationship between cerebral blood flow density 
(Q') and PtC02 (see eqn (A3)) As reasoned above brain metabolism will not be changed 
Apparently the slope of the blood C0 2 dissociation curve remained also constant, since the 
dose of 4 mg kg 1 did not result in a P(a-ET)C02 gradient and since subsequent intravenous 
infusion of carbonic anhydrase did not further influence the effects of acetazolamide on the 
C02 response curve The effects of the drug on S and Β should thus be caused by an alter­
ation of the relationship between Q' and PtC02, resulting in a change in the PtC02-PaC02 
relationship 
Figure 4 shows the relationship between brain blood flow density and artenal and brain 
tissue PC02, the dashed curves show the calculated course of both hyperbolas after aceta­
zolamide infusion if the effects of the agent on the C0 2 response curve were entirely due to 
an action on cerebral vessels We calculate from the slope ratio of the C0 2 response curve 
after and before drug infusion (0 63) that a decrease of about 50% in the "shape factor" of 
the hyperbola (parameter a in eqns (A2) and (A3)) accounts for the observed decrease m S 
The change in Β would result from this decrease in a, combined with a left shift of the 
asymptotes of the hyperbolas (parameter b in the equations in the Appendix) This effect of 
acetazolamide on cerebral blood flow leads to a change in the PtC02-PaC02 relationship 
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shown in Fig 5 Figure 4 implies that the effects of acetazolamide on Q', in a dose which 
does not completely inhibit the erythrocytic enzyme, depends on the PaC02 at which it is 
given In many studies a considerable increase in Q' was reported, but in most of these 
large doses were used cf [25-27] This appreciable effect on Q' is probably mediated via an 
increase in brain tissue PC02 (see also Vorstrup ef al [26]) resulting from a decrease in 
slope of the blood C0 2 dissociation curve [20] However, at a usual clinical dose, when 
given at normocapmc or slightly hypocapmc PaC02 values, acetazolamide did not increase 
cerebral blood flow in man (cf [28] As illustrated in Fig 4 our calculations show that in 
normocapmc PaC02 range, a low dose acetazolamide will have an effect on Q' which is 
hard to detect, thus explaining the findings of Huang ef al [28] The effect of a low dose 
acetazolamide on the Q'-PaC02 and Q'-PtC02 relationship may be due to a direct action on 
cerebral vessels There are indeed experimental data indicating that vascular carbonic 
anhydrase may play an important role in the control of vascular tone by endothelial cells (for 
references see [29]) We also mentioned that acetazolamide has been shown to induce 
vasoconstnction in an in vitro choroid plexus preparation from the rat [30] We suggest that 
acetazolamide may act on a carbonic anhydrase isoenzyme located mtracellularly in brain 
arteriolar and/or capillary endothelial cells, to which, due to its physical and chemical 
properties, benzolamide has no access [31] These properties also deny benzolamide 
access to the brain [4, 8] 
An alternative explanation for the observed effects of acetazolamide on Sc and Β might be 
that despite incomplete red cell inhibition the slope of the in vitro C02 dissociation curve 
was reduced by inhibition of a membrane-bound carbonic anhydrase at the luminal side of 
brain capillanes cf [24] Ridderstrâle and Hanson [5] showed that the structure of the cat 
brain which was most intensely stained for carbonic anhydrase is the capillary endothelium 
It is reasonable to assume that this easily accessible luminal carbonic anhydrase will be 
inhibited by the low dose of acetazolamide This may tend to affect the C02 transport 
capacity of the capillary blood while perfusing the brain, albeit to a much lesser degree than 
during complete red cell inhibition However, under these circumstances, assuming an 
unchanged tissue PC02, one would expect an increase in the contnbution of 
carboxyhaemoglobm to total C02 transport cf [32], thus compensating for the lesser 
contribution of rapidly formed bicarbonate 
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Figure 4 Cerebral blood flow density (Q') as a function of arterial or brain tissue PC02 
Cerebral blood flow density (Q') calculated from the hyperbolic relation 
α = 
PCO, 
m which either PaCOj (left panel) or PtC02 (nght panel) can be taken as independent vanable The 
continuous curves represent the control situation, the dashed curves that after 4 mg kg1 acetazol­
amide For calculation of parameters a and b in both conditions see Appendix 
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Figure 5 Relation between PtC02 and PaC02 
Applying the mass balance equation for C02 for a brain compartment yields a linear relationship 
between PtC02 and PaC02 (eqn (A3)) The continuous line represents the control situation and the 
dashed line the one calculated after administration of 4 mg kg1 acetazolamide The difference in 
slope and intercept between both conditions is caused by an effect on the coupling between brain 
blood flow and brain tissue PCO, 
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This would tend to restore the slope of the in vivo C02 dissociation curve of the capillary 
blood towards normal, thus masking a physiological effect of inhibition of the luminal 
carbonic anhydrase 
In our opinion, the facts that after infusion of acetazolamide a P(a-ET)C02 gradient was 
absent and that large quantities of intravenously infused carbonic anhydrase (probably 
sufficient to restore the normal contnbution of rapidly formed bicarbonate) failed to reverse 
the decrease in Sc and B, indicate that this indeed might have been the case This led us to 
suggest the effect of acetazolamide on the Q,-PaC02 and Q'-PtC02 relationships as 
mechanism by which acetazolamide, at a low dose, may change slope and intercept of the 
C0 2 response curve It is obvious, however, that our explanation awaits further expenmental 
venfication 
Our model predicts that if the only additional effect of a supplemental dose of about 30 
mg kg1 acetazolamide is to decrease the slope of the in vivo blood C02 dissociation curve 
to the same value as with 70 mg kg 1 benzolamide [20], the slope of the ventilatory C0 2 
response curve should decrease to 23% of the control value (see Appendix) This 
corresponds closely to the observed value of 20% in the four denervated animals in which 
the effect of 32 mg kg 1 acetazolamide was studied 
We cannot exclude the possibility that the effects of acetazolamide on Sc and Β are 
mediated by an action on the central nervous system, however, for reasons mentioned 
above we consider this less likely Furthermore, the decrease in Sc and Β developed within 
30-50 mm, a penod too short for this effect to be mediated centrally (see [23]) We are 
unaware of central actions of acetazolamide occumng independently of inhibition of 
carbonic anhydrase 
In carotid body intact cats the decrease in Sc was of about the same magnitude as in 
denervated animals (45 vs 38 %) as expected The decrease in mean B, in the intact 
animals also did not differ significantly from that observed in the denervated animals, 
although the effect tended to be more pronounced in the former Note that the numeric 
values for the parameters a and b after acetazolamide administration used in Fig 4 were 
calculated for denervated animals only In the intact animals, these values could have been 
somewhat different, thus resulting in different values for Β Furthermore, in intact cats the 
intercept on the PaCOj axis (B) of the C0 2 response curve is also dependent on the penp-
heral chemoreflex loop [18] Finally, as remarked earlier, the DEF technique is not able to 
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separate the effect on Β into a peripheral and a central part but can only separate the 
change in ventilation following a change in end-tidal C0 2 into parts belonging to the 
peripheral and central chemoreflex loops cf. [18]. 
If the effect of acetazolamide is mediated by a direct action on the central nervous system, 
the effect on the peripheral chemoreflex loop (decrease in Sp) in the intact animals is 
probably caused by a local action on the carotid bodies Several studies have indeed 
reported a decrease in baseline carotid body activity and/or sensitivity to PaC02 changes 
e g [33, 34] In these studies, however, high inhibitor doses were used. We believe we have 
indirect evidence that carotid body output may be decreased by a dose of acetazolamide as 
small as 4 mg.kg1 Figure 2 shows that, shortly after a bolus infusion of the drug, ventilation 
decreased and then underwent a secondary gradual increase. This was also found in the 
other cat (carotid body intact) receiving the bolus but not in the two denervated animals 
receiving the drug in this way During hypoxia, when the contribution of the carotid bodies to 
ventilation is relatively large, we consistently observe a considerable initial decrease in 
ventilation (authors' unpublished observations). When larger doses are infused during 
hypoxia, an initial period of apnoea ensues [9]. 
Acetazolamide may also act on respiratory muscles. The role of muscle carbonic anhydrase 
may be complicated, since isoenzymes have been identified at various muscular sites We 
mention cytosolic CA III in muscle cells (mainly type I), cytosolic CA I and II in muscle cells 
as well as in capillary endothelium, and a membrane-bound form in sarcolemma, 
sarcoplasmatic reticulum and capillary endothelium [35]. 
Scheid and Siffert [36] showed that concentrations > ΙΟ"4 M acetazolamide were necessary 
to inhibit maximal isometric force of frog skeletal muscle by 50% Barclay [37] found that 
exposing mouse soleus muscle to 105 M acetazolamide for 25 min did not affect isometric 
tension From these and other data no conclusions can be drawn as to a possible effect of 
low doses acetazolamide on respiratory muscles in vivo in the anaesthetized cat. Given the 
low permeability of acetazolamide and the small dose that we used, we think, however, that 
the observed decreases in S and Β are unlikely to be mediated at muscular level Further 
studies are necessary to investigate this. 
The present observation of a decrease in slope of the CO2 response curve may seem to 
conflict with known studies in humans reporting either an increase (cf. [12, 13]) or no 
change in slope, but only an upward shift of the response curve (cf. [10, 11]). 
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Several of these studies used the Read rebreathmg technique or a modification to 
determine CO2 sensitivity However, chronic use of acetazolamide (as applied in these 
studies) by humans usually leads to a considerable metabolic acidosis, an increase in 
ventilation and a substantial decrease in artenal PC02 However, dunng metabolic acidosis, 
using conditions formulated by Read, the rebreathmg technique results in a considerable 
overestimation of the response slope (see [14, 15]) In most studies in which a conventional 
steady state technique was used, end-tidal PC02 was taken as independent variable 
However, in patients suffenng from lung disease a relatively large P(a-ET)C02 gradient may 
be present which, in addition, may be altered if lung carbonic anhydrase is inhibited [38] If 
sufficiently large oral doses of the drug are used to cause partial inhibition of erythrocytic 
carbonic anhydrase, a gradient may also be present in healthy subjects (cf [12, 13]) One 
should therefore preferably use artenal PC02 as the independent vanable, combined with 
end-tidal data it can then be judged if an unusual artenal-to-end-tidal gradient exists It may 
be illustrative that in re-analysing the data of Lerche ei al [10] by means of linear 
regression, using their artenal PC02 values (see their table 2), we found a decrease of 30% 
in the slope of their C0 2 response curve by acetazolamide Finally, Swenson and Hughes 
[13] showed that chronic and acute treatments with the drug led to different effects on the 
C 0 2 response curve Although baseline ventilation was increased, they concluded that 
acute (intravenous) treatment has an inhibitory effect on the control of breathing Obviously 
further studies are needed to document the effect of clinical doses of acetazolamide on the 
control of breathing in humans, taking into consideration these methodological problems 
In conclusion, the effects of low dose acetazolamide on Sc and Β are probably due to an 
effect on cerebral vessels resulting in an altered relationship between cerebral blood flow 
and brain tissue PC02 The effect on the penpheral chemoreflex loop may be caused by a 
direct action on the carotid bodies 
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2.6. Appendix 
The mass balance for C0 2 of a brain compartment in steady state can be written as [15, 
17]. 
PtC02 -
 ( 1
 -VW - ">
 + PaC02 (A1) 
2
 IQ' 2 
where PaC02 and PtC02 denote the arterial PC02 and brain tissue PC02 respectively. Q' 
and M' are the brain blood flow density and brain metabolism density, respectively, / the 
slope of the linearized blood C0 2 dissociation curves, h the Haldane parameter and γ a 
parameter which locates PtC02 between PaC02 and the cerebral venous PC02 (PvC02). 
The cerebral blood flow density is assumed to be coupled to PtC02 in a hyperbolic fashion 
[20]. 
Q ' = (A2) 
(Û - PfC02) 
with "shape factor" a and PC02-asymptote b. Substituting eqn (A2) in eqn (A1) yields a 
linear relation between PtC02 and PaC02 
PfCO, = PaC02 + {A3) 
2
 ι . (1 - Y)(M ' - h)
 1 ,. al 
al (1 - γ)(Μ ' - h) 
A linear relation between PtC02 and PaC02 was indeed found experimentally [39] accord­
ing to 
PtC02 = aPaC02 + β (A4) 
with slope α and intercept β. Using eqns (A3) and (A4) it follows that: 
b =7-5— (Λ5) 
1 - α 
We assume that in carotid body denervated animals ventilation (V,) is linearly related to 
PtC02 so thaf 
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V ', = St(PtC02 - Bt) (A6) 
in which St is the C0 2 sensitivity at the site of the central chemoreceptors and Bt an offset 
The ventilation as function of the PaC02 is 
V ', = S (PaC02 - B) (AT) 
with the slope S and the intercept Β on the PaC02 axis 
From eqns (A1), (A4) and (A6) it follows that the slope S is 
S = aSf = St (A8) 
1 + (1 - Y)(M ' - h) 
al 
Using eqns (A4), (A5), (A6), (A7) and (A8) the intercept on the PaC02 axis can be written 
as 
Β =
Bt
 '
 b
 + b (A9) 
α 
From eqn (A8) it follows that 
a = q ( 1 - YXM ' - » (A10) 
/(1 - a) 
In the control situation, were a= 0 48, y= 0 5, M'= 8 17 χ 10" ml ml 1 s1, h = 1 83 χ 10 " 
and/ = 2 4 x 102 ml ml1 kPa1 [20] we calculate a value for a of 1 23 χ 102 ml ml 1 s 1 kPa 
Since acetazolamide crosses the blood-brain bamer only very slowly we assume that under 
the present expenmental conditions the parameters γ, M', h, and St remained constant after 
administration of the drug Since infusion of 4 mg kg 1 was not followed by a P(a-ET)C02 
gradient and since the decreases in S and Β were not affected by a subsequent 
intravenous infusion of carbonic anhydrase, we conclude that parameter / also remained 
constant In this way the change m S by acetazolamide can be entirely attributed to a 
change in a, (cf eqn (A8)) ι e to a change in the shape of the hyperbola relating Q' to PtC02 
(eqn (A2)) Introducing the subscnpts d for the parameters after drug administration and 'n' 
for the control situation, the ratio ad/an can be wntten as 
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—(1 - «J 
-1 = — (A11) 
η Λ α _. 
s n " 
where we have used the relation: 
« . = Sd - ^ (Λί2) 
In the carotid body denervated cats we found for the ratio SJSn a value of 0 63 Taking a 
value of 1.23 χ 102 ml.ml'1.s1 kPa for an (see above) it can now be calculated that a d= 
0.057 ml.ml·1 s"1 kPa. It also follows from eqn (A8) that if α
π
 = 0.48, the value of ad should 
be 0 30. Using eqn (A5) and (A9), taking a value of 4.45 for β
η
 (see Teppema et al. 1995 
[20]) and assuming that B, remained constant, it can be calculated that the observed 
change in the intercept on the PaC02 axis (B) from 4.5 to 4.2 kPa can be explained by a 
shift in the value of b (i.e. the asymptote of the Q'-PtC02 relation) from 8 6 to 7.6 kPa, 
together with the change in α from 0.48 to 0.30. It is thus possible to attribute the effect of 4 
mg.kg'1 acetazolamide on the C0 2 response curve entirely to an effect of this agent on 
cerebral vessels. 
Since acetazolamide is relatively excluded from the brain [4, 23], even an additional dose of 
about 30 mg.kg'1 will not result in effective inhibition of CNS carbonic anhydrase within a 
time span as short as 30 min (see also [24]). We thus assume that the only additional short-
term effect of this dose will consist of a decrease in the slope / of the in vivo blood C0 2 
dissociation curve, due to inhibition of erythrocytic carbonic anhydrase. In a previous study 
[20] we have calculated that complete inhibition of the red cell enzyme leads to a decrease 
in / from 2 4 χ 10'2 to 6.9 χ 10"3 ml.ml1 kPa1 Using eqn (A8) and taking a value for a of 
0 057 ml.ml"1.s"1.kPa already existing after 4 mg.kg"1 acetazolamide (see above), we 
calculate that infusion of this large dose of the drug should result in a 77% decrease in 
slope of the C0 2 response curve. This corresponds closely to the observed mean decrease 
of 80% in slope in the four carotid body denervated animals tested. 
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3.1. Summary 
Acetazolamide, a carbonic anhydrase inhibitor, is used in patients with chronic obstructive 
pulmonary diseases and central sleep apnoea syndrome and in the prevention and treat­
ment of the symptoms of acute mountain sickness. In these patients, the drug increases 
minute ventilation, resulting in an improvement in arterial oxygen saturation. However, the 
mechanism by which it stimulates ventilation is still under debate. 
Since hypoxaemia is a frequently observed phenomenon in these patients, the effect of 4 
mg.kg'1 acetazolamide (i.v.) on the ventilatory response to hypercapnia during hypoxaemia 
(arterial oxygen tension (Pa02) = 6.8 ± 0.8 kPa, mean ± SD) was investigated in seven 
anaesthetized cats The dynamic end-tidal forcing (DEF) technique was used enabling the 
relative contributions of the peripheral and central chemoreflex loops to the ventilatory 
response to a step change in end-tidal carbon dioxide tension, (PETC02) to be separated. 
Acetazolamide reduced the CO, sensitivities of the peripheral (Sp) and central (Sc) 
chemoreflex loops from 0.22 ± 0.08 to 0.11 ± 0.03 Lmin-1.kPa'1 (mean±SD) (p<0.01) and 
from 0.74 ± 0.32 to 0.40 ± 0.10 L.mm1 .kPa"1 (p<0.01), respectively. The apnoeic threshold 
Β (x-intercept of the ventilatory C0 2 response curve) decreased from 2.88 ± 0.97 to 0.95 ± 
0.92 kPa (p<0.01) The net-result was a stimulation of ventilation at PETC02 <5 kPa. 
The effect of acetazolamide is possibly due to a direct effect on the peripheral 
chemoreceptors as well as to an effect on the cerebral blood flow regulation. Possible 
clinical implications of these results are discussed. 
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3.2. INTRODUCTION 
The carbonic anhydrase inhibitor acetazolamide stimulates ventilation, resulting in an 
improvement in arterial oxygen tension (PaC02) in patients with chronic obstructive pulmo­
nary disease (COPD) or central sleep apnoea syndrome and in those suffering from acute 
mountain sickness [1-10] The ventilatory effect with the drug is believed to be mediated by 
a metabolic acidosis, induced by inhibition of renal carbonic anhydrase [11-14] However, 
other local effects of acetazolamide could also contribute to the observed ventilatory ef­
fects, since carbonic anhydrase is present in several tissues of the pathways involved in the 
control of breathing For example, the enzyme is present in the penpheral and possibly also 
the central chemoreceptors [15-18], erythrocytes [16] and muscles [19] and in lung- as well 
as brain capillary endothelium [20-22] Usually, acetazolamide is administered in doses 
which do not completely inhibit red cell carbonic anhydrase Complete inhibition of erythro­
cytic carbonic anhydrase occurs at a fractional inhibition > 99 8%, for which doses >10 
mg kg 1 acetazolamide are required [16,23] In COPD patients, this situation would result in 
impeded washout of C0 2 from the lungs, leading to C0 2 accumulation in the tissues Such 
an undesired complication can be avoided by administering small doses, preventing an 
increase in the arterial to end-tidal carbon dioxide tension (P(a ET)C02) gradient 
In a previous study in anaesthetized cats, it was found that doses up to 4 mg kg 1 
acetazolamide (ι ν ) did not cause a P(aET)C02 gradient [24] In the same study the effect of 
4 mg kg1 acetazolamide on the ventilatory response to C0 2 dunng normoxaemia was also 
investigated utilizing the technique of dynamic end-tidal forcing (DEF) [25], decreases in 
the C0 2 sensitivities of the penpheral (Sp) and central (Sc) chemoreflex loops and in the 
apnoeic threshold (extrapolated carbon dioxide tension (PC02) at zero ventilation) were 
found These effects were attnbuted to a possible direct action of acetazolamide on the 
penpheral chemoreceptors and to a change in the relation between brain tissue PC02 
(PbtC02) and artenal PC02 (PaC02), due to a possible effect of the drug on cerebral blood 
flow regulation 
Since this previous study was performed during normoxia, its results may not be directly 
relevant to a situation of hypoxaemia, such as frequently occurs in patients with COPD 
Dunng hypoxaemia, both cerebral blood flow and the relative contnbution of the penpheral 
chemoreceptors to total ventilation are different from that in normoxaemia Therefore, the 
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aim of this study, in anaesthetized cats, was to investigate the acute ventilatory effects of 4 
mg k g 1 acetazolamide on the penpheral and central chemoreflex loops on a background of 
moderate hypoxaemia (Pa02~6 θ kPa) 
Owing to different pharmacokinetics, the ventilatory effect of oral acetazolamide in patients 
with C0 2 retention may differ from that after an acute ι ν infusion of a low dose, as per­
formed in the present study However, both situations are the same to the extent that the 
effects of the drug will be mediated independently of erythrocytic carbonic anhydrase 
inhibition, since in both cases the red cell enzyme will not be inhibited effectively So despite 
different pharmacokinetics to those after chronic oral administration, it was decided to study 
the effect of a low dose of acetazolamide in an acute animal preparation which was made 
moderately hypoxaemic, a condition which frequently occurs in the clinical situations in 
which the drug is used 
3.3. METHODS 
Animals, surgery and measurements 
Seven adult cats (body weight 4 0-5 6 kg) were premedicated with 15 mg kg 1 ketamme 
hydrochloride (ι m ) and atropine sulphate (0 5 mg s c ) Anaesthesia was induced via 
inhalation of a gas mixture containing 0 5-1% halothane and 30% 0 2 in N2 After 
cannulation of the femoral veins and artenes, an initial dose of 20 mg k g 1 a-chloralose and 
100 mg kg 1 urethane was slowly infused intravenously and the addition of halothane to the 
inspirate was discontinued Anaesthesia was maintained with a continuous infusion of 1-1 5 
mg kg 1 h 1 a-chloralose and 5 0-7 5 mg kg 1 h 1 urethane This anaesthetic regimen pro­
vides a constant level of ventilatory control [26] Rectal temperature was monitored with a 
thermistor, kept within 1 °C in each cat and ranged from 36 3 to 38 2 "C among the animals 
The trachea was cannulated and connected to a respiratory circuit One femoral artery and 
vein were connected to an extracorporeal circuit (ECC, flow 6 ml mm1) for continuous blood 
gas measurement 
The ventilatory responses to C0 2 were studied before and 1 hour after ι ν administration of 
4 mg kg 1 acetazolamide, using the DEF technique (see below) 
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The end-tidal PC02 (PETC02) was forced stepwise, while the end tidal oxygen tension 
(PET02) was kept constant This was achieved by manipulating the inspired CO 2 and 0 2 
concentrations by feedback control with a computer. Respiratory airflow was measured with 
a Fleisch No. 0 flow transducer (Fleisch, Lausanne, Switzerland) connected to a differential 
pressure transducer (Statham PM197, Statham, Los Angeles, CA, USA), and was electroni-
cally integrated to yield tidal volume. The composition of the inspirate was regulated by 
computer-controlled mass flow controllers (type AFC 260, Advanced Semi-conductor 
Materials, De Bilt, The Netherlands), using pure 02, C02 and N2 The C02 and 02 concentra-
tions in the tracheal gas were continuously measured with an infrared analyser (Gould 
Godart MK2 Capnograph, Gould Godart, Bilthoven, The Netherlands) and a fast-responding 
zirconium oxide cell (Jaeger 02-test, Jaeger, Würzburg, Germany), respectively. 
Arterial pH, PC02 and P02 in the blood passing through the ECC were measured continu-
ously with a pH electrode (Radiometer E-5037-0, Radiometer, Copenhagen, Denmark), cali-
brated with phosphate buffers, a PC02 electrode (General Electric A312AB, General 
Electric, Milwaukee, Wl, USA) and a home made Clark-type oxygen tension P02 electrode. 
The PC02 and P02-electrodes were calibrated with water equilibrated with C02-02-N2 gas 
mixtures delivered by a gas mixing pump (Wösthoff, Bochum, Germany) The PCOj elec-
trode was recalibrated approximately every 2 hours and corrections were made for drift 
when necessary. Arterial blood pressure was measured using a pressure transducer 
(Statham P23ac) 
All signals were recorded on polygraphs, digitized (sample frequency 100 Hz), processed by 
a PDP 11/23 computer (Digital Equipment Corp., Maynard, MA, USA) and stored on disk. 
Values for ventilation, tidal volume, respiratory frequency, arterial blood pressure, end-tidal 
and arterial blood gas tensions (PETC02, PET02, PaC02, Pa02) were stored on breath by 
breath basis. 
Experimental protocol and data analysis 
Each DEF-run was started after a steady-state penod of ventilation of about 2 min. Next, 
the PETC02was elevated by about 1-1.5 kPa within one or two breaths, maintained constant 
for a period of 6 - 7 min, and then lowered stepwise to the previous value and kept constant 
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for a further 6 - 7 mm (fig 1) The Pa02 was kept constant at 6 8±0 8 kPa throughout all 
runs In each cat three to five control DEF-runs were performed After the control runs, all 
cats received an ι ν injection of 4 mg kg 1 acetazolamide (Diamox, AHP-Pharma, 
Hoofddorp, The Netherlands), dissolved in saline (2 mg ml1) PETC02 and PET02 were kept 
constant dunng infusion Sixty minutes after infusion, another three to five DEF-runs 
(acetazolamide runs) were performed 
3 0-[ 
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ir P^CO.IkP·) 3 0 η 
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LT ftrCO^kPa) 
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Figure 1 Dynamic End-tidal Forcing runs before (left panel)and after 4 mg kg1 acetazolamide (right 
panel) Examples of two DEF runs and the model fits of the ventilatory responses The upper trace of 
each panel shows the input function of end-tidal carbon dioxide tension PETC02 The curve through 
the breath to breath ventilatory data points (dots) is the model fit The two lower traces show the 
contributions to ventilation of the central (V'c) and penpheral (V'p) chemoreflex loops, respectively, to 
the model output Insets Sc and Sp are the C02 sensitivities of the central and penpheral 
chemoreflex loops (L mm1 kPa '), respectively, and Β is the extrapolated X-mtercept of the ventilatory 
C02 response curve (kPa) 
For the analysis of the breath-to-breath data obtained in the DEF-runs a two-compartment 
model was used [25] 
τ« J V'c(t) + V'c = Sc[PETC02(t-Tc)-B] 
tp J Vp(t) + V p = Sp[PETC02(t-Tp)-B] 
V'M = V'c(t) + V'p(t) + C t 
(1) 
(2) 
(3) 
(4) 
Equation (1) describes the ventilatory dynamics of the slow central chemoreflex loop with 
the contnbution of the central chemoreceptors to the ventilation (V'c), C0 2 sensitivity (Sc), 
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time constant (TC) and transport delay time (Tc) of the C0 2 change from lungs to central 
chemoreceptors, similarly, equation (2) descnbes the ventilatory dynamics of the fast 
peripheral chemoreflex loop with the contnbution to the ventilation (V'p), C0 2 sensitivity (Sp), 
time constant (τ
ρ
) and transport delay time (Tp) The offset Β (equations (1) and (2)) repre­
sents the apnoeic threshold, / e the extrapolated ventilatory response to PEJCOJ at zero 
ventilation Equation (3) was used to model the difference in the central time constant of the 
on-transient (τ
οη
) versus the off-transient (τ^,) When PETCC^ IS raised (on-transient) we use 
χ = 1 and when PETC0 2 IS lowered (off-transient) we use χ = 0 In some expenments a small 
dnft in the ventilation (V',) was present Therefore, we a dnft term C t was included (equation 
(4)) The parameters of the model were estimated by fitting the model to the data with a 
least squares method A gnd search was performed to obtain optimal time delays All 
combinations of Tc and Tp (increments of 1s and Tc ^ Tp) were tned until a minimum in the 
residual sum of squares was found The minimal and maximal time delays were, somewhat 
arbitranly, chosen to be 1 s and 15 s, respectively and τ
ρ
 was constrained to be at least 
0 3s 
Statistical analysis 
To compare the means of the values obtained from the analysis of the DEF runs in the 
control situation with those after acetazolamide infusion, a two-way analysis of vanance 
(ANOVA) was performed, using a fixed model The level of significance was set at 0 05 
Results are given as mean of the means ± S D 
The design of this study and the use of cats were approved by the Ethical Committee for 
Animal Expenments of the Leiden University 
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3.4. RESULTS 
After an initial transient decrease in minute ventilation, all cats responded with a slow 
increase in ventilation to an ι ν infusion of 4 mg.kg"1 acetazolamide at the prevailing PFTC02 
level. An example is shown in figure 2. 
Paco, (kPa) 
Tim· (min) 
Figure 2. Acute effect of an i.v. infusion of 4 mg.kg'1 acetazolamide in a hypoxaemic cat (arrow). An 
initial decrease in ventilation (V'i) when a constant end-tidal PC02was maintained, was followed by a 
slow secondary increase. Pa02: arterial oxygen tension; PC02: carbon dioxide tension in the respira­
tory air; PaC02 arterial carbon dioxide tension 
Thirty-one DEF-runs were performed during the control situation and 31 runs after infusion 
of 4 mg.kg"1 acetazolamide. Two examples of DEF-runs in the same cat are shown in figure 
1 together with the computer analysis, one run before and one after administration of the 
drug. This figure illustrates that Sc and Sp were decreased after acetazolamide infusion. 
The effects of acetazolamide on Sc and Sp and on the apnoeic threshold of all individual 
cats are shown in the scatter diagrams of figure 3. As shown, in all individual cats each 
parameter decreased after infusion of 4 mg.kg1 acetazolamide. Table 1 summanzes all of 
the parameters obtained by the analysis of the DEF responses before and after infusion of 
4 mg.kg1 acetazolamide as well as the effect on standard bicarbonate (PC02 = 5 32 kPa, 
pH=7 4) and on the P(a-ET)C02 difference. 
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The apnoeic threshold Β diminished significantly by about 2 kPa (from 2.88±0.97 to 0.95 ± 
0.92 kPa). Sp and Sc decreased significantly to about half their control values (from 0.22 ± 
0.08 to 0.11 ± 0.03 L min"1.kPa"1 and from 0.74 ± 0.32 to 0.40 ± 0.10 Lmin"1. kPa"1, respec­
tively). Of all remaining DEF-parameters only Tpand το η changed significantly. A small, but 
significant, increase in the P(a-Er)C02 gradient and a slight decrease in standard bicarbon­
ate was observed. 
As shown in figure 4, the decrease in total C0 2 sensitivity (Sp+Sc) combined with a dimin­
ished apnoeic threshold imply that the ventilatory response curves to C0 2 intersect at a 
PETC0 2 of about 5 kPa. At a PETC0 2 below this value acetazolamide stimulates ventilation 
during moderate hypoxaemia in anaesthetized cats. 
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Figure 3. Scatter diagrams of the effect of 4 mg.kg1 acetazolamide on Sc, Sp and B. 
Intravenous infusion of 4 mg.kg'1 acetazolamide results in a decrease in the values of all parameters 
shown. Each individual cat is represented by a separate symbol. 
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PARAMETERS CONTROL ACETAZOLAMIDE 
Β (kPa) 
Sc(L.min-1.kPa-1) 
Sp(L.min-1.kPa-1) 
Tp(s) 
Xp(S) 
Tc(s) 
τ„„(5) 
τ„«(5) 
St. Bicarbonate (mmol.L1) 
P(a.ET)C02 (kPa) 
2.88 ± 0.97 
0.74 ± 0.32 
0.22 ± 0.08 
4.2 ±1.1 
2.6 ±1.9 
9.9 ±2.4 
56.3 ±21.5 
108.7 ±24.2 
21.89 ±1.42 
0.30 ± 0.20 
0.95 ± 0.92* 
0.40 ±0.10* 
0.11 ±0.03* 
5.6 ± 0.9* 
2.9 ±2.0 
9.3 ±2.8 
73.8 ± 30.9* 
119.1 ±22.4 
19.94 ±1.00* 
0.44 ± 0.25* 
Table 1. Effects of 4 mg.kg1 acetazolamide on the ventilatory C0 2 response curve in seven cats 
during hypoxaemia (Pa02=6.8 ± 0.8 kPa). Β is the X-intercept of the ventilatory C0 2 response curve 
Sp and Se are the gains of the peripheral and central chemorefiex loops, with time constants τ
ρ
 and 
τ
ο η
 or τ^, respectively and delay times Tp and T c . Values are presented as mean of the means per 
animal ± S.D. *: significantly different from control. 
PETC02(kPa) 
Figure 4. Effect of acetazolamide on the ventilatory C 0 2 response curve. 
Effect of 4 mg.kg'1 acetazolamide on the ventilatory C0 2 response curve, calculated from the mean 
data in eight cats The continuous line represents the control situation and the dashed line the 
situation after 4 mg.kg'1 acetazolamide. The dotted line is a hypothetical line representing the C0 2 
response curve when an additional metabolic acidosis is allowed to develop as in chronic administra­
tion in humans. Note that a metabolic acidosis causes an appreciable left shift of the curve resulting 
in a widening of the therapeutic range in which acetazolamide induces an increase in ventilation. 
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3.5. DISCUSSION 
In this study the effects of acetazolamide on the ventilatory C02 response curve were 
investigated in hypoxaemic cats A dose of 4 mg.kg"1 caused an increase in the P(a-ET)C02 
difference as small as 0.14 kPa, indicating marginal inhibition of erythrocytic carbonic 
anhydrase [11,25]. Based on this finding it was concluded that the effects of acetazolamide 
could be studied without the complication of significant tissue C02 retention. 
The main results of this study are that, in hypoxaemic cats, 4 mg. kg1 acetazolamide causes 
a decrease in both the Sp and Sc and a decrease in the value of the apnoeic threshold B, 
resulting in a ventilatory stimulation at PETCC^ levels below 5 kPa. 
The decrease in Sp from 0.22 ± 0.08 to 0.11 ± 0.03 Lmin'1.kPa"1 could possibly be ex-
plained by a direct effect of the drug on the carotid bodies, since they contain the enzyme 
carbonic anhydrase [15]. The decrease in Sp found in the present study is in agreement 
with our previous observation in normoxaemic cats [24]. The absolute values of Sp and Sc 
in this study are lower than the ones in the normoxaemic study [24]. For unknown reasons, 
the cats in the present study needed more supplemental anaesthesia than the previous 
group This made both Sp and Sc decline by the same percentage. This means that the 
ratio Sp/Sc is unaffected by anaesthesia as shown by van Dissel et al. [27]. 
After a bolus infusion of 4 mg. kg"1 acetazolamide a transient initial fall in ventilation was 
observed (fig. 2). This may indicate that acetazolamide acts directly on the carotid bodies 
since, during hypoxaemia, the contribution of the peripheral chemoreceptors to the ventila-
tion is larger than in normoxaemia. This is illustrated by the fact that in the present study 
the ratio Sp/Sc was 0.30, while in the previous study in normoxaemic cats - where the initial 
fall in ventilation induced by acetazolamide was smaller - this ratio was 0.18 [24]. In 
hypoxaemic cats, 50 mg.kg1 acetazolamide causes a short initial period of apnoea, while 
the ventilatory response to hypoxia is virtually abolished at this dose [28,29]. Several other 
studies have shown that acetazolamide at doses of 25-100 mg.kg1 (i.v.) causes a decrease 
in chemosensitivity of the carotid bodies [30,31]. 
The central nervous system, particularly glial cells, and possibly also the central 
chemoreceptors contain carbonic anhydrase [16,17,21]. Consequently, the decrease in Sc 
could be due to a direct effect on the central chemoreceptors, affecting the central 
chemoreflex loop 
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This is unlikely for the following reasons 1 because of its physicochemical properties, 
acetazolamide passes the blood brain bamer very slowly [16,18,32] and 2 to achieve the 
full physiological effect, more than 99% inhibition of the carbonic anhydrase is needed 
[16,18] Therefore, 1 hour after administration of 4 mg kg 1 acetazolamide insufficient 
inhibitor will have reached the central chemoreceptors to cause effective inhibition of local 
carbonic anhydrase Inhibition of central nervous system carbonic anhydrase by the more 
lipophilic drug methazolamide results in an increase in Sc [33], the opposite effect to that 
observed in the present study 
It was previously suggested that the effect of acetazolamide on Sc is probably due to an 
indirect effect on the central chemoreflex loop, namely by a direct effect on cerebral vessels 
and consequently on cerebral blood flow regulation This results in a change in the relation­
ship between PbtCC^ (which is considered as the direct stimulus to the central 
chemoreceptors) and PaC02 [24] This relationship was previously descnbed by 
Berkenbosch et al [34], Read et al [35] and Teppema ef al [33] and is simplified to 
PbtC02 = aPaC02 + β 
Among other factors, the slope α depends on the cerebral blood flow response to changes 
in PaCO, The intercept β includes brain metabolism density and the slope of the linearized 
blood CO2 dissociation curve, which we assumed to be constant [24] 
During hypoxaemia, cerebral blood flow is increased resulting in a parallel shift of this linear 
relation between PbtC02 and PaC02 to lower levels of PbtC02 without a change in slope 
(ι e no change in parameter α in the above formula) [36] So, the present finding that 
dunng hypoxaemia the decrease in Sc by acetazolamide was about equal to that observed 
in normoxaemic cats is not unexpected, and indicates that the effect of low-dose 
acetazolamide on the slope of the relation between PbtC02 and PaC02 is not influenced by 
the level of Pa02 and the concomitant change in cerebral blood flow 
There is no clear explanation for the fact that the decrease in the apnoeic threshold in the 
hypoxaemic cats of the present study was larger than in normoxaemic animals (2 vs 1 kPa) 
[24] The DEF technique is unable to separate the apnoeic threshold Β into a penpheral and 
a central part As shown previously, the value of Β depends on the relation between PbtC02 
and PaC02 (ι e parameter α in the above formula) [24], but also on Sp [37] 
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Companson with human studies 
In a previous study in the authors' laboratory [4] in which hypercapnic and hypoxaemic 
COPD patients were examined, an increase in the slope of the expiratory minute ventilation 
(V'E) - PETCO2 response curve was observed after administration of acetazolamide This 
was also found in healthy volunteers [13, 38] These results differ from the present data 
obtained in anaesthetized animals, since a decrease was found in both slope and apnoeic 
threshold 
Apart from the use of anaesthesia [39] and from species differences [16] there are several 
other possible explanations for these differences 
The use of PETC02 as independent vanable In most human studies, ventilatory CO2 re­
sponse curves are measured using the PETCO2 as the independent variable In COPD 
patients, however, PETCO2 will not be representative of PaC02 because of the presence of a 
Ρ(3ΕηΟθ2 gradient Furthermore, after acetazolamide infusion the relationship between 
PaC02 and PETCOJ may change, due to both a higher level of ventilation and a change in 
ventilation/perfusion ratio's So, to find out whether the sensitivities of the chemoreceptors 
to changes in PC02 are altered, PETC02 seems to be an mappropnate independent vanable 
Illustrative in this context may be the study of Lerche et al [12] who reported a parallel shift 
of the C0 2 response curve in healthy subjects Re-analysing their data by means of linear 
regression, using PaC02 as the independent vanable, reveals that acetazolamide reduced 
the slope of the Ve-PaCC^ relationship by approximately 30% 
The use of the rebreathmg method for the C0 2 response In several human studies the 
Read rebreathmg method was used to estimate ventilatory CO2 sensitivity [1,9,13] Dunng 
chronic use of acetazolamide, however, a considerable metabolic acidosis ensues, resulting 
in a decrease in PaCC^ (and PerGCy As argued by Linton ei al [40] and Berkenbosch et 
al [34] this may lead to a considerable overestimation of the CO2 response slope in this 
situation 
Acute versus chronic use of acetazolamide Acetazolamide is used in COPD-patients in a 
chronic setting and administered orally Swenson and Hughes [38] showed that chronic and 
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acute administration of acetazolamide affected the slope of the V'E-PETC02 response curve 
differently chronic use resulted in an increase in slope of the hypoxaemic V'E-PETC02 
response curve, whereas acute administration of the drug had the opposite effect There-
fore, acute and chronic administration of acetazolamide may have different effects on the 
C02 response slope and this may explain why acute administration in cats - as in humans -
results in a decrease in slope of the hypoxaemic V'E-PETC02 response curve 
Another difference in the effect of chronic and acute administration of acetazolamide is that 
in the former case a metabolic acidosis ensues, while this is absent in the latter [38] This 
agrees with the present study in which acute administration of acetazolamide only caused a 
very limited metabolic acidosis 
Clinically, the chronic use of acetazolamide can be extra advantageous since even in the 
case of a decrease m slope of the V'E-PaC02 response curve the point of iso-ventilation will 
be shifted to a higher PC02 level Consequently, the PaC02 range in which acetazolamide 
increases the level of ventilation will be extended considerably (see fig 4) This is caused 
by a shift of the ventilatory C02 response curve to lower PC02 values induced by the 
ensuing metabolic acidosis 
Further clinical studies are needed to document the effects of chronic use of acetazolamide 
in patients with chronic obstructive pulmonary disease, using arterial carbon dioxide tension 
as independent variable 
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4.1. SUMMARY 
Both medroxyprogesterone acetate (MPA) and acetazolamide (ACET) increase ventilation 
Combined administration of these agents could result in an additional improvement of blood 
gases, for example in patients with chronic obstructive pulmonary diseases The aim of this 
study in anaesthetized female (ovanohysterectomized, pre-treated with 17-ß-estradiol) cats 
was to compare the effects on the C02 response curve of MPA alone (4 pg kg1, ι ν ) with 
those after MPA followed by ACET (4 mg kg 1 ,ι ν ) We performed dynamic end-tidal C02 
forcing and analysed the data with a two-compartment model comprising a fast peripheral 
and slow central compartment, characterized by C0 2 sensitivities (Sp and Sc, respectively) 
and a single offset (the apnoeic threshold B) MPA reduced Sp from 0 22 ± 0 09 (mean ± 
S D ) to 0 13 ± 0 06 L mm1 kPa1 (p<0 01) and Sc from 1 01 ± 0 38 to 0 88 ± 0 32 L mm1 
kPa1 (p<0 01) Β decreased from 4 02 ± 0 27 to 3 64 ± 0 42 kPa (P<0 01) Subsequent 
administration of ACET reduced Sp and Sc further to 0 09 ± 0 06 and to 0 70 ± 0 49 L mm1 
kPa1 (p<0 01), respectively The apnoeic threshold decreased further to 2 46 ± 1 50 kPa 
(p<0 01) Because both treatments reduced ventilatory C0 2 sensitivity, we conclude that a 
simulating effect on ventilation is due to a decrease in the apnoeic threshold Combined 
administration of MPA and ACET may lead to larger increases in ventilation than treatment 
with either drugs alone 
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4.2. INTRODUCTION 
During human pregnancy and the luteal phase of the menstrual cycle ventilation is 
increased, for which the high plasma level of progesterone may be responsible (for review 
see Dempsey ef al, 1986 [1]) Progesterone, or the synthetic progestérones 
medroxyprogesterone acetate (MPA) and Chlormadinone acetate are sometimes used in 
hypoxic and hypercapmc patients with severe chronic obstructive pulmonary disease to 
stimulate ventilation and improve blood gas values [2-4] In man, progesterone may 
increase ventilation by an effect on the hypothalamus and/or structures in the medulla 
oblongata eg [1, 2, 5-7] A possible action on the peripheral chemoreceptors is indicated 
by the finding that during human pregnancy the hypoxic ventilatory response is increased 
[8] Progesterone may also influence the tone of upper airway muscles in patients with 
obstructive sleep apnea, MPA was found to reduce the frequency of upper airway 
obstructions [9, 10] Data from animal studies also indicate that progesterone may stimulate 
breathing by an effect on peripheral and/or central sites [11-13] Guinea pigs, dogs and cats 
but not rats, goats, ponies and cows respond with an increased hypercapmc ventilatory 
response to progesterone administration [1] Failure to show this response may be related 
to species or gender, or may be due to specific expenmental circumstances such as level of 
arousal, pre-treatment with estradiol and dose [1, 14, 15] An increase in hypoxic sensitivity 
by progesterone was reported in cat and rat [13, 16] A second agent used to improve blood 
gases in some hypercapmc and hypoxic patients with chronic obstructive pulmonary 
disease is the carbonic anhydrase inhibitor acetazolamide (ACET) e g [3, 4] It is generally 
believed that this beneficial effect of ACET is due to a metabolic acidosis - induced increase 
m ventilatory dnve However, since carbonic anhydrase is present in many tissues and cells 
involved m the control of breathing, the respiratory effects of ACET may be much more 
complicated For example, in a previous study in anaesthetized cats we showed that low-
dose ACET (4 mg kg Ί) causes a decrease in both the slope and X-mtercept of the C0 2 
response curve [17] A large dose of the agent (50 mg kg1) totally abolishes the hypoxic 
ventilatory response [18, 19] Although MPA and ACET may act via different mechanisms, it 
is possible that (part of) their respiratory effects are due to an action on common structures, 
for example carotid bodies It would be interesting, therefore, to compare the effects of a 
combined application with those of single treatments, and this was the aim of this study In 
ovanohysterectomized, lightly anaesthetized female cats pre-treated with estradiol, we 
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measured the effects of MPA and those of a subsequent administration of acetazolamide 
on the slope and intercept of the C02 response curve. This enabled us to compare the 
effects of combined MPA + ACET administration with those of a single treatment with ACET 
as documented in a previous study [17]. To be able to separate the effects of MPA and 
ACET on the peripheral and central chemoreflex loops, we applied the dynamic end-tidal 
forcing technique and analysed the ventilatory data with a two-compartment model, 
comprising a fast peripheral and slow central component [20]. 
4.3. METHODS 
Animals, surgery and measurements 
The present experiments were performed in eight female cats (body weight 3.4-4.1 kg). 
The use of the animals was approved by the Ethical Committee for Animal Experiments of 
the Leiden University Medical Center. An ovariohysterectomy was performed at least 1 
month prior to the experiments The animals were pre-medicated with 10 Mg.kg'1 17-ß-
estradiol (E2 ) (Sigma-Aldrich, Bomem, Belgium), dissolved in sesame oil (100 Mg.ml"1), 
twice daily subcutaneously during 3 days immediately prior to the study [11]. Plasma 
concentration of 17-ß-estradiol in seven cats was estimated by a radioimmunoassay (RIA) 
method with extraction using anti-estradiol antibody-coated tubes (Coat-A-Count TKE; 
Diagnostic Products, Los Angeles, CA, USA) [21] For the RIA of 17-ß-estradiol, the limit of 
quantitation was 2 pg.ml1 and the intra- and interassay coefficients of variation were 8 and 
10%, respectively. On the day of the experiment the animals were pre-medicated with 15 
mg kg"1 ketamine hydrochloride (i.m.). Anaesthesia was induced by inhalation of a gas 
mixture containing 0.5-1% halothane and 30% 0 2 in N2 . After cannulation of the femoral 
veins and arteries, an initial dose of 20 mg.kg'1 α-chloralose and 100 mg.kg'1 urethane was 
slowly infused intravenously and the addition of halothane to the inspirate was discontinued. 
Anaesthesia was maintained with a continuous infusion of 1-1.5 mg.kg"1 h'1 a-chloralose 
and 5.0-7.5 mg.kg1.h1 urethane. Comparison of our studies with those of others in awake 
cats shows that this anaesthetic regimen has little effect on the ventilatory response to C02, 
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and does not yield systemic changes of the ventilatory parameters in time [22] Rectal 
temperature was monitored with a thermistor and ranged from 36 1 to 38 3°C among 
animals The trachea was cannulated and connected to a respiratory circuit One femoral 
artery and vein were connected to an extracorporeal circuit (ECC, flow 6 ml mm1) for 
continuous blood gas measurements Respiratory airflow was measured with a Fleisch No 
0 flow transducer (Fleisch, Lausanne, Switzerland) connected to a differential pressure 
transducer (Statham PM197, Los Angeles, CA USA), and was electronically integrated to 
yield tidal volume The composition of the inspirate was regulated by computer-steered 
mass flow controllers (type AFC 260, Advanced Semi-conductor Matenals, De Bilt, The 
Netherlands), using pure 02, C02 and N2 The C02 and 02 concentrations in the tracheal 
gas were continuously measured with an infrared analyser (Gould Godart MK2 
Capnograph, Bilthoven, The Netherlands) and a fast-responding zirconium oxide cell 
(Jaeger 02-test, Wurzburg, Germany), respectively Artenal pH, PC02 and P02 in the blood 
passing through the ECC were measured continuously with a pH electrode (Radiometer E-
5037-0, Copenhagen, Denmark), calibrated with phosphate buffers, a PC02 electrode 
(General Electnc A312AB, Milwaukee, Wisonscm, USA) and a home made Clark-type P02 
electrode The PC02 and P02 electrodes were calibrated with water equilibrated with C02 -
0 2 - N2 gas mixtures delivered by a gas-mixing pump (Wosthoff Bochum, Germany) The 
PC02 electrode was recalibrated approximately every 2 h and corrections were made for 
drift when necessary Artenal blood pressure was measured using a pressure transducer 
(Statham P23ac, Los Angeles, CA, USA) All signals were recorded on polygraphs, digitized 
(sample frequency 100 Hz), processed by a PDP 11/23 computer (Digital Equipment Corp , 
Maynard, MA, USA) and stored on disc Values of ventilation, tidal volume, breathing 
frequency, arterial blood pressure, end-tidal and artenal blood gas tensions (PrrC02, PET02, 
PaC02 Pa02 ) were stored on a breath-by-breath basis 
Expenmental protocol 
The ventilatory responses to CO2 were studied using the dynamic end-tidal forcing 
technique (DEF) [20] This technique was developed to force the end-tidal PC02 (PETC02) 
and P02 (PET02) to follow a specific dynamic pattern by manipulating the inspired C02 and 
02 concentrations, performed automatically by feedback control with a computer 
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The PBTC0 2 and PET02 can be adjusted to desired values independent of the ventilatory 
response and of the gas tensions in the mixed venous return [20]. Each DEF-run started 
with a steady-state period of ventilation of about 2 min. Next, the PETC02 was elevated 
stepwise by about 1-1.5 kPa within one or two breaths, maintained constant for a period of 
6-7 min, and then lowered stepwise to the previous value and kept constant for a further 
6-7 min (Fig. 1). The PET02 was kept constant at about 15 kPa throughout all runs. In each 
cat three to five control DEF-runs were performed. After the control runs, 4 Mg.kg1 
medroxyprogesterone acetate (MPA) (Sigma-Aldrich, Bomem, Belgium), dissolved in 9.6% 
ethanol (0.4 ml.kg1) was administered intravenously. About 15 min after administration of 
the drug, another three to five DEF runs were performed. Thereafter, 4 mg.kg1 
acetazolamide (ACET; Diamox, ΑΗΡ Pharma, Hoofddorp, The Netherlands) in saline (2 
mg.ml'1) was given intravenously. After a stabilisation period of about 45 min, three to five 
final DEF runs were performed. 
Data analysis 
The steady-state relation of ventilation (V',) to PETC02 at constant PET02 in the cat is linear 
down to the PETC02 axis: 
V', = (SP+SC)(PETC02 - B) (1) 
The parameters Sc and Sp are the C0 2 sensitivities of the peripheral and central 
chemoreflex loops, respectively and the offset Β represents the apnoeic threshold or 
extrapolated PETC02 at zero ventilation. 
For the analysis of the dynamic ventilatory response, we used a two-compartment model 
[20] 
^VVdt + V'e = SC(PETC02 (t-Tc)-Bc) (2) 
TpV'p/dt + V p = SP(PETC0 2 (t-TpJ-Bp) (3) 
το = τ 0 ηΧ
 +
 (1-Χ)τ
Ο Ι Τ
 (4) 
Vffl = Veit) + V'p(t) + C.t (5) 
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Fig 1 Examples of three DEF runs and the model fits of the ventilatory responses control situation, 
after MPA and after additional ACET administration 
The upper trace shows the input function of PETC02 The curve through the breath-by-breath 
ventilatory data points (dots) is the model fit The two lower traces show the contnbutions of the 
central (V'c) and penpheral (V'p) chemoreflex loops, respectively, to the model output (V'i) 
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Eq (2) descnbes the dynamics of the slow central chemoreflex loop with the central C0 2 
sensitivity Sc, time constant TC and transport delay time to the central chemoreceptors Tc , 
similarly Eq (3) descnbes the dynamics of the fast penpheral chemoreflex loop with the 
penpheral C0 2 sensitivity Sp , time constant τ ρ and delay time Tp The offset Β represents 
the apnoeic threshold or extrapolated PETC02 at zero ventilation To model the central time 
constant of the on-transient to be different from the off-transient, we used Eq (4) When 
PETC02 IS high (on-transient) we take x=1 and when PETCC^ IS low (off-transient) we take 
x=0 In most experiments a small drift in the ventilation was present Therefore, we included 
a drift term C t, as can be seen in Eq (5) The parameters of the model were estimated 
simultaneously using the actual PETC02 as input and by fitting the data with a least squares 
method To obtain optimal time delays, we performed a "gnd search" All combinations of Tc 
and Tp (increments of 1 sec and Tc>Tp ) were tned until a minimum in the residual sum of 
squares was found The minimal time delays were, somewhat arbitrarily, chosen to be 1 sec 
and τ
ρ
 was constrained to be at least 0 3s [20] 
Statistical analysis 
To compare the values of the parameters obtained in the three different expenmental 
conditions with each other, ANOVA was performed, using a fixed model The level of 
significance was set at 0 02 (with Bonferrom correction) To compare the combined therapy 
(MPA+ACET) with the results of single ACET administration from our previous study [17], 
the Rayn-Emot-Gabnel-Welsh multiple range test was performed (significance at p<0 05) 
Unless otherwise indicated, results are given as means ± S D 
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4.4. RESULTS 
One month after ovanohysterectomy in seven of eight cats, the mean plasma concentration 
of (E2 ) was 6 92 ± 1 7 pg ml1 (see also [16]) After E2 -pnmmg, the E2 concentration in 
these cats increased to a mean of 567 2 ± 396 4 pg ml 1 (in one animal, E2 concentrations 
were not determined) Thirty-seven DEF runs were performed dunng the control situation, 
33 after MPA administration and 24 after additional infusion of ACET In Fig 1 examples of 
three DEF-runs in one animal are shown, each performed under these three different 
experimental conditions In Table 1 the effects of 4 pg kg 1 MPA and 4 mg kg 1 ACET on all 
relevant parameters are summarized After treatment with MPA, the mean C02-sensitivity of 
the penpheral chemoreflex loop (Sp) in eight cats decreased significantly from 0 22 ± 0 09 
to 0 13 ± 0 06 L mm1 kPa1 , while that of the central chemoreflex loop (Sc) was reduced 
from 1 01 ± 0 30 to 0 88 ± 0 32 L mm1 kPa1 The mean apnoeic threshold Β decreased 
from 4 02 ± 0 27 to 3 64 ± 0 42 kPa 
Parameter 
Β (kPa) 
Stot (L mm1 kPa1) 
Sc(Lmin 1 kPa 1 ) 
Sp(Lmin 1 kPa 1 ) 
St bicarbonate 
(mmolL1) 
control 
(a) 
4 02 ± 0 27 
1 23 ± 0 39 
1 01 ± 0 38 
0 22 ± 0 09 
20 61 ± 2 98 
MPA 
(b) 
3 64 ± 0 42 
1 02 ± 0 33 
0 88 ± 0 32 
0 1 3 ± 0 0 6 
21 11 ± 2 55 
MPA+ACET 
(c) 
2 46 ± 1 50 
0 78 ± 0 51 
0 70 ± 0 49 
0 09 ± 0 06 
20 44 ± 3 91 
p-value 
(a-b) 
0 0001 
0 0001 
0 0001 
0 0001 
0 2000 
(b-c) 
0 0001 
0 0001 
0 0001 
0 0248 
0 0003 
(a-c) 
0 0001 
0 0001 
0 0001 
0 0001 
0 0056 
Table 1 Effects of 4 \ig kg1 MPA and additional infusion of 4 mg kg1 acetazolamide on the ventilatory 
C02 response curve m eight cats 
Sc and Sp are the C02-sensitivities of the central and penpheral chemoreflex loops Β is the intercept 
on the PETC02 -axis of the C02 ventilatory response curve Values are presented as mean of the 
means per cat ± S D The p-values are obtained from the ANOVA on all individual data 
The effects of MPA in each individual animal are shown in the scatter diagrams of Fig 2 
After ACET administration, the mean Sp and Sc were further reduced to 0 09 ± 0 06 and to 
0 70 ± 0 49 L mm1 kPa1, respectively The mean apnoeic threshold Β decreased further to 
2 46 ± 1 50 kPa 
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Fig. 2. Scatter diagrams of the effect on 4 pg.kg1MPA on the ventilatory parameters 
Intravenous infusion of 4 pg.kg1 MPA results in a decrease in the values of the parameters shown. 
Each individual cat is represented by a separate symbol. Sc and Sp are the C02 sensitivities of the 
central and peripheral chemoreflex loops (Lmin1. kPa1), respectively, and Β is the x-intercept of the 
ventilatory PETC02 response curve (kPa). 
Fig. 3 shows the effects of ACET in each individual animal. For comparison, in Table 2 we 
also show the effects of a treatment with 4 mg.kg"1 ACET alone as reported previously in 
anaesthetized cats [17]. Since both MPA and ACET cause a reduction in both slope and X-
intercept of the C0 2 response curve, the qualitative effect on ventilation (stimulation or 
inhibition) will depend on the arterial PC02 level at which the infusions are performed. Any 
stimulatory effect on ventilation must result from the reduction in the apnoeic threshold. 
Conversely, any inhibiting effect would result from the decrease in C0 2 sensitivity, despite 
the reduction in B. The mean values of the slope (Stot) and intercept (B) of the C0 2 
response curve shown in Tables 1 and 2 can be used to calculate the level of ventilation at 
any constant end-tidal PC02 value after the different drug treatments. The overall result of a 
combined administration of MPA and ACET was a reduction in slope by 37%. 
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A slightly larger reduction (42%) was observed after ACET alone (Table 2, from Wagenaar 
et al., 1996 [17] comparison with the Rayn-Einot-Gabriel-Welsh multiple range test yielded 
no significant difference between these decreases in slope). MPA alone caused a slope 
reduction by 17% only (Table 1). Given the much larger decrease in mean apnoeic 
threshold after the combined treatment (1.56 kPa; Table 1) than after MPA (0.38 kPa; Table 
1) or ACET (1.00 kPa; Table 2) alone, it can be calculated that the stimulatory effect on 
ventilation of MPA+ACET, when administered at normo- and hypocapnic PC02 values, is 
considerably larger than that of a single treatment with MPA or ACET. 
0 1 2 3 4 
Β MPA (kPa) 
E 1-6 • 
< 
Q. 
a. 
+ 
υ 
< 
u 
(0 
Sp MPA (Lmin .kPa ) 
Sc MPA (L.min '.kPa ' ) 
Fig. 3. Scatter diagrams of the effect on 4 mg.kg1 ACET after pre-treatment with MPA on the 
ventilatory parameters. 
Intravenous infusion of 4 mg.kg'1 ACET after pre-treatment with MPA results in a decrease in the 
values of the parameters B, Sc and Sp. Each individual cat is represented by a separate symbol. Sc 
and Sp are the C0 2 sensitivities of the central and peripheral chemoreflex loops (L.min'1.kPa1), 
respectively, and Β is the x-intercept of the ventilatory PETC0 2 response curve (kPa). 
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Parameter Control ACET p-value 
Β (kPa) 4 0 ± 0 5 
Stot (L mm 1 kPa1) 1 80 ± 0 69 
Sc (L mm1 kPa1 ) 1 52 ± 0 55 
Sp(Lmin1kPa1) 0 28 ±0 18 
3 0 ± 0 6 
1 03 ± 0 26 
0 84 ± 0 21 
0 1 9 ± 0 1 2 
0 0001 
0 0001 
0 0001 
0 0001 
Table 2 Effects of a single ACET treatment (4mg kg1) on the ventilatory C0 2 response curve in eight 
cats as determined m a previous study [17] 
Sc and Sp are the C02-sensitivities of the central and penpheral chemoreflex loops Β is the intercept 
on the PETC0 2 -axis of the C0 2 ventilatory response curve Values are presented as mean of the 
means per cat ± S D The p-values are obtained from the ANOVA on all individual data 
4.5. DISCUSSION 
In this study we found that in ovanohysterectomized cats pre-treated with 17-ß-estradiol, 4 
pg kg1 MPA decreased the C02 -sensitivities of the penpheral (Sp) and central chemoreflex 
(Sc) loops with 41 and 13%, respectively A subsequent administration of 4 mg kg1 ACET 
caused a further reduction in carbon dioxide sensitivities (Sp 31% and Sc 20%) Both 
agents lowered the mean apneic threshold by 0 38 and 118 kPa, respectively 
Effect of 17'-^-estradiol 
We used 17-ß-estradiol for premedication Bayhss et al [11] showed that priming with E2 is 
required to achieve a sustained facilitation of phrenic nerve activity by progesterone They 
showed progesterone receptors to be up-regulated by estradiol as was earlier described by 
MacLusky and McEwen [23] and Brodeur et al [14] 
Effects of MPA 
In man, progesterone increases the isocapmc acute hypoxic ventilatory response (AHR)[5, 
8, 24] Tatsumi ef al [25] showed that Chlormadinone acetate increased the AHR, provided 
it was measured at pre-drug PETC02 level Ovanohysterectomized cats possess smaller 
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isocapnic acute hypoxic ventilatory and carotid sinus nerve (CSN) responses to hypoxia 
than intact cats [26] Hannhart ef al [27] showed that CSN responses to isocapnic hypoxia 
increased after chronic exogenous or endogenous elevations in progesterone. Male rats 
treated with female hormones show a larger hypoxic ventilatory response than untreated 
males [13] The above studies clearly suggest a stimulatory action of female hormones on 
the peripheral chemoreceptors. Favier et al [13] showed that a direct effect may consist of 
a reduction in carotid body catecholamine content and -turnover. It seems unlikely, 
therefore, that the decrease in carbon dioxide sensitivity of the peripheral chemoreflex loop 
by MPA that we observed, is due to a direct effect on the carotid bodies. Apart from the 
peripheral chemoreceptors, the peripheral chemoreflex loop contains all afferent projection 
sites of chemosensory CSN fibers, respiratory integrating centres and the neuro mechanical 
link between the brain stem respiratory network and respiratory muscles. In caudal regions 
of the nucleus tractus solitarius (NTS) where chemosensory CSN afférents terminate, 
progesterone inhibits noradrenergic activity in the A2 catecholaminergic cell group [13] This 
may have a modulating effect on local afferent impulse transmission resulting in an 
alteration of the penpheral chemoreflex gam An important observation in the present study 
was that MPA not only reduced the peripheral, but also the central carbon dioxide 
sensitivity This decrease in chemoreflex gain is reminiscent of the decrease in baroreflex 
gain observed in pregnant rats and animals treated with 3a-OH dihydroprogesterone (3a-
OHDHP), an important metabolite of progesterone [28]. This effect is probably due to a 
potentiation by 3a-OHDHP of GABAA inhibitory influences in the NTS and in the rostro 
ventrolateral medulla, in the region were baro- as well as chemoreceptor inputs are 
integrated [28]. MPA, or its metabolites, may have reduced the C02 sensitivity in our 
animals via a GABA-related mechanism: an increase in GABA-ergic tonus in brain stem has 
an inhibitory effect on ventilation [29]. A similar mechanism could play a role in the 
hypothalamus, some regions of which contain progesterone receptors [11]. C02 sensitive 
neurons in the caudal hypothalamus modulate the respiratory response to increases in 
PC02 and are exposed a tonic GABA-ergic inhibition [30] 
Metabolites of progesterone increase anaesthetic depth and lessen the need for 
anaesthetics for surgery [31, 32]. This effect could be due to an increase in GABA-induced 
chloride conductance, and in this respect 3a-OHDHP may also be an important modulator 
[28]. It is possible that both factors, an increase in GABA-ergic tonus in the brain stem 
and/or hypothalamus and an increase in anaesthetic depth contributed to the observed 
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decrease in carbon dioxide sensitivity by MPA or its metabolites Apart from different routes 
of administration and experimental techniques, an effect related to anaesthetic depth may 
explain why no progesterone-induced decrease in ventilatory C0 2 sensitivity was reported in 
awake animals [15, 33, 34] or in humans [4, 5, 24, 35] 
The finding that the synthetic progestagenes MPA and Chlormadinone acetate, despite a 
much larger progestational activity, do not have larger effects on ventilation than 
progesterone [2, 36], may indicate that progesterone's metabolites are responsible for its 
respiratory effects, rather than the hormone itself 
The data in Table 1 show that the effect of MPA on ventilation is a mixture of excitatory 
(decrease in apnoeic threshold) and inhibitory (decrease in S) effects In other words, the 
net effect on ventilation depends on the PC02 level at which the agent is administered The 
rise in phrenic activity by progesterone in cats pre-treated with estrogen is probably 
mediated via hypothalamic structures [12] Stimulation of hypothalamic progesterone 
receptors may result in an increased excitatory input into the respiratory integrating centres 
explaining the decrease in apnoeic threshold that we observed in our cats An alternative 
explanation for the decrease in Β is a possible excitatory action of MPA on the carotid 
bodies (despite the decrease in Sp) A fall in the value of Β with approximately 0 4 kPa is 
within the range reported in the literature From data reported in humans and animals, we 
calculate that it vanes between 0 2-1 7 kPa [16, 24, 35-37] 
Effect ofACET after MPA treatment 
After pre-treatment with MPA, ACET administration caused an additional decrease in C0 2 
sensitivity of both the penpheral and central chemoreflex loops and a decrease in Β The 
latter effect, a fall in the mean apnoeic threshold by 1 18 kPa, was equal to that found 
without MPA pre-treatment (1 0 kPa, see Table 2, unpaired t-test yields p=0 34) The 
relative reduction in carbon dioxide sensitivity of the penpheral chemoreflex loop by ACET 
seems also independent of the pre-treatment with MPA in both studies we found a 
decrease by 32% ACET may cause this reduction in Sp by a direct action on the penpheral 
chemoreceptors [17] The relative decreases in Sc, with and without MPA pre-treatment, 
however, were 20 and 45%, respectively The relative changes in Stot were 37 and 42%, 
respectively Although unpaired t-tests yielded no significant difference between these 
changes in Sc and Stot by ACET, we cannot exclude that the respiratory effects of both 
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agents are not quite independent from each other. Previously, we ascribed the reduction in 
central carbon dioxide sensitivity by ACET to a possible action of the agent on cerebral 
vessels [17]. The fact that - to our knowledge - no direct effects of MPA on cerebral vessels 
have been described, could argue against an influence of MPA on the acetazolamide -
induced decrease in central CO2 sensitivity The additional finding that MPA apparently 
does not influence the ACET-induced considerable decrease in B, means that after 
pretreatment with MPA, ACET will cause a much larger net ventilatory stimulation than 
without pretreatment with the steroid. From the data in Tables 1 and 2, we calculate that a 
combined treatment (i.e. MPA followed by ACET), when applied at a constant end-tidal 
PC02 of 4.5 kPa, would augment ventilation by 116%. Without MPA pre-treatment, ACET 
would cause an increase by 66%. Single treatment with MPA would result m a rise of 35% 
only Note, however, that these calculations apply to a situation in which the end-tidal PC02 
is clamped, and that these differences in ventilatory effects depend on the prevailing PC02 
level. An extra ventilatory drive induced by a combined treatment of MPA with ACET could 
be efficient in (severe) hypercapnic COPD patients. Before treatment, resting ventilation 
and PC02 in these patients may be on the flat portion of the metabolic hyperbola. 
Independent decreases by both agents of the apnoeic threshold Β (as shown in this study in 
cats), would then result in a relatively small increase in ventilatory drive (shift of the C0 2 
response curve to the left), but to a large fall in artenal PC02 and, depending on the 
occurrence of lung regions with very low ventilation perfusion ratios, possibly also to a large 
rise in artenal P02. So in this respect, a combined treatment of MPA and ACET may be 
clearly more beneficial than single treatments. The present data were obtained after acute 
infusion of both agents. In clinical practice, however, ventilatory stimulants for patients with 
COPD are usually applied chronically, and this may lead to different pharmacodynamic 
effects. We have no animal data on effects of a combined treatment in which the agents 
were administered in the reverse order, i.e. ACET followed by MPA. In this study we did not 
exclude that MPA might modulate the effects of ACET on central C0 2 sensitivity. If this 
would be indeed the case, the respiratory effects of ACET followed by MPA could differ 
from the effects reported in this study. From what is known about the mechanisms of action 
of both agents, however, we consider it more likely that MPA and ACET act independently 
on the control of breathing. Our data do not conflict with this scenario. 
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5.1. SUMMARY 
Background. Acetazolamide (ACET) and medroxyprogesterone acetate (MPA) are two 
respiratory stimulants that can be used in patients with stable hypercapnic chronic 
obstructive pulmonary disease (COPD). 
Design and methods. The effects of ACET (250 mg b.i.d.) and MPA (30 mg b.i.d.) on day-
and nighttime blood gas values and the influences on the hypercapnic and hypoxic 
ventilatory and Poi response were studied in a cross-over design in 12 hypercapnic patients 
with stable COPD (mean F E ^ 33 ± 4 % Pred, mean ±sem). 
Results. The daytime PaC02 decreased from 6.3 ±0.1 (placebo) to 5.6 ± 0.2 kPa during 
ACET treatment (p<0.05) and to 5.7 ± 0.2 kPa during MPA (p<0.05). The daytime Pa02 
improved with ACET from 8.7 ± 0.3 to 10.0 ± 0.4 kPa (p<0 05), whereas no significant 
changes were seen with MPA. Mean noctumal PBTCOJ decreased with both treatments; 
from 5.6 ± 0.3 to 4.7 ± 0.3 kPa with ACET (p<0.05) and to 4.6 ± 0.1 kPa with MPA (p<0.05). 
The percentage of time that the noctumal Sa02 was lower than 90%, was reduced 
significantly with ACET from 34.9 ± 10.7 to 16.3 ± 7.5% (p<0.05). Mean noctumal saturation 
did not change with MPA. 
Resting minute ventilation increased significantly only with MPA from 9.6 ± 0.7 to 10.8 ± 0.8 
L.min'1 (p<0.05). The slope of the hypercapnic ventilatory response did not change during 
ACET and MPA therapy. The hypoxic ventilatory response increased from -0.2 ± 0.05 to 
-0.4 ± 0.1 Lmin1.%' during ACET (p<0.05) and to -0.3 ± 0.1 L.min-1.%-1 during MPA 
(p<0.05). The hypoxic Po ι response improved with ACET treatment from -0.007 ± 0.002 to 
-0.02 ± 0.003 kPa.%-1(p<0.05). 
Conclusions. This study shows that ACET and MPA both have favourable effects on day-
and nighttime blood gas parameters in ventilatory limited patients with stable COPD. 
However, the use of ACET is preferred because of its extra effect on noctumal saturation. 
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5.2. INTRODUCTION 
Some patients with severe chronic obstructive pulmonary disease (COPD) become 
chronically hypoxic and/or hypercapnic as the disease progresses In general, their 
prognosis is poor as shown by Cooper et al [1], who analyzed COPD patients 
retrospectively from the moment of death and concluded that hypoxia as well as 
hypercapnia were signs of imminent death within three years Moreover, Foucher et al [2] 
found that the rate of death in COPD patients on long term oxygen therapy (LTOT) was 
higher in the hypercapnic group (PaC02 > 5 7 kPa) as compared to the normocapnic group 
(PaC02 < 5 7 kPa) Hence, hypercapnia itself is probably an independent poor prognostic 
factor, although this is not supported by all investigators [1-3] Treatment of hypoxia with 
supplemental oxygen improves survival [4, 5] However, the degree of hypercapnia worsens 
in many patients dunng oxygen therapy, which may influence the prognosis This 
hypercapnia is probably due to a combination of a slightly worsened V7Q' mismatch, initial 
C02 retention with 0 2 mediated blunting of the peripheral chemoreceptor dnve, Haldane-
effect related changes in C02 and H+ buffering by hemoglobin [6] Dunng sleep, hypoxia 
and hypercapnia increase due to hypoventilation caused by a diminished intercostal and 
accessory muscle function dunng REM sleep stage, supenmposed on a dysfunctional 
diaphragm [7] Also, low hypoxic and hypercapnic ventilatory responses may contribute to 
the nocturnal hypoventilation 
The respiratory stimulants medroxyprogesterone acetate (MPA) and acetazolamide (ACET) 
may improve day- and nighttime blood gas values in COPD patients, although not all 
studies are consistent [8-13] 
ACET stimulates ventilation by inducing a metabolic acidosis [8, 14] In a previous study, we 
found an increase in the slope of the hypercapnic ventilatory response (HCVR) with ACET 
in COPD patients [9], in contrast to other studies in which only changes in intercept are 
shown [15, 16] The effect of ACET on the hypoxic ventilatory response (HVR) is equivocal 
in vanous studies ranging from no change [9, 15, 17] to an improvement [16] 
Progesterone increases ventilation via progesterone receptors in the hypothalamus [18] 
Most human studies show an increase in HCVR dunng (synthetic) progestagens [9, 13, 19] 
The results, however, on HVR are conflicting [9, 13, 19-21] 
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The aim of the present study is to compare the effects of ACET and of MPA on day- and 
nighttime blood gas values as well as hypercapmc and hypoxic ventilatory responses in 
chronic hypercapmc patients with COPD 
5.3. METHODS 
Patients 
Nineteen hypercapmc patients with severe COPD (age 68 ± 2 years), as defined by the 
American Thoracic Society [22], were enrolled in this study The patient's charactenstics are 
shown in table 1 Inclusion cntena were optimal bronchodilator treatment, daytime PaC02 i 
6 0 kPa, no long term oxygen treatment and the ability to lower the PETC02 at least 1 kPa, in 
a voluntary hyperventilation test, to establish the ventilatory pump reserve Exclusion cntena 
were exacerbation of COPD within the last three months, abnormal renal and liver 
functions, use of respiratory stimulating drugs and obstructive sleep apnea/hypopnea 
syndrome Seven patients dropped out of the study, after inclusion, because of an 
exacerbation, evenly distnbuted over both treatment modalities 
Study design 
In a double blind, randomized, cross-over study, the effects of ACET and MPA on daytime 
and nocturnal blood gas and ventilatory parameters were investigated The design is shown 
in figure 1 The patients were studied four times in six weeks, at the start of the study and 
before a change in medication (study points Ti-4 fig 1 ) All patients received placebo dunng 
the first two weeks to assess the intra-mdividual variability After the second and third 
measurements patients received either ACET (250 mg) + placebo or MPA (30 mg) + 
placebo twice a day (b id ) , all in identical capsules Written informed consent was 
obtained from all patients and the study was approved by the Hospital Ethics Committee 
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Placebo 
A A 
2 weeks 
ACET+Placebo MPA+Placebo 
250mg b.i.d. 30mg b.i.d. 
TaA T4M 
3M I 4A 
MPA+Placebo 
30mg b.i.d. 
ACET+Placebo 
250mg b.i.d. 
2 weeks t t 
2 weeks | 
Fig 1. Study protocol double blind cross over study. 
Tx,t=measurement. ACET= acetazolamide, MPA=medroxyprogesterone acetate. 
Daytime measurements 
Laboratory tests 
After each study night (at 9 a.m.) an arterial blood sample was taken after 15 minutes of 
rest (Ciba-Coming 278 blood gas analyzer, Houten, The Netherlands). Liver and renal 
functions were tested. 
Pulmonary function tests 
-Hypercapnic ventilatory response (HCVR) and hypoxic ventilatory response (HVR)-
The HCVR was assessed by the steady-state method [23]. The patient was connected to a 
closed spirometrie circuit (Pulmotest, Godart, Bilthoven, The Netherlands) via a mouthpiece. 
A Rudolph valve 2700 (Kansas City, Miss, USA) was placed in the system, to maintain a 
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one way circuit. The end-tidal carbon dioxide tension (PETCC^) level was measured by a 
side stream capnograph (Drager, Lübeck, Germany). Inspiratory PC02 could be gradually 
raised by adjusting a three-way valve, partly short-circuiting the C02 absorber in the 
inspiratory limb of the circuit. Two different levels of PETC02 were studied (PETC02 at zero 
PiC02, and PETC02 1-1.5 kPa above resting value). Both levels of PETC02 were maintained 
for at least 7 minutes. Oxygen was added to the system to keep Sa02 level >90%. Sa02 
was measured with a pulse oximeter (Oxyshuttle; Sensor Medics, Anaheim, CA, USA). At 
the end of each steady state period of the HCVR ("high" PC02 level) an arterialized capillary 
blood sample was taken. 
The steady state relation of ventilation (V'E) to PETC02 at constant PET02 was considered to 
be linear down to the PETC02 axis· 
V ' E = S ( P E T C 0 2 - B ) , 
in which the parameter S is the C02 sensitivity of the peripheral and central chemoreflex 
loops and the offset Β the apnoeic threshold or extrapolated PETC02 at zero ventilation. 
The mouth occlusion pressure (Po i) [24] was measured during the final two minutes of each 
steady state period at the two different levels of PETC02 using a solenoid valve, in the 
inspiratory part of the circuit. 
The HVR was performed by inducing progressive hypoxia. PETC02 was maintained at the 
initial pre-drug level (placebo, T2) during all HVR tests, by adding C0 2 to the inspirate, when 
necessary. All patients started the test at a Sa02 level of 98% by adding supplemental 
oxygen. Then, the oxygen supplementation was stopped and the HVR test was performed 
until Sa02 reached 80%, which took less than seven minutes. 
-Spimmetry-
Forced expiratory volume in 1 second (FEV,), inspiratory vital capacity (IVC), total lung 
capacity (TLC) and residual volume (RV) were performed with a wet spirometer and He 
dilution technique (Pulmonet III, SensorMedics, Anaheim, CA, USA), respectively 
Reference spirometnc values were derived from ERS standards [25]. 
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Subjective parameters 
After each study period the dyspnea sensation was scored with the modified Medical 
Research Council (MRC)-scale [26]. Side effects of the drugs were noted. 
Nocturnal measurements 
The nocturnal arterial oxygen saturation (Sa02) was measured with a pulse oximeter The 
baseline Sa02 'awake' was defined as the mean Sa02 during the first 15 minutes, when the 
patient was awake and in supine position [27]. The PETC02 was measured by sampling air 
through a naso-pharyngeal cannula (Mijnhardt capnolyser, Bilthoven, The Netherlands) [9] 
The mean PETC0 2 and SaOj were defined as the mean PETC02 and Sa02 of the total 
recording time. Oxygen saturation, and PETC02 signals during the night were stored on a 
computer (Compaq 4/66, Houston, TX, USA). 
Statistical analysis 
Data are presented as mean values ± sem. Carryover effects were analyzed according to 
Pocock [28] by comparing the treatment with ACET as well as MPA in the different study 
arms (Mann-Whitney-U-test) (;'.e. for ACET: TSA minus Ts and TIA minus T2, for MPA· TIM 
minus T2 and TSM minus T2 ;(fig 1.)). After determining that there were no significant 
differences in mean values of the group between control (Τι) and placebo (T2), and that 
carryover effects could not be measured two weeks after stopping the previous medication, 
the data obtained in the "baseline situation" (mean of Ti and T2) were compared with those 
after ACET and MPA treatment (Wilcoxon signed rank tests). Statistical significance was 
defined as a p-value <0.05. For all analyzes SPSS (version 6.1.3, SPSS ine, Chicago, ILL, 
1995) was used. 
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5.4. RESULTS 
No significant differences were observed in ventilatory or in blood gas vanables after 
placebo treatment compared to control Hence, the mean data of the control and placebo 
measurements were used as baseline values in the analysis of the effects of ACET and 
MPA treatment Baseline charactenstics are shown in table 1 No carryover effects could be 
demonstrated with either drug regimen as shown in table 2 Therefore the analysis of the 
drug treatment could be simplified to baseline vs ACET treatment and baseline vs MPA 
treatment, irrespective of the sequence of the drugs 
general 
sex (M/F) 
age (years) 
weight (kg) 
height (cm) 
BMI (kg m ^ 
lung function 
TLC ("/opred ) 
RV (%pred ) 
FEV, (L) 
(%pred ) 
FEVJH/C (%pred ) 
arterial blood gases 
PH 
Pao2(kPa) 
PaCOj (kPa) 
BE (mmol L1) 
Sa0 2 (%) 
8/4 
68 ± 2 
68 ± 3 
170 ± 3 
23 ± 1 
105 ± 5 
168 ±14 
0 9 ± 0 1 
33 ± 4 
46 ± 3 
7 40 ± 0 01 
8 8 ± 0 3 
6 3 ± 0 2 
3 9 ± 0 5 
92 4 ± 0 9 
Table 1 Baseline charactenstics (Τι) (n=12) 
Data are presented as mean ± sem BMI=body mass index, TLC=total lung capacity, RV=residual 
volume, FEV, =forced expiratory volume in 1 second, IVC=inspiratory vital capacity, PaC02 = arterial 
carbon dioxide tension, Pa02 = artenal oxygen tension, BE = base excess, Sa02 = arterial oxygen 
saturation,%pred [25]. 
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PARAMETER 
PaCOj (kPa) 
Pa02 (kPa) 
VEO-.min1) 
Poi(kPa) 
SHCVR (L.min'.kPa·1) 
SHVR(L.min1.%-1) 
T4A minus T2 
0.510.1 
0.5 ±0.3 
0 7 ±0.9 
0 1 ±0.2 
4.6 ±1.3 
-0.1 ±0.1 
ACET 
TSA minus T2 
0.9 ±0.2 
0.6 ±0.5 
1.6 ±0.7 
0.1 ±0.0 
5.8 ±1.3 
-0.2 ±0.1 
Ρ 
0.24 
0.94 
0.59 
0.43 
0.59 
0 49 
T4M minus T2 
0.6 ± 0.2 
1.1 ±0.3 
0.0 ± 0.8 
0.1 ±0.1 
4.5 ± 1 1 
-0.3 ±0.1 
MPA 
T3M minus T2 
0 7 ± 0 1 
1 7 ±0.7 
0.9 ± 0 6 
0.2 ±0.1 
3 7 ± 0 4 
-0.3 ±0.1 
Ρ 
0.94 
0.49 
0.7 
1 
0.59 
0.31 
Table 2 Carryover effects. 
Differences in ventilatory and blood gas parameters between the various stages in the study, 
indicating that at Τι, no carryover effects from the previous medication could be shown Data are 
presented as mean ± sem. PaC02 = arterial carbon dioxide tension; Pa0 2 = arterial oxygen tension, 
V E =minute ventilation; P01 = mouth occlusion pressure at 100 msec; SHCVR (AVWAPaCOJ = the 
slope of the ventilatory CO, response curve; SHVR (AV'E/ASao2) = the slope of the hypoxic ventilatory 
response 
Daytime laboratory measurements 
The effects of ACET and MPA on daytime blood gas parameters are shown in table 3. The 
mean Pa02 improved significantly during ACET treatment by 1.3 ± 0.4 kPa (p<0.05), 
whereas the mean PaOj did not significantly increase with MPA. The mean PaCOj 
decreased significantly after treatment with ACET (0.7 ± 0.1 kPa) and MPA (0.6 ± 0.1 kPa) 
(both p<0.05). The mean decrease of PaC02 with ACET was significantly larger than that 
obtained with MPA treatment (p<0.05) (table 3, fig 2.). The base excess (BE) decreased 
significantly after ACET (-6.0 mmol.L1) and after MPA treatment (~2 mmol.L'1). 
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PARAMETER 
pH 
Pao2(kPa) 
PaC02 (kPa) 
APaC02 (kPa) 
BE (mmol L1) 
P(a-^C02 (kPa) 
Sa0 2 (%) 
BASELINE 
(Ti and Ti) 
7 40 ± 0 01 
8 8 ± 0 3 
6 3 ± 0 2 
-
3 9 ± 0 5 
0 8 ± 0 2 
92 4 ± 0 9 
ACET 
(T3A and T4A) 
7 35 ± 0 01* 
10 0 ± 0 4 * 
5 6 ± 0 2* 
-0 72 ±0 131 
-2 0 ± 0 7* 
0 7 ± 0 2 
93 8 ± 0 7 
MPA 
(TSM and T4M) 
7 41 ± 0 01 
9 3 ± 0 4 
5 7 ± 0 2* 
-0 61 ± 0 10 
2 1 ± 0 4* 
0 6 ± 0 2 
93 4 ± 0 8 
Table 3 Effect of ACET and MPA on daytime blood gas parameters 
Data are presented as mean±sem P(a-ET)C02 = artenal-to-end-tidal PC02 gradient hPaC02= mean 
change in PaC02 (drug versus baseline) (*p<0 05 between treatment and baseline, t p<0 05 between 
ACET and MPA treatment) 
re 
Q. 
< 
Q. 
ο 
η 
Q. 
< 
Ü.6 -
0.0 -
0.5 -
1.0 -
1.6 -
2.0 -
A A 
A 
A 
A A 
A 
A 
A 
1 1 —1 1 
-2.0 -1.5 -1.0 -0.5 0.0 
APaC02 (ACET) (kPa) 
0.5 
Fig 2 Effect of ACET and MPA on Δ PaC02 
The effect of Δ PaC02 (ACET) versus Δ PaC02 (MPA) in twelve COPD patients All data points are 
the individual data of each patient Dotted line identity 
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Ventilation and hypercapnic/hypoxic responses (table 4) 
Minute ventilation did not change significantly with ACET but increased significantly with 
MPA treatment (1.2 L.min1). The slope of the HCVR-curve did not differ significantly during 
ACET nor during MPA, as compared to baseline (fig 3). The ventilatory C 0 2 response curve 
showed a non significant shift to the left as indicated by a small decrease in apnoeic 
threshold BHCVR (x-intercept) both with ACET (from 3.2 to 2.1 kPa) and with MPA (from 3.2 
to 2 6 kPa). 
Po ι increased significantly with MPA, however, the slope and x-mtercept of the response of 
Po ι to PaC0 2 did not change significantly with ACET nor with MPA treatment 
The slope of the HVR significantly increased during ACET as well as during MPA therapy 
(fig 4) Only during ACET, the slope of the relationship between ΔΡο ι and ASao 2 was 
significantly increased (fig 5). 
PARAMETER BASELINE ACET MPA 
(Τι and Tz) (TSA and Τω) (Tam and ΤΑΜ) 
V'EO-mirV1) 9.7 ±0.8 10.0 ±0.6 10.8 ±0.8* 
Po ι at rest (kPa) 0 4 ± 0.04 0.4 ± 0.03 0 5 ± 0.04* 
SHCVR (L.min 1.kPa-1) 5.0 ±0.8 4.1 ±0.6 5.2 ±0.9 
BHCVR (kPa) 3.6 ± 0.6 2.1 ±0.7 2.6 ±0.7 
SHCR0 , (kPa.kPa1 ) 0.20 ± 0.02 0.3 ± 0.05 0.3 ± 0.04 
BHCR0 , (kPa) 4.0 ± 0.3 3.6 ± 0.3 3.4 ± 0.4 
SHVR (L.min'1.%1) -0 16 ±0.04 -0.4 ± 0 . 1 * -0.3 ± 0 . 1 * 
SHR^kPa.'/o1) -0.007 ± 0.001 -0.02 ± 0.003* -0.01 ± 0.003 
Table 4. Effect of ACET and MPA on ventilatory variables 
Data are presented as: mean ± sem. V'E = minute ventilation; VT = tidal volume; fresp = respiratory 
frequency; Pen at rest = mouth occlusion pressure at rest; SHCVR (AV'E/APaCOJ = slope of the 
ventilatory C 0 2 response curve; BHCVR (x-intercept) = apnoeic threshold or extrapolated PETC0 2 at 
zero ventilation; SHCRJ, (ΔΡΟ Ι /APaCOJ = slope of the mouth occlusion response to C0 2 ; BHCR01 = x-
mtercept of the mouth occlusion pressure response to C0 2 ; SHVR (AV'E/ASaOJ = slope of the hypoxic 
ventilatory response. SHR,,, (APoi/ASaOJ = slope of the mouth occlusion response to 0 2 . (*p<0.05 
between baseline and treatment) 
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Fig 3 Effect of ACET and MPA on the ventilatory COj response curve (HCVR). 
The effect of treatment with 250 mg b.i.d. ACET and with 30 mg b.i.d. MPA on the ventilatory C0 2 
response curve, calculated from the mean data in twelve severe COPD patients. 
The continuous line reprsents the baseline situation and the dashed lines the situations during ACET 
and MPA therapy. The continuous line of the metabolic hyperbola represents the situation with ACET 
treatment, the dashed metabolic hyperbola the one during MPA administration (calculated lines; 
Standard temperature and pressure (STPD)). 
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Fig 4. Effect of ACET and MPA on the relation Hypoxic Ventilatory Response (HVR). 
The effect of treatment with 250 mg b.i.d. ACET and with 30 mg b.i.d. MPA on the ventilatory 
response to 0 2 , calculated from the mean data in twelve severe COPD patients. 
The continuous line represents the baseline situation and the dashed lines the situations during ACET 
and MPA therapy. 
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Fig 5. Effect of ACET and MPA on the relation between Po ι and Sao2. 
The effect of treatment with 250 mg b.i.d. ACET and with 30 mg b.i.d MPA on the relation between 
Po ι and Sao2 calculated from the mean data in twelve severe COPD patients. 
The continuous line represents the baseline situation and the dashed lines the situations after 250 mg 
b.i.d. ACET and after 30 mg b.i.d. MPA, respectively. 
Subjective parameters 
In the ACET group three patients complained of paraesthesias and three patients with 
gastro-mtestmal discomfort. Seven patients reported side effects during MPA therapy 
(gastro-intestinal discomfort (n=5) and fatigue (n=2)). Dyspnea sensation (MRC-scale) did 
not change significantly after introduction of the drugs. 1.83 ± 0.17 at baseline to 1.83 ± 
0.24 (n.s.) during ACET therapy and to 2.33 ± 0.31 (n.s.) during MPA therapy. 
Nocturnal parameters 
Mean PETC0 2 decreased significantly by both ACET and MPA, with 0.9 and 1.0 kPa, 
respectively (table 5). The mean Sa02did not improve significantly with ACET. However, 
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the percentage of nocturnal recording time with saturation below 90% did improve 
significantly with ACET therapy from 34.9 ± 10.7 to 16 3 ± 7 5%. MPA did not significantly 
change nocturnal saturation. 
Mean PETC0 2 (kPa) 
MeanSao2(%) 
Lowest SaOj (%) 
% time Sa0 2 <90% 
BASELINE 
(Τι and T2) 
5.6 ±0.3 
90.6 ±1.0 
84.0 ±1.8 
33.3 ±10 5 
ACET 
(TSA and T«) 
4.7 ±0.3* 
92.0 ± 0.9 
83.7 ±2.7 
16.3 ±7.5* 
MPA 
( T M and T4M) 
4.6 ± 0 . 1 * 
91.6 ±1.0 
83.8 ±2.1 
23.8 ±11 5 
Table 5. Nocturnal parameters (n=12) 
Data are presented as: mean ± sem.(*p<0.05 treatment and baseline) 
5.5. DISCUSSION 
The present study showed that, in hypercapnic COPD patients, ACET and MPA both have 
favourable effects on several day- and nighttime blood gas parameters as well as on 
ventilatory responses; ACET showed more and larger effects than MPA. 
Daytime laboratory tests 
The present study showed that ACET improved daytime PaC02 and Pa02. This is in 
agreement with the literature [8, 9, 15]. The mechanism by which ACET improves daytime 
blood gas values is not yet clear. However, it is generally believed that the metabolic 
acidosis induced by ACET is responsible for the improvements. We observed an increase in 
daytime Pa02 of 1.3 kPa only with ACET. If one calculates A-aP02 differences, it appears 
that (assuming a respiratory exchange ratio of 0 8) acetazolamide has reduced the A-aP02 
difference by 0 5 kPa. Therefore, the improvement in Pa02 cannot be caused by an 
increase in alveolar ventilation alone, but it may also be due to a slight improvement of V7Q' 
matching and/or a small diuretic effect resulting in a decrease in interstitial lung water [6, 
29]. 
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In our previous animal studies [30, 31], we discussed that the effect of ACET on the HCVR 
may be caused by a direct effect on the carotid bodies as well as on the cerebral vessels, 
which may be responsible for the decrease in PaC02 and increase in Pa02. 
MPA improved daytime PaC02 as was shown by others [11, 32]. Skatrud et al. [33] divided 
their COPD patients in "correctors" (10/15), in whom tidal volume increased and PaC02 
decreased ( i 0.67 kPa) during both MPA and ACET administration, versus "non-
coiTectors"(5/15), showing no fall in PaC02 (< 0.67 kPa). This is in agreement with our study 
where minute ventilation increased by MPA treatment. In 7 out of 12 patients Paco2 
decreased >0.67 kPa and they should thus be considered "correctors". Our figure 2 
suggests that there is a wide inter individual range of responses, but we found no 
suggestion of two distinct groups of responders and non responders. 
Ventilation and hypercapnic/hypoxic responses 
The present data showed that neither ACET nor MPA therapy changed the slope and x-
mtercept of the hypercapnic ventilatory response (HCVR). This is in contrast with animal 
studies. In anaesthetized cats it was shown that the slope of the HCVR decreased by an 
acute low intravenous dose of ACET, which was attributed to a direct effect of ACET on the 
peripheral chemoreflex loop as well as an effect on cerebral blood flow regulation [30]. In 
humans, several authors studied the effect of acetazolamide on the ventilatory C02-
response using the Read rebreathing technique [17, 34]. It has been shown however, that 
during metabolic acidosis the Read rebreathing technique results in a considerable 
overestimation of the response slope [35] Swenson et al. [15] showed that in healthy 
volunteers acute intravenous infusion of the drug (1 intravenous dose of 500 mg ACET) 
resulted in a parallel shift of the HCVR to the left, whereas chronic administration (3 oral 
doses of 500 mg over 24 hours ACET) resulted in an increase in the slope of the HCVR. An 
explanation for the contradiction with our study could be the large chronic dose of ACET 
used by Swenson [15], the time sequence the drug was administered (2 vs 3 oral doses), as 
well as the different study group (hypercapnic patients vs healthy volunteers). 
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We found that MPA did not significantly influence the slope and x-mtercept of the HCVR 
This was also found by Monkawa [21] 
Po ι is considered to be useful in the assessment of central inspiratory neuromuscular drive, 
especially in COPD patients, since Po ι is less affected by airway resistance [24] Therefore, 
mouth occlusion pressure (Poi) was measured at rest and the Poi response to C0 2 was 
calculated However, Poi may underestimate the respiratory dnve in COPD patients 
because it reflects the force output of respiratory muscles, which are sometimes weak, and 
reflects the neuro-mechamcal coupling which is changed [36] In our patients the Po ι values 
prior to drug administration were higher and the relation between ΔΡοι and APaC02 were 
lower than in healthy subjects, which is in agreement with literature [8, 37] During ACET 
treatment no significant change in Poi and in the relationship between ΔΡοι and APaC02 
was observed, whereas Poi increased significantly by MPA This is consistent with the 
observed increase in ventilation with MPA therapy The relation ΔΡ01 and APaC02did not 
change with MPA treatment These findings are in agreement with Skatrud ef al and 
Monkawa ef al, who also did not find any change in this relationship [8, 21] When 
considering the C0 2 -response curves in COPD, the ventilation of the patients will increase 
during hypercapma This will lead to increased hypennflation, taking the lungs and thoracic 
wall to a stiffer part of their pressure-volume curve Furthermore, the process of shortening 
of the diaphragm due to hypennflation will bring it on a disadvantageous part of the length-
tension curve This might explain the lack of response in Poi in the C02-response curves 
[37] 
The ventilatory control system can be subdivided into a controller or controlling system, and 
a controlled system The controller has an input (PaC02) and an output (minute ventilation) 
The charactenstic of the controller is the ventilatory response to C0 2 The controlled system 
is the gas exchanging process in the lungs, its input is minute ventilation and its output is 
the PaC02 The charactenstic of the controlled system depends on the metabolic C02-
production, and is called the metabolic hyperbola In our model, due to a higher metabolic 
rate in COPD patients [38], we calculated a resting C02-production of 400 ml mm1 by using 
the steady state resting PaC02 and V E values as points of the hyperbola Metabolism will 
even be a little higher dunng MPA Therefore, C02-production was calculated at 450 
ml mm 1 (steady state resting PaC02 and VE values dunng MPA therapy) [19, 32] Dunng 
spontaneously breathing, the output of the controlled system (PaC02) is at the same time 
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input of the controller Alternatively, the output of the controller (minute ventilation) is the 
input of the controlled system Thus the system settles at the point where the COj-response 
curve crosses the metabolic hyperbola This is called the 'closed loop' situation 
As shown in figure 3, for both ACET and MPA, this model will predict a decrease in PaC02 
of 0 8 and 0 5 kPa, respectively This is in close agreement with the actual decrease of 0 7 
and 0 6 kPa that we found in our patients Since the point of intersection of the ventilatory 
C0 2 response curve with the metabolic hyperbola is in the relatively flat part of the 
hyperbola, it is not surpnsmg that with ACET treatment, a decrease in PaC02 was observed 
without a significant increase in ventilation This also means that ACET seems to be able to 
improve blood gas values without adding a substantial load to the ventilatory muscles As 
shown in figure 3 the (non-significant) ventilatory increase of 0 4 L mm1 (ΔΝ/Έ) would result 
in a decrease in PaC02 of only ± 0 3 kPa as indicated by the metabolic hyperbola Since we 
observed a larger decrease in PaC02 (0 8 kPa) other factors in the gas exchange must be 
responsible for this "extra" decrease in PaC02 A decrease in V'co2 as observed by Hirahara 
[39] could possibly explain this extra decrease This is due to the fact that the point of 
intersection of the ventilatory C0 2 response curve with the metabolic hyperbola is in the 
relatively flat part of the hyperbola Another explanation could be the appearance of tissue 
C02-retention, since the carbonic anhydrase is inhibited, leading to a relative tissue 
hypercapma, with either no change or a relative arterial hypocapma [15] 
Taken all together, the concern of Swenson ei al [10] about prescribing ACET to severe 
COPD patients with ventilatory pump failure seem to be of great clinical importance as can 
also be concluded from the present study ACET should not be used in patients with very 
severe obstruction and hypercapma (FEV., <25% and PaC02 >8 kPa) or in those who have 
not the mechanical ability to lower their PaC02 by voluntary hyperventilation 
In the current study as well as in others, the HVR was augmented by ACET and MPA, which 
indicates that both respiratory stimulants have an effect on the peripheral chemoreflex loop 
[19, 20] The HVR was not increased in all ACET and MPA studies [9, 12, 17] A possible 
explanation could be a different technique measurement of the HVR at pre-drug PC02 level 
resulted in an increased HVR [12, 15, 19] instead of a decrease under lower post-drug 
PC02 levels [9, 12, 17] 
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The slope of ΔΡο ι versus ASao2 was significantly increased by ACET (fig 5), but did not 
reach any significance with MPA For MPA this is in agreement with the observations of 
Schoene ef al [40], although this is inconsistent with the observed increase in HVR This 
might be due to the large inter and intra individual variability as mentioned by Whitelaw [24] 
Nocturnal parameters 
ACET significantly decreased nocturnal desaturation time (% time Sao2 <90%) It is known 
that the respiratory stimulant may contribute to improvement of desaturation time by 
diminishing central sleep apnea and penodic breathing [41] This supports the opinion that 
ACET augments the chemical drive as was shown in those patients This may also explain 
the decrease in PETC02, although occasional nocturnal hypoventilation may still be present 
MPA has a beneficial effect on PETC02 as shown in table 5 This findings corroborates that 
of others [42] 
Clinical implications 
The current study showed that short-term ACET treatment is more beneficial compared to 
short term MPA treatment as can be seen from a larger change in daytime PaCOj in 
hypercapmc COPD patients However, the long-term clinical benefit of ACET and MPA 
treatment on severe COPD patients remains to be investigated The possible effect on 
survival of a modest increase in Pa02 and a decrease in PaC02 is not yet clear Hypoxia 
and hypercapma are both considered to be independent poor prognostic factors for survival 
[2, 4, 43], yet others question the prognostic role of hypercapma [3] If the role of PaC02 as 
an independent predictor for a prognostic poor prognosis will be further established, the use 
of ACET might be preferred because of its extra effect on nocturnal saturation 
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6.1. SUMMARY 
Medroxyprogesterone acetate (MPA) and Acetazolamide (ACET) are two ventilatory 
stimulants which are used in hypoxic and hypercapnic patients with chronic obstructive 
pulmonary diseases 
In a double blind, randomized study, the effects of a two week treatment with MPA (30 mg 
bid) or ACET (250 mg bid), followed by a two week treatment with a combination of both 
drugs (MPA-ACET), were investigated on daytime and nocturnal ventilatory and blood gas 
parameters in 17 stable hypercapnic COPD patients 
ACET, MPA and MPA-ACET treatment decreased mean daytime PaC02 by 0 4, 0 7 and 1 2 
kPa (all p<0 02), respectively V'E was improved only with combined therapy from 9 3 to 
11 2 L mm1 (p<0 02) 
The hypercapnic and hypoxic ventilatory responses were significantly increased by MPA-
ACET therapy from 3 7 to 5 8 L mm1 kPa1 and from -0 13 to -0 40 L mm1 %1, respectively 
The Po ι response to hypoxia increased dunng the combination therapy from -0 01 to -0 03 
kPa % 1 Nocturnal PETC02 decreased with MPA and MPA-ACET treatment by 0 9 and 1 4 
kPa (p<0 02), respectively MPA-ACET significantly increased mean nocturnal Sa02 values 
from 85 5 to 90 2% 
We concluded that combined treatment with MPA-ACET has a more favourable effect on 
day and night-time blood gas values and chemical drive, than single drug treatment 
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6.2. INTRODUCTION 
A sub-group of patients with severe chronic obstructive disease (COPD) are not able to 
maintain their blood gas values at normal levels The life expectancy of these patients 
depends on both the seventy of hypoxaemia and hypercapnia, although the latter is under 
debate [1] Long term oxygen treatment improves survival rate in these patients [2,3], 
however, in some COPD patients, this will aggravate the carbon dioxide retention [1] It was 
suggested that the hypercapmc ventilatory failure was associated with early death in 
patients using long-term oxygen therapy 
The goal of the treatment in this patient group is to avoid total respiratory failure In the 
model of Karpel ef al [4] respiratory failure is the result of a decrease in central respiratory 
drive, an excessive respiratory work load, inadequate respiratory muscle endurance and 
malnutrition Therefore, non invasive ventilation, supplemental oxygen, respiratory 
stimulants, inspiratory muscle training and nutntional support may be beneficial, although 
vanable degrees of success were reported [5-7] 
The current study focuses on the effect of the respiratory stimulants acetazolamide (ACET) 
and medroxyprogesterone acetate (MPA), which can be used to increase the ventilatory 
drive and so avoid respiratory failure 
The carbonic anhydrase inhibitor ACET has successfully been used in the treatment of 
hypoventilation in COPD patients and nocturnal hypoventilation [7-9] By inhibition of renal 
carbonic anhydrase, ACET causes a metabolic acidosis which induces an increase in 
ventilatory dnve However, since ACET is present in many tissues and cells that are 
involved in the regulation of breathing, the effect of ACET on the control of breathing may 
be much more complicated Our previous animal studies showed a decrease in the slope 
and X-mtercept of the ventilatory C02 response curve, which suggests that acetazolamide 
may also act on the peripheral chemoreceptors and on the cerebral blood flow [10-12] 
The other respiratory stimulant, the synthetic progestagene MPA, increases arterial oxygen 
tension (Pa02) and reduces artenal carton dioxide tension (PaC02) in COPD patients [7, 
13, 14] The ventilatory effect of MPA is controlled by receptors in the hypothalamus [15] 
Ventilatory effects via the central and penpheral chemoreflex loops have also been 
desenbed, e g [12, 16] Vertraecken et al [17] desenbed a persistent ventilatory stimulation 
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with ACET in patients with central hypoventilation, that lasted 1-6 months. The possible 
sustained effects of MPA and ACET are not known 
Simultaneous administration of both respiratory stimulants, aiming for a more efficient 
ventilatory stimulation in COPD patients has not yet been described. We hypothesised that 
stimulating both afferent systems (chemoreceptor and hypothalamus) to the ventilatory 
centers in the brainstem, will yield a better ventilatory stimulation. 
The aim of this study was to determine to what extent combined treatment with MPA-ACET 
ameliorates hypoxia and hypercapnia, and to compare the results with a single drug 
treatment, in a group of hypercapnic COPD patients. 
6.3. METHODS 
Siucfy design and patients 
Twenty-three hypercapnic out-patients with stable severe COPD, as defined by the 
European Respiratory Society [18], were enrolled in this study. Inclusion criteria were: 
daytime arterial PC02 (PaC02) à 6.0 kPa and ventilatory pump reserve. The latter was 
measured prior to supplying the respiratory stimulants, by a voluntary hyperventilation test 
with capnography. Exclusion criteria were: non-stable COPD, i.e. exacerbation in the last 
three months, long term oxygen treatment, abnormal renal and liver functions, use of 
respiratory stimulating drugs and obstructive sleep apnea/hypopnea syndrome. Six patients 
were withdrawn because of an exacerbation during the study. The remaining seventeen 
patients received optimal medication, consisting of bronchodilators and in some cases loop 
diuretics and inhaled corticosteroids. The medication remained unchanged during the study 
period 
Study protocol 
In a double blind, double dummy, randomized study the effects of a two week treatment of 
ACET (250 mg b.i.d.) or MPA (30 mg b.i.d.), followed by a combination of MPA-ACET on 
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daytime and nocturnal ventilatory and blood gas parameters were studied The study design 
is shown in figure 1 The patients were studied four times over a period of six weeks at the 
beginning of the study and before a change of medication, after introduction of the placebo, 
single or combined drug treatment, at intervals of two weeks (study points Ti-4 fig 1 ) The 
measurements consisted of nocturnal measurements followed by daytime tests All patients 
received a placebo dunng the first two weeks to determine the mtra-mdividual vanabihty in 
the outcome parameters After the second measurements (T2) patients received either MPA 
(30 mg) + placebo (arm I) or ACET (250 mg) + placebo (arm II) twice a day ( b i d ) Over the 
last study penod all patients received combined treatment with MPA (30 mg bid) and ACET 
(250 mg bid), all in identical capsules 
At one and three months after the end of the last treatment, hypercapnic ventilatory 
response and arterial blood gas values were measured in nine and seven patients 
respectively, to observe possible sustained effects of MPA-ACET Wntten informed consent 
was obtained from all patients and the study was approved by the Hospital Ethics 
Committee 
ACET+ Placebo ACET/MPA 
2S0mg bid _ 250/30mg bid 
Τ3A T4AM
 N _ 9 
2 weeks 2 weeks 
TsM T4MA
 N = 8 
MPA+Placebo MPA/ACET 
30mg bid 30/250mg bid 
Fig 1 Study design 
Tx = fneasurement Interval between every measurement was two weeks MPA = 
medroxyprogesterone acetate, ACET= acetazolamide Ti= baseline measurements, T2 = 
measurements after 2 weeks placebo, T3A = measurements after 2 weeks acetazolamide + placebo, 
T3M = measurements after 2 weeks medroxyprogesterone acetate + placebo , T4AM = measurements 
after 2 weeks acetazolamide + placebo followed by 2 week treatment with acetazolamide and 
medroxyprogesterone acetate and T4MA = measurements after 2 weeks medroxyprogesterone 
acetate + placebo followed by 2 week treatment with and medroxyprogesterone acetate and 
acetazolamide 
Placebo 
2 weeks 
Arm Π 
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Daytime measurements 
All daytime measurements were performed on the morning after the nocturnal 
measurement 
-Artenal blood gas values 
After each study night at 9 a m an artenal blood sample was taken after 15 minutes of rest 
(Ciba-Commg 278 blood gas analyser, Houten, The Netherlands) 
-Pulmonary function tests 
Spirometnc tests, including inspiratory vital capacity (IVC), total lung capacity (TLC), 
residual volume (RV) and forced expiratory volume in 1 second (FEV,) were performed with 
a wet spirometer and He dilution technique (Pulmonet III, SensorMedics, Anaheim, CA, 
USA) Reference values were derived from ERS standards [19] 
-Pressure measurements 
Maximal inspiratory and expiratory mouth pressure ( Ρ ^ and PEmax) were measured as 
described by Wilson et al [20] 
-Hypercapnic ventilatory response (HCVR) and Hypoxic ventilatory response (HVR) 
The HCVR was assessed by the steady-state method [21] The patient was connected to a 
closed spirometnc circuit (Pulmotest, Godart, Bilthoven, The Netherlands) via a mouthpiece 
A Rudolph valve 2700 (Kansas City, USA) was placed in the system, to maintain a one way 
circuit The end-tidal carbon dioxide tension (PETC02) level was measured by a side stream 
capnograph (Drager, Lübeck, Germany) Inspiratory PC02 could be raised by adjusting a 
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three-way valve, partly short-circuiting the C0 2 absorber in the inspiratory limb of the circuit 
Two different levels of PETC02 were determined (PETC0 2 at zero P1CO2, and PETC02 at 1-1 5 
kPa above resting value) and the slope (AV7APETC0 2 ) and x-mtercept Β were calculated, 
according to the equation of the steady state relation of ventilation and PETC02 at constant 
PET02 
V ' ^ S Î P E T C C V B ) 
Each level of PETC02 was maintained for at least 7 minutes Oxygen was added to the 
system to keep arterial oxygen saturation (Sa02) constant at levels >90% Sa02 was 
measured with a pulse oximeter (Oxyshuttle, SensorMedics, Anaheim, California, USA) At 
the end of the steady state penod of the HCVR an artenahzed capillary blood sample was 
taken Mouth occlusion pressure (P01) was measured during the final 2 minutes of each 
steady state penod at the two different levels of PC02 using a solenoid valve, in the 
inspiratory part of the circuit 
The HVR was performed by inducing progressive isocapmc hypoxia PETC02 was 
maintained at the pre-drug level (T2, placebo treatment) during all HVR tests, by adding C02 
to the inspirate, when necessary All patients started the test at normoxia Sa02 level of 
>95% by adding an adequate amount of oxygen Next, inspiratory 0 2 was decreased by 
stopping the oxygen supplementation and the HVR test was performed until Sa02 reached 
80% 
During the recording of both the HCVR and HVR, the PETC02, breathing frequency (f), tidal 
volume (VT), ventilation (V'E), Sa02 and P01 were measured and stored on an analogue 
chart recorder (BD101, Kipp & zonen, Delft, The Netherlands) 
Nocturnal measurements 
The artenal oxygen saturation (Sa02) was measured by a pulse oximeter The baseline 
Sa02 awake was defined as the mean Sa02 during the first 15 minutes of the recording, 
when the patient was awake and in supine position The PFTC02 was measured by sampling 
air through a naso-pharyngeal cannula inserted via the nose and connected to the sampling 
capnograph (Mijnhardt capnolyser, Bilthoven, The Netherlands) Oxygen saturation, and 
PETCO2 signals dunng the night were stored on a computer (Compaq 4/66, Houston, TX, 
USA) 
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Subjective parameters 
After each study penod patients were asked for side effects of the drugs The dyspnea 
sensation was analysed with the modified Medical Research Council (MRC) scale [22] 
Statistical analysis 
In this study four repeated measurements were made, at the beginning and at the end of 
each penod (Ti to T4) Data are presented as mean ± sem In order to test whether the 
effect of the combined treatment was different in both arms of the study (arm-effects), we 
compared the differences (T-MAM- T2 arm I) and (T1-4MA - T2, arm II) using the Mann-
Whitney-U-test After showing that there was no significant intra-individual vanability by 
companng Τι and T2 and that there were no arm effects at T4 the data obtained in the 
placebo situation were compared with those after combined treatment with MPA-ACET 
Combination therapy was compared with single drug treatment (Wilcoxon signed rank 
tests) A Bonferom correction was used because of multiple compansons, a p<0 025 was 
considered statistically significant For all analysis SPSS version 6 13 was used (SPSS 
mc, Chicago, 1995) 
6.4. RESULTS 
The anthropometric charactenstics, baseline respiratory function data, acid base status and 
nocturnal parameters of the patients in both arms are summarized in table 1 After placebo, 
no significant differences were observed in ventilatory and blood gas parameters as well as 
nocturnal measurements compared to baseline (T2 -Τι) Hence, there was no significant 
intra- individual vanability, and the data of the placebo measurements were used as 
reference values in the analysis of the effects of ACET, MPA and the combined drug 
treatment No arm-effects were found with MPA-ACET (table 2), therefore the data of the 
combined treatment of both arms were analysed as one group Furthermore, placebo vs 
single treatments with either MPA (n=8) or ACET (n=9) were compared to placebo vs 
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combined treatment with MPA/ACET (n=17) and combined treatment was compared to 
single treatment 
age (years) 
weight (kg) 
height (m) 
Body Mass Index (kg m2) 
FEV, (%pred) 
ΡΕν,Λ/Ο (%pred) 
TLC (%pred) 
IVC (%pred) 
RV (%pred) 
PH 
Pa02(kPa) 
PaC02(kPa) 
BE (mmol L1) 
Sa02 (%) 
nocturnal parameters 
mean Sa02(%) 84 8 ± 2 0 86 7 ± 2 6 
% time SaO2<90% (%) 72 2 ± 12 8 48 9 ± 15 3 
Lowest Sa0 2 (%) 70 5 ± 3 2 72 1 ± 4 2 
Mean PETC02(kPa) 6 1 ± 0 3 5 0 ± 0.3 
Table 1 Baseline charactenstics (Ti) 
Data are presented as mean ± sem %pred = percentage of predicted value [19] 
a r m i 
(n=9) 
66 ± 2 
83 ± 8 
1 72 ± 0 04 
28 ± 2 
37 ± 6 
46 ± 7 
100 ± 6 
80 ± 4 
145 ±20 
7 39 ± 0 01 
8 2 ± 0 4 
6 6 ± 0 1 
4 3 ± 1 0 
90 0 ± 1 0 
arm II 
(η=β) 
69 ± 2 
70 ± 5 
1 65 ± 0 03 
26 ± 2 
30 ± 4 
48 ± 6 
92 ± 7 
68 ± 1 
137 ±10 
7 41 ± 0 01 
8 4 ± 0 5 
6 3 ± 0 2 
4 6 ± 0 9 
91 1 ± 1 6 
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parameter XI-4AM-X2 XI-4MA-X2 
APaCOj (kPa) 
APa02 (kPa) 
A V E (Lmm1) 
ΔΡ01 (kPa) 
-1 0 ± 0 2 
1 4 ± 0 2 
0 5 ± 0 3 
0 3 ± 0 1 
-1 4 ± 0 2 
2 2 ± 0 4 
0 6 ± 0 4 
-0 2 ± 0 1 
0 09 
0 06 
0 82 
0 41 
Table 2 Analysis of arm-effects 
Data are presented as mean ± sem 
Daytime blood gas parameters 
Single treatment 
Compared to the placebo, as shown in table 3, ACET significantly decreased PaC02, pH 
and Base Excess (BE) and improved Pa02 and Sa02 values MPA increased Pa02 and 
Sa02 and decreased PaC02 and BE 
Combined treatment 
Dunng combined treatment, patients became normocapmc and almost normoxic compared 
to the placebo treatment (table 3) 
Analysis of differences between combined and single treatment resulted in a significant 
difference in pH (combined vs MPA), Pa02 and BE (combined vs both single drug 
treatments) and PaC02 (combined vs ACET) (table 3) 
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pH 
Pa02 (kPa) 
PaC02(kPa) 
BE (mmol L1) 
P(a-ET)C02 (kPa) 
Sa02(%) 
nocturnal parameters 
Mean PETC02(kPa) 
MeanSa02(%) 
Lowest Sa02(%) 
% time SaO2<90% 
PLACEBO 
(T2) 
(n=17) 
7 39 ± 0 01 
7 9 ± 0 3 
6 5 ± 0 2 
4 5 ± 0 7 
0 7 ± 0 2 
89 0 ± 1 3 
5 5 ± 0 2 
85 5 ± 1 6 
70 9 ± 2 9 
61 8 ± 9 9 
ACET 
(T3A) 
(n=9) 
7 34 ± 0 01* 
8 5 ± 0 2* 
6 1 ± 0 2* 
0 8 ± 1 3* 
0 6 ± 0 2 
90 6 ± 0 8* 
5 2 ± 0 3 
87 2 ± 1 3 
74 9 ± 3 Γ 
63 4 ±13 4 
MPA 
(T3M) 
(η=β) 
7 40 ± 0 01* 
8 9 ± 0 6* 
5 8 ± 0 3* 
2 6 ± 1 0* 
0 7 ± 0 2 
92 0 ± 1 7* 
4 6 ± 0 3 
88 6 ± 2 3 
80 1 ± 3 3 
46 8 ± 16 7 
MPA-ACET 
(T4) 
(n=17) 
7 36 ± 0 01** 
9 6 ± 0 4 * η 
5 3 ± 0 2 " 
-2 4 ± 0 8* t t 
0 7 ± 0 2 
92 3 ± 1 0* 
4 1 ± 0 2* n 
90 2 ± 1 0* η 
78 6 ± 1 8* 
42 0±10 4* 
Table 3 Effect of Medroxyprogesterone acetate and Acetazolamide on daytime and nocturnal 
parameters 
Data are presented as mean ± sem P(a-ET)C02 = artenal-to-end-tidal PC02 gradient *p < 0 025 any 
treatment versus placebo, tp< 0 025 combined treatment vs ACET *p< 0 025 combined treatment vs 
MPA 
Ventilatory parameters 
The mam results of the ventilatory data including HCVR and HVR are shown in table 4 
Ventilation did not increase after single treatment but did significantly increase after 
combined therapy compared to the placebo 
The slope of the ventilatory C0 2 response curve significantly increased with combination 
therapy compared to the placebo (fig 2) The slope of the hypoxic ventilatory response 
(SHVR=AV'E/ASa02) and the Poi response to hypoxia, expressed as function of Sa02 
(SHPO Ι=ΔΡΟ Ι /ASa02) increased with combined treatment, both compared to placebo No 
significant changes were found with the single drug therapy SHPO Ι expressed as function of 
VE resulted in a correlation coefficient of r=0 98 
A significant increase in maximal inspiratory mouth pressure was found with combination 
therapy compared to placebo 
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V E (L.min-1) 
V T ( L ) 
Po ι at rest (kPa) 
SHCVR (L.min 1.kPa'1) 
BHCVR (kPa) 
SHCPOI (kPa.kPa-1) 
BHCPOI (kPa) 
SHVR (L.minV0/«) 
SHPOI (kPa/%) 
P ^ ( k P a ) 
PEm„(kPa) 
PLACEBO 
(T2) 
(n=17) 
9.3 ±0.5 
0.6 ± 0.06 
0.5 ±0.04 
3.7 ±0.6 
2.9 ±0.5 
0.3 ± 0.04 
4.2 ± 0.3 
-0 13 ±0.03 
-0.01 ± 0.0 
5.7 ±0.5 
9.3 ± 0.7 
ACET 
(T3A) 
(n=9) 
9.5 ±0.9 
0.8 ± 0.2 
0.5 ± 0.03 
5.5 ±1.4 
3.6 ±0.4 
0.2 ± 0.04 
3.7 ±0.3 
-0.20 ± 0.05 
-0.01 ± 0.0 
6.3 ±0.8 
10.0±1.1 
MPA 
(T3«) 
(η=β) 
10.2 ±0.6 
0.6 ± 0.04 
0.6 ± 0.05 
4.8 ±1.4 
2.8 ±0.5 
0.4 ± 0.08 
3.6 ± 0.4 
-0.40 ±0.11 
-0.02 ± 0.01 
5.4 ±0.5 
8.6 ±0.8 
MPA-ACET 
(T4) 
(n=17) 
11.2 ± 0 . 8 * 
0.7 ± 0 . 1 * 
0.5 ± 0.04 
5.8 ±1.0* 
2.9 ±0.3 
0.4 ± 0.04 
2.9 ±0.3 
-0.40 ± 0.07* 
-0.03 ±0.01* 
6.7 ± 0.7* 
9.6 ± 0.7 
Table 4. Effect of Medroxyprogesterone acetate and Acetazolamide on ventilatory parameters and 
respiratory muscle strength. 
Po ι at rest (kPa) = mouth occlusion pressure at rest; SHCVR (AV'E/APaCOJ = slope of the ventilatory 
C 0 2 response curve; BHCVR (x-intercept) = apnoeic threshold or extrapolated PETC0 2 at zero 
ventilation; SHCPOI (ΔΡ01 /APaCOj) = slope of the mouth occlusion response to C02; BHCPOI = x-
intercept of the mouth occlusion pressure response to C0 2 . SHVR (AV'E/ASaOJ = slope of the hypoxic 
ventilatory response. SHPOI (APoi/ASaOJ = slope of the mouth occlusion response to hypoxia. Pimal= 
inspiratory mouth occlusion pressure, PEm„= expiratory mouth occlusion pressure. 
Nocturnal measurements 
Single treatment 
As shown in table 3, the lowest nocturnal Sa02 increased significantly with single drug 
therapies 
Combined treatment 
In comparing the combined treatment with the single drug and the placebo treatments, there 
was a significant decrease in PETC02 and a significant improvement of Sa02 values. In 
comparing only the placebo with the combined treatment, the lowest Sa02 values were 
improved and the percentage of time Sa02 <90% was significantly reduced (table 3) 
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20 η 
^ 15 -
ι 
c I 
d. 10 
> 
5 I 
0 -i 
MPA/ACET 
ι ι r-
V'COj =0.45 Lmln·1 
V'CO, =0.40 L.min1 
-| 1 1 ' j | ι 1 1 1 1 1 1 1 
4 6 8 10 
PaCO^kPa) 
Fig 2 Effect of combined therapy with Medroxyprogesterone acetate and Acetazolamide on the 
ventilatory control system. The continuous straight line of the ventilatory C0 2 response curve 
represents the placebo situation and the dashed lines the situations dunng combination therapy 
(MPA/ACET). The continuous line of Ihe metabolic hyperbola represents the situation with placebo, 
the dashed metabolic hyperbola the one after combination therapy (MPA/ACET). 
Subjective Parameters 
Single treatment 
During single MPA therapy 4 patients reported gastro-intestinal discomfort and 4 patients 
fatigue. In the single ACET-group two patients complained of gastro-intestinal discomfort, 
one patient of headaches and three patients complained of fatigue. Dyspnea sensation 
(MRC-scale) remained unchanged: 2.06 ± 0.1 θ at placebo to 2.00 ± 0 33 with ACET therapy 
and to 2.88 ± 0.23 during MPA therapy. 
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Combined therapy 
During combined treatment gastro-intestinal complaints (n=3), headache (n=1), fatigue 
(n=3) and paraesthesia (n=6) were reported. The dyspnea score did not change 
significantly (2.47 ±0.19). 
Off-treatment 
At one month and three months after discontinuing the combined treatment, no significant 
differences were found between placebo and the off-treatment data (table 5). 
PARAMETER PLACEBO 1 MONTH Al 3 MONTHS Al 
n=9 n=7 
Pa02(kPa) 79±0.3 9.0 ± 0.4 7.8 ± 0.5 
PaC02(kPa) 6.5 ±0.2 5.9 ±0.1 6.6 ± 0.4 
V'EÌLmin-1) 9.3 ±0.5 9.3 ±1.4 11.2 ±1.7 
SHcvRfl-.min-'.kPa·1) 3 7 ±0.6 6.7 ± 1 6 41 ±1 9 
Table 5. Off-treatment effects 
Data are presented as mean ± sem Al = after interruption ACET/MPA treatment 
6.5. DISCUSSION 
The present study showed that in hypercapnic patients with COPD, combination therapy 
with MPA-ACET normalized daytime blood gas values and improved night-time and 
ventilatory parameters. The improvement was greater with the combined drug treatment 
than with either of the single drug treatments. 
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Daytime blood gas parameters 
ACET and MPA given as a single drug, decreased the daytime PaC02 (0.4 kPa (6%) and 
0.7 kPa (11%), respectively) and increased PaO2(0.6 kPa (9%) and 1.0 kPa (13%), 
respectively). The effect of combined treatment was additive; PaC02 decreased 1.2 kPa 
(19%) and Pa02 increased 1.7 kPa (23%), reaching normocapnic and almost normoxic 
values. The findings on monotherapy are not new and in agreement with the literature [7, 
14, 23, 24], in contrast to the results of combination therapy, which has not been shown 
before. The reason for the improvement of combination therapy might be that MPA and 
ACET both slightly increased V'E, whereas a combination of both drugs significantly 
increased V'E by 1 9 L.min"1, which was more than the sum of the increase in V'E with single 
drug treatment. 
Hypercapnic ventilatory response (HCVR) 
The slope of the HCVR increased significantly with MPA-ACET therapy, whereas with the 
single drug treatments no significant change were observed The latter agrees with some 
existing data [14], although an increase in HCVR on monotherapy was found by others [7, 
23]. The fact that combined treatment with MPA-ACET on the HCVR and on the blood gas 
parameters was slightly better than the single drug treatment suggests that combination 
therapy was additive. This also suggests that there is no interaction between the ventilatory 
drive from the chemoreceptors and the drive mediated by the hypothalamus. 
The ventilatory control system as graphically shown in figure 2 consists of two parts: (a) the 
linear ventilatory response to C02, which represents the controller or controlling system with 
PaC02 as input parameter and minute ventilation as output parameter, and (b) the 
metabolic hyperbola which represents the controlled system and depends on the metabolic 
CCVproduction. The controlled system comprises of the gas exchanging process in the 
lungs, with input parameter minute ventilation and output parameter the PaC02. In a 
spontaneously breathing man, in the so-called "closed loop" situation, the working-point is 
represented by the intersection of both curves: the output of the controlled system (PaC02) 
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is the input of the controller and the output of the controller (minute ventilation) is the input 
of the controlled system In our model we calculated a resting C02-production of 400 ml mm 
\ which increased dunng MPA to a calculated 450 ml mm 1, based on the actual values of 
V'E and PaC02 of our patient groups 
It is important to recognize whether the chronic hypercapma is due to neuromuscular 
weakness, the excessive work of breathing ("Can't Breathe") or due to inadequate dnve 
from the ventilatory centers in the CNS ("Won't breathe") According to the metabolic 
hyperbola, a substantial decrease m PaC02 of 1 2 kPa can be generated by a very small 
increase in ventilation of 1 9 L mm1 dunng chronic hypercapma 
Therefore, respiratory stimulants like ACET and MPA can be considered for hypercapmc 
patients with severe COPD, as also discussed by Teppema [25], because they are able to 
improve blood gas values considerably with only minimal changes m ventilation and without 
an increase m dyspnea sensation 
Hypoxic ventilatory response (HVR) 
We found that the hypoxic ventilatory response was not augmented by single drug 
treatment, whereas combination therapy increased HVR In the current literature, the effects 
of MPA and ACET on the HVR are confounded by the fact that the same pre- and post-drug 
levels of PETC02 were not always maintained [7, 26] HVR is not only determined by P02 but 
also by the prevailing PCO2 This is well illustrated by the study of Tojima ef al [26], who 
showed that the effect on HVR measured dunng acetazolamide-mduced hypocapma did not 
significantly increase, whereas responses to hypoxia measured under pre-drug PETCOJ 
levels did increase significantly 
Vos et al [7] showed no significant increase in HVR with Chlormadinone acetate (CMA), 
which was measured at hypocapmc post-drug level We used pre-drug PETCOJ levels in this 
study Both ACET and MPA probably have an effect on the penpheral chemoreceptors, 
whereas progesterone induces an increase in metabolic rate, which m tum may be 
responsible for the increase in HVR [27] The lower BE (metabolic acidosis) will also 
contnbute to the increased HVR dunng the combined treatment 
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Whitelaw [28] introduced Po ι measurement as an output parameter of the controlling part of 
the respiratory control system, because in COPD patients ventilation as an output 
parameter can be influenced by chronic airway obstruction Poi is a measure of 
neuromuscular drive, minimizing the influences of airway obstruction The Poi values at 
rest, measured in our COPD patients, were comparable with those descnbed in other 
studies [14,28] 
The Po 1-Sa02 response slope was augmented by combination therapy, whereas single drug 
treatment only caused a slight, non-significant, increase Apparently, in our COPD patients 
the measurement of P01 as an output parameter of the respiratory controlling system, is 
comparable to V'E as shown by the high correlation coefficient 
The combination of MPA and ACET showed a significant increase in inspiratory mouth 
pressure A possible mechanism could be an increase in central and voluntary drive, 
although this could not be confirmed with the rare data in the literature [29] Single drug 
treatment did not improve respiratory muscle function and for MPA this was shown by 
Contreras [30] 
Nocturnal measurements 
In COPD patients MPA and ACET are proven to have a beneficial effect on central sleep 
apnea and oxygenation, respectively [8, 9, 13, 17] In the present study we found an 
improvement of mean nocturnal PETC02, Sa02 and lowest Sa02 and a decrease of the 
percentage of time Sa02 <90% It remains to be established whether nocturnal desaturation 
needs to be treated at all [31] 
One month after discontinuation of the combined treatment with MPA-ACET, all parameters 
which were found to have changed significantly had returned to baseline values 
Verbraecken ef al [17] showed in five out of eight patients with central sleep apneas who 
were six months after cessation of ACET, that the number of central apneas were still 
reduced, whereas the number of obstructive apneas and hypopneas did not significantly 
differ from the selection night They argued that ACET induces a resetting of the central 
chemoreceptor dnve, which may continue after stopping the drug therapy We could not 
confirm this finding, as our patients have only been treated for a penod of four weeks, 
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whereas theirs were treated for five months Furthermore, we studied hypercapnic COPD 
patients instead of patients with non-hypercapmc central sleep apnea syndrome 
In conclusion, the present study shows that combined treatment with MPA-ACET, in 
hypercapnic COPD patients, normalizes artenal blood gas values and improves nocturnal 
saturation and the chemical dnve The combination of MPA-ACET is more favourable than 
either single drug treatments 
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7.1. Introduction. 
Some patients with severe chronic obstmctive pulmonary disease (COPD) are hypercapnic 
and hypoxic, due to respiratory pump failure Hypoxia influences life expectancy Several 
studies have shown a beneficial effect of long term oxygen therapy (LTOT) on survival 
However, LTOT is an expensive and cumbersome treatment Furthermore, LTOT may lead 
to an increase in hypercapma due to increased ventilation-perfusion mismatching and 
suppression of the hypoxic ventilatory drive Hypercapma by itself may independently 
influence survival adversely Therefore, other therapeutic options than LTOT or in addition 
to LTOT such as respiratory stimulants, could be considered 
In this thesis the short-term effects on the ventilation of the respiratory stimulants 
acetazolamide (ACET), a carbonic anhydrase inhibitor and medroxyprogesterone acetate 
(MPA), a synthetic progesterone, were studied as monotherapy and in a combined 
treatment 
In Chapter 1 the physiology and measurements of the control of breathing are described 
The major respiratory stimulants used in COPD patients and the objectives of the current 
thesis are outlined 
The thesis can be divided into two parts 
Part I consists of three animal studies The specific questions in these studies were 
• What dose of ACET does not impede C02-transport by inhibition of the erythrocytic 
carbonic anhydrase? 
• What is the effect of low dose ACET on the control of breathing dunng normoxia'? 
(Chapter 2) 
• What is the effect of low dose ACET on the control of breathing under hypoxic 
conditions? (Chapter 3) 
• Is there an interaction (supra-additive effect) between the ventilatory effects of ACET 
and MPA? (Chapter 4) 
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Part II consists of two human studies On the basis of the animal studies the specific 
questions were 
What is the effect of 250 mg twice daily ( b i d ) ACET(equivalent to the optimal dose 
found in chapter 2) and 30 mg b ι d MPA as monotherapy in hypercapnic COPD 
patients'? (Chapter 5) 
• Does a combined therapy with ACET and MPA (thus influencing the ventilation via 
chemoreceptors as well as via hypothalamic pathways) provide a better ventilatory 
stimulation and better treatment of hypoventilation in patients with severe COPD, 
than single drug therapy? (Chapter 6) 
7.2 Transition from animal model to human studies 
Acetazolamide (ACET) 
• In cats a low dose of 4 mg kg 1 ACET does not cause an artenal-to-end-tidal PCO: 
gradient, indicating no complete inhibition of erythrocytic carbonic anhydrase The 
acute effects of ACET on ventilation in the animal studies were performed with this 
dose Extrapolation to human doses is in fact precanous, since (1) in humans we 
have studied the "chronic effects" of ACET (2 weeks therapy) It is known from 
literature data that the effects of acute vs chronic administration of ACET on the 
ventilation may be different (2) We are not precisely informed about the distribution 
of the drug to intra and extracellular compartments of the human body compared to 
the situation in animals In the literature no dose response curves are available 
leading to the answer what dose one should use in a chronic situation in humans In 
the human studies in the present thesis a dose of 250 mg twice daily ( b i d ) ACET 
was administered based on extrapolation of the dose found in the animal study and 
on literature data (3) The animal studies were performed on anaesthetized cats, 
whereas the human studies were evidently in unanaesthetized condition 
Anaesthesia influences ventilation and may likewise influences the ventilatory 
responses to drugs 
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The findings of the animal and human studies seem not consistent In the animal 
studies the sensitivities of the peripheral and central chemoreflex loops and the 
apnoeic threshold decreased after administration of ACET (open loop situation), 
whereas in human studies a tendency of increase of the sensitivity of the ventilatory 
CO;, response curve was found Extrapolation to the ventilation using the equation, 
Vi =S(PaC02-B) would imply that in cats ventilation only increases in relative 
hypocapma after administration of the drug in contrast to the human studies 
However, all studies were performed in an open loop situation Considering the 
closed loop situation, the working point of the ventilatory control system changes 
along the metabolic hyperbola (the representation of the controlled system) 
Considenng this, the acute effect of 4 mg kg 1 ACET, both intravenously and orally 
administered is the same a decrease in PaC02with a small increase in ventilation 
A possible explanation for the decrease in slope of the ventilatory C0 2 response 
curve in the animal studies after ACET administration may be an effect of 
anaesthesia 
In the animal studies it is argued that the effect of 4 mg kg 1 ACET is caused by a 
direct effect on the peripheral chemoreceptors (carotid bodies), because of an 
inhibiting effect of the drug on the C0 2 sensitivity of the penpheral chemoreflex loop 
The effect of the drug on the C0 2 sensitivity of the central chemoreflex loop may not 
be due to a direct effect on the central nervous system, but rather to an effect on 
cerebral vessels resulting in an altered relationship between PaC02 and brain tissue 
PC02 as discussed in chapter 2 
Under hypoxic condition in cats the effect of 4 mg kg 1 ACET on the ventilation was 
confirmed, being a larger effect on the penpheral chemoreceptors 
Starting from the findings in the animal studies, two studies with ACET were 
performed in hypercapmc COPD patients A dose of 250 mg b ι d ACET improved 
blood gas values to normocapnia and almost normoxia This is important, since 
literature data suggest that hypercapma may be an independent determinant of life 
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expectancy in COPD patients. Whether chronic administration of ACET (>2 weeks 
treatment) will yield a better life expectancy has to be established in further studies. 
Medroxyprogesterone acetate (MPA) 
In cats and in COPD patients MPA leads to a decrease in PaC02 and an increase in 
ventilation. 
The mechanisms by which MPA act on the ventilatory control system is probably via 
two pathways: on one hand the female hormone has a stimulatory action on the 
peripheral chemoreceptors. On the other hand a central pathway may be active, 
since data in the literature suggest that the hypothalamus contains progesterone 
receptors, which may be an input to the ventilatory control mechanism. Whether 
MPA alone or its metabolites are responsible for the effects, has to be studied 
further. From the results in this thesis no clear distinction can be made between 
action via chemical and humoral ventilatory drives. 
MPA +ACET 
In cats, combined treatment of (4 pg.kg'1) MPA and (4 mg.kg1) ACET causes a 
larger net ventilatory stimulation than either drug alone. The same was found in 
hypercapnic COPD patients; combined treatment with MPA and ACET improved the 
day-time and night-time arterial blood gas values and the chemical drive more than 
compared with single drug treatment. Combination of both drugs works favourably 
on the nocturnal Sa02 as compared with single drug treatment. 
Whether MPA modulates the effect of ACET on the central C02 sensitivity could not 
be excluded nor confirmed. However, from the findings in the present thesis as well 
as what is known from literature data it seems more likely that both agents 
independently affect the ventilatory control system. 
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7.3. The effect of low-dose acetazolamide on the ventilatory C0 2 response 
curve in the anaesthetized cat during nonmoxia. 
Chapter 2 describes a dose response study of intravenous acetazolamide (ACET) in intact 
and in carotid body denervated cats on the artenal-to-end-tidal PC02 (P(a-ET)C02) gradient 
A low dose of ACET (4 mg kg1) caused an increase in ventilation of approximately 65% at a 
feline nonmocapmc value of a PaC02 of 4 5 kPa without inducing an P(a-ET)C02 gradient, 
indicating that C02-transport was not impeded by complete blockade of erythrocytic 
carbonic anhydrase Within the first two hours after administration, this small dose caused 
only a slight decrease in mean standard bicarbonate of 1 8 and 1 7 mmol L1 in intact (n=7) 
(p<0 05) and in carotid body denervated animals (n=7) (p>0 05), respectively Doses of 
ACET larger than 4 mg kg 1 caused a significant increase in P(a-ET)C02 gradient 
In addition, in both carotid body intact and in denervated cats the effect of 4 mg kg 1 ACET 
on the central and both central and peripheral chemoreflex loops were studied 
In this chapter, as well as in the other animal studies, the dynamic end-tidal forcing 
technique was used By applying stepwise changes in P E T C 0 2 and by analysing the 
ventilatory responses with a two compartment model, we were able to separate the 
contnbutions from the penpheral and central chemoreflex loops (chapter 1) 
As shown in table 1 in carotid body-denervated cats, 4 mg kg 1 ACET caused an increase 
in ventilation of 64% at a PaC02 of 4 5 kPa A decrease in the C0 2 sensitivity of the central 
chemoreflex loop (Sc) of 0 56 L mm1 kPa1 was observed, whereas the intercept on the 
PaC02 axis or apnoeic threshold (B) decreased by 0 3 kPa In carotid body-intact animals, 
the same dose caused an increase in ventilation of 66% at a PaC02 of 4 5 kPa The C0 2 
sensitivity of the penpheral chemoreflex loop (Sp) decreased by 0 09 L mm1 kPa1 Sc and 
Β decreased by 0 68 L mm1 kPa1, and by 1 0 kPa, respectively The latter findings were not 
significantly different from the changes found m the denervated animals 
The effect of ACET on the C0 2 sensitivity of the penpheral chemoreflex loop may be 
caused by a direct effect on the carotid bodies The effects of the drug on Sc and Β may not 
be due to a direct action on the central nervous system, since from the literature it is known 
that the drug hardly penetrates into the brain It is argued that the effect of ACET on Sc and 
Β can be due to an effect of the drug on cerebral vessels, which results m an altered 
relationship between artenal PC02 and brain tissue PC02 
-152-
Summary and conclusions 
7.4. Effect of low dose acetazolamide on the ventilatory C 0 2 response during 
hypoxia in the anaesthetized cat. 
Hypoxia is a frequently observed phenomenon in patients with severe COPD Therefore we 
have studied the acute effect of acetazolamide (ACET) (4 mg kg1) on the ventilatory 
response to C0 2 dunng hypoxaemia in seven anaesthetized cats (chapter 3) After a bolus 
of 4 mg kg 1 ACET a transient initial fall in ventilation was observed, suggesting a direct 
action of ACET on the penpheral chemoreceptors, since during hypoxia the contribution of 
the peripheral chemoreceptors to the ventilation is larger than dunng normoxia In the 
subsequent steady state, ACET caused an increase in ventilation As shown in table 1 the 
drug reduced the C0 2 sensitivities of the peripheral (Sp) and central (Sc) chemoreflex loops 
with 0 11 and 0 34 L mm1 kPa1, respectively The apnoeic threshold Β (x-mtercept of the 
ventilatory C0 2 response curve) decreased by 1 93 kPa (all parameters p<0 01) The net 
result was a stimulation of ventilation of about 50% at a fixed PaC02 of 4 kPa It is argued 
that the steady state effect of ACET is probably due to a direct effect on the peripheral 
chemoreceptors as well as an indirect central effect on the cerebral blood flow regulation as 
discussed in chapter 2 
7.5. Medroxyprogesterone acetate with acetazolamide stimulates breathing 
in cats. 
Chapter 4 descnbes the effect of medroxyprogesterone acetate (MPA), and MPA followed 
by acetazolamide (ACET), on the ventilatory C0 2 response curve in eight anaesthetized 
female cats, which underwent an ovanohysterectomy 1 month pnor the study The animals 
were pre-treated with 17 ß-estradiol(E2), since pnmmg with a standard dose of 10 pg kg1 E2 
is required to achieve a sustained facilitation of phrenic activity by progesterone The effects 
of 0 4 pg kg1 MPA and 4 mg kg1 ACET on the ventilatory parameters are summanzed in 
table 1 After infusion of 0 4 pg kg1 MPA the ventilation increased by 35% at a fixed PaC02 
of 4 5 kPa Sp was reduced with 0 09 Lmin1kPa1 and Sc with 0 13 Lmin1kPa1 A 
decrease of the apnoeic threshold was observed ( a decrease in Β by 0 38 kPa (all 
parameters ρ < 0 01) 
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Subsequent administration of ACET increased ventilation up to a total of 
116%(MPA+ACET) at a fixed PaC02 of 4.5 kPa. Sp and Sc further decreased by 0.04 and 
0.18 Lmin1.kPa"1, respectively The apnoeic threshold further decreased by 1.18 kPa (all 
parameters ρ < 0.01). These results imply a more than twofold increase of ventilation at 
resting PCOj (=4.5 kPa) as compared to separate treatment with either one of the drugs. 
Because both treatments reduced ventilatory C0 2 sensitivity, it is concluded that a 
stimulating effect on ventilation is due to a decrease in the apnoeic threshold. Combined 
administration of MPA and ACET will lead to larger increases in ventilation than treatment 
with either drugs alone. 
animal studies 
(chapter) 
Vi*' Sp Sc Β 
(% control) (L.minVkPa-1) (LmirrVkPa-1) (kPa) 
normoxia (7 3.) 
intact cats 
CSD cats 
hypoxia (7.4.) 
normoxia(7.5.) 
control 
ACET 
control 
ACET 
control 
ACET 
control 
MPA 
MPA+ACET 
100 
166 
100 
164 
100 
150**» 
100 
135 
216 
0.28 ±0.18 
0.19 ±0.12 
-
-
0.22 ± 0.08 
0.11 ±0.03 
0.22 ± 0.09 
0.13 ±0.06 
0.09 ± 0.06 
1.52 ±0.55 
0.84 ± 0.21 
1.52 ±0.42 
0.96 ± 0.32 
0.74 ± 0.32 
0.40 ±0.10 
1.01 ±0.38 
0.88 ± 0.32 
0.70 ± 0.49 
4.0 ±0.5 
3.0 ±0.6 
4.5 ±0.5 
4.2 ±0.7 
2.88 ± 0.97 
0.95 ± 0.92 
4.02 ± 0.27 
3.64 ± 0.42 
2.46 ±1.50 
Table 1. Summary of the data obtained by analysis of the ventilatory responses to C02 from the 
different animal studies 
*' at a fixed PaC02 =4.5 (kPa), **' at a fixed PaC02 =4.0 (kPa). Sp, Sc and Β data are presented as 
mean ± SD. CBD cats = carotid body denervated cats. 
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7.6. Comparison of acetazolamide and medroxyprogesterone as respiratory 
stimulants in hypercapnic COPD patients. 
In Chapter 5 the effects of acetazolamide (ACET) (250 mg b i.d.) and medroxyprogesterone 
acetate (MPA) (30 mg b.i.d.) on day- and nighttime blood gas values and the influences on 
the hypercapnic and hypoxic ventilatory and Poi response were studied in a cross-over 
design in 12 hypercapnic patients with stable COPD (mean FEV, 33 ± 4 % pred (mean ± 
sem)). 
As shown in table 2., the daytime PaC02 was decreased by 0.7 kPa during ACET treatment 
and by 0.6 kPa during MPA. The daytime Pa02 improved with ACET by 1.3 kPa, whereas 
no significant changes were seen with MPA. Mean nocturnal P E T C 0 2 decreased by both 
treatments, with 0 9 kPa during ACET and with 1 0 kPa during MPA treatment. The 
percentage of time that the nocturnal Sa02 was lower than <90%, was reduced with ACET 
by almost 50%. Nocturnal saturation parameters did not change with MPA. 
Resting minute ventilation increased only with MPA by 1.2 L.min1. The slope of the 
hypercapnic ventilatory response did not change during ACET and MPA therapy. The 
hypoxic ventilatory response increased by 0.2 L.min 1.%"1 during ACET and with 0.1 L.min' 
1
.%'1 during MPA. The hypoxic Poi response improved with ACET treatment by 0.013 
kPa.%1, (all parameters p<0.05). 
This study shows that ACET and MPA both have favourable effects on day- and nighttime 
blood gas parameters in hypercapnic COPD patients, however, the effects of ACET are 
more evident, especially on nocturnal saturation. 
7.7. Combined treatment with acetazolamide and medroxyprogesterone in 
COPD patients 
In chapter 6 we describe the second human study, in which the effects of a two week 
treatment with medroxyprogesterone acetate (MPA) (30 mg b.i.d.) or acetazolamide (ACET) 
(250 mg b.i.d.) followed by a two week treatment with a combination of both drugs (MPA-
ACET) was investigated. The effect on daytime and nocturnal ventilatory and blood gas 
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parameters was studied m 17 severe stable COPD patients (FEV! 34 ± 4% pred ) in a 
double blind controlled fashion 
Single treatment with ACET and MPA decreased mean daytime PaC02 by 0 4 and 0 7 kPa, 
respectively Mean daytime Pa02 improved with both drugs with 0 6 and 1 0 kPa, 
respectively 
As shown in table 2 , MPA-ACET treatment significantly decreased mean daytime PaC02 
by 1 2 kPa V E increased with combined therapy by 1 9 L mm1 
The hypercapnic and hypoxic ventilatory responses were significantly increased by MPA-
ACET therapy with 2 1 L mm1 kPa1 and 0 27 L mm1 %1, respectively The Po ι response to 
hypoxia increased dunng the combination therapy by 0 02 kPa % 1 Nocturnal PETCO2 
significantly decreased with MPA-ACET treatment by 1 4 kPa MPA-ACET significantly 
increased mean nocturnal Sa02 values by 4 7% 
We concluded that under hypercapnic conditions combined treatment with ACET and MPA 
induced a larger improvement m day- and night-time PaC02 than separate treatments with 
either drug The increase in ventilation that is necessary to 'blow-off an excess of C02, in 
the hypercapnic situation, is very limited (approx 2 L mm1 in our patients) The combination 
of MPA-ACET treatment in stable hypercapnic COPD patients is concluded to be effective 
in a short penod Whether chronic administration of both drugs alone or in a combined 
fashion may alter life expectancy and/or quality needs further to be investigated 
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human studies (chapter) single treatment (7.6.) combined treatment (7.7.) 
VE (L min1) 
PaC02(KPa) 
Pa02(KPa) 
nod. PETC02(KPa) 
% time noct. Sa02 
<90% (%) 
SHcvR(Lmin"1.kPa"1) 
SHVR(L.min-1 .%•'') 
SHPo^kPa/yo) 
placebo 
9.6 ±0.7 
6.3 ±0.1 
8.7 ± 0.3 
5.6 ±0.3 
34.9 ±10.7 
4 3 ± 0 6 
-0.2 ± 0.05 
-0.007 ± 0.002 
ACET 
100±06 
5.6 ± 0.2 
10.0 ±0.4 
4.7 ±0.3 
16.3 ±7.5 
4 1±06 
-0.4 ± 0.1 
-0.02 ± 0.003 
MPA 
10.8 ±0.8 
5.7 ± 0.2 
93±04 
4.6 ±0.1 
23 8±J15 
52±09 
-0.3 ±0.1 
-0 01 ±0 003 
placebo 
9.3 ±0.5 
6.5 ±0.2 
7.9 ±0.3 
5.5 ±0.2 
61.8 ±9.9 
3.7 ±0.6 
-0.13 ±0.03 
-0.01 ± 0.00 
MPA+ACET 
11.2±0.8 
5.3 ±0.2 
9.6 ± 0.4 
4.1 ±0.2 
42.0 ±10.4 
5.8 ±1.0 
-0.40 ± 0 07 
-0.03 ± 0.01 
Table 2. Selection of data obtained from the human studies described in chapter 7.5 and 7 6 which 
changed significantly (Data denoted in italics did not significantly change from placebo) Data are 
presented as mean ± sem. 
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8.1. inleiding 
Sommige patiënten met een ernstige chronisch obstructieve longziekte (COPD) zijn 
hypercapnisch en hypoxisch ten gevolge van het falen van de adempomp Hypoxie beïnvloedt 
de levensverwachting Uit een aantal studies is gebleken, dat de langdurige toediening van 
zuurstof (LTOT) een gunstig effect heeft op de overleving Echter, LTOT is een dure en 
omslachtige behandeling Daarnaast kan het gebruik van LTOT leiden tot een toename van 
de hypercapnie ten gevolge van een toegenomen ongelijkmatigheid van de ventilatie-perfusie 
verhoudingen en onderdrukking van de hypoxische ademstimulus 
Hypercapnie heeft zelf, onafhankelijk van andere factoren, een slechte invloed op de 
levensverwachting Daarom zouden andere en additionele therapeutische opties naast LTOT, 
zoals het gebruik van ademhalmgsstimulatia, overwogen kunnen worden 
In dit proefschnft zijn de korte termijn effecten van de respiratoire stimulantia acetazolamide 
(ACET), een carbo anhydrase remmer, en medroxyprogesteron acetaat (MPA), een 
synthetisch progestageen, op de ventilatie beschreven Deze behandelingen zijn als 
monotherapie en in combinatie gegeven 
In hoofdstuk 1 worden de fysiologie en de metingen van de regeling van de ademhaling 
beschreven De meest gebruikte respiratoire stimulantia die gebruikt worden bij COPD 
patiënten en de doelstellingen van dit proefschnft worden toegelicht 
Het proefschnft kan verdeeld worden in twee delen 
Deel I bevat dne dierexpenmentele studies De specifieke vragen in deze studies waren 
• Welke dosis van ACET geeft geen vermindenng van het C02- transport door remming 
van het carbo anhydrase in de erythrocyte 
• Wat is het effect van lage dosis ACET op de regeling van de ademhaling tijdens 
normoxie'? (Hoofdstuk 2) 
• Wat is het effect van lage dosis ACET op de regeling van de ademhaling tijdens 
hypoxie? (Hoofdstuk 3) 
• Is er een interactie (supra-additief effect) tussen de ventilatoire effecten van ACET en 
MPA? (Hoofdstuk 4) 
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Deel II bevat 2 humane studies Op basis van de gegevens uit de dierexpenmentele studies 
waren de vragen 
• Wat zijn de effecten van 2 dd 250 mg ACET (equivalent aan de optimale dosis welke 
gevonden is als beschreven is in hoofdstuk 2) en 2 dd 30 mg MPA als monotherapie 
bij hypercapmsche COPD patiënten? (Hoofdstuk 5) 
• Geeft gecombineerde behandeling van ACET en MPA (dus het stimuleren van de 
ventilatie via chemoreceptoren en via de hypothalame weg) een betere stimulatie van 
de ademhaling en zo een betere behandeling van hypoventilatie bij ernstige COPD 
patiënten dan enkelvoudige behandeling? (Hoofdstuk 6) 
8.2. Herleiden van diermodel naar humane studies 
Acetazolamide (ACET) 
• Een lage dosis ACET (4 mg kg1) veroorzaakt geen gradient tussen de artenële en eind 
expiratoire PC02, wat inhoudt dat er geen complete remming is van het carbo 
anhydrase in de erythrocyt De acute effecten van ACET op de ventilatie werden met 
deze dosis uitgevoerd Extrapolatie naar doses die gebruikt worden bij mensen is 
hachelijk, (1) omdat we de "chronische effecten" van ACET (2 weken durende therapie) 
hebben bestudeerd Uit de literatuur is bekend dat, de effecten van acute vs chronische 
toediening van ACET op de ventilatie verschillend zijn (2) We weten met precies hoe 
de verdeling van het geneesmiddel over de intra- en extra cellulaire compartimenten in 
het menselijk lichaam is, vergeleken met de situatie in dier modellen Er zijn in de 
literatuur geen dosis-respons studies beschikbaar die een antwoord kunnen geven op 
de vraag welke dosis in de chronische situatie gebruikt moet worden Gebaseerd op 
extrapolatie van de dosis die werd gevonden in de dierexpenmentele studies en de 
gegevens uit de literatuur werd In de humane studies in dit proefschrift een dosis van 
2 dd 250 mg ACET gebruikt (3) De dierexpenmentele studies werden uitgevoerd op 
genarcotiseerde proefdieren Narcose veroorzaakt altijd enige ventilatoire depressie, 
en zal dus mogelijk ook de ventilatoire responsen op de medicatie beïnvloeden 
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De bevindingen van de dierexpenmentele studies en de humane studies lijken niet 
eenduidig. In de dierexperimentele studies werd een daling gevonden van de 
gevoeligheden van de perifere en centrale chemoreflex lussen en van het apneupunt 
na toediening van ACET. Daarentegen werd er in de humane studies een stijgende 
tendens werd gezien van de gevoeligheden van de ventilatoire C02 responscurve. 
Extrapolatie naar de ventilatie, gebruik makend van de vergelijking V'i=S(PaC02-B) zou 
betekenen dat de ventilatie in katten alleen toeneemt tijdens relatieve hypocapnie na 
toediening van het geneesmiddel in tegenstelling tot de humane studies. Echter, alle 
studies werden verricht in de "open systeem" situatie. Gaan we uit van de "gesloten 
systeem" situatie, dan verschuift het "werkpunf langs de metabole hyperbool (het 
geregelde systeem). Als we hiervan uitgaan is het netto-effect van acute en chronische 
toediening van 4 mg.kg"1 ACET, zowel i.v. als oraal hetzelfde: een daling in PaC02en 
een kleine toename van de ventilatie. 
Een potentiële verklaring voor de daling in helling van de ventilatoire C02 respons curve 
in de dierexperimentele studies na toediening van ACET is mogelijk een anaesthesie 
effect. 
In de dierexperimentele studies wordt bediscussieerd dat het effect van 4 mg kg1 
ACET wordt veroorzaakt door een direct effect op de perifere chemoreceptoren 
("glomuslichaampjes"), vanwege een inhiberend effect van het geneesmiddel op de 
C02 gevoeligheid van de perifere chemoreflex lus. Het effect van het geneesmiddel op 
de C02 gevoeligheid van de centrale chemoreflex lus is mogelijk niet het gevolg van 
een direct effect op het centraal zenuwstelsel, maar een effect op de cerebrale vaten 
resulterend in een veranderde relatie tussen de PaC02 en de PC02 van het 
hersenweefsel hetgeen bediscussieerd wordt in hoofdstuk 2. 
Het effect van 4 mg.kg1 ACET op de ventilatie onder hypoxische condities in de kat 
werd bevestigd, zijnde een groter effect op de perifere chemoreceptoren, die verhoogd 
actief zijn in hypoxie. 
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Uitgaande van de bevindingen uit de dierexperimentele studies werden twee humane 
studies met ACET uitgevoerd in COPD patiënten met een totale respiratoire 
insufficientie Een dosis van 2 dd 250 mg ACET gaf een verbetering van de bloedgas 
waarden tot normocapnie en bijna normoxie Dit is een belangnjke bevinding, omdat uit 
de literatuur blijkt dat hypercapme een onafhankelijke factor is voor de 
levensverwachting van COPD patiënten Of chronische toediening van ACET (>2 
weken behandeling) zal leiden tot een betere levensverwachting zal moeten worden 
bevestigd in toekomstige studies 
Medroxyprogesteron acetaat (MPA) 
Zowel bij katten als bij COPD patiënten leidt de toediening van MPA tot een verlaging 
in PaC02 en tot een toename van de ventilatie 
Het mechanisme waardoor MPA zijn effect heeft op de ventilatie is mogelijk via twee 
wegen enerzijds heeft het vrouwelijke geslachtshormoon zijn werking via de penfere 
chemoreceptoren Anderzijds is een centrale weg beschikbaar, omdat uit literatuur 
gegevens blijkt dat de hypothalamus progesteronreceptoren bevat, die de ademhaling 
stimuleren Of MPA of de metabolieten van MPA verantwoordelijk zijn voor de 
gevonden effecten moet nog verder worden bestudeerd Uitgaande van de gevonden 
effecten uit dit proefschnft kan geen onderscheid gemaakt worden tussen een effect 
via de chemische of humorale ademstimulus 
MPA +ACET 
Gecombineerde behandeling met (4 pg kg1) MPA en (4 mg kg1) ACET in katten 
veroorzaakt een grotere netto-ventilatoire stimulatie dan separate toediening van beide 
geneesmiddelen Dit werd ook gevonden bij hypercapmsche COPD patiënten, 
gecombineerde behandeling met MPA en ACET gaf een grotere verbetenng van de 
artenele bloedgas waarden overdag en 's nachts als ook van de chemische "drive" 
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(gevoeligheid van de centrale en perifere chemoreceptoren) in vergelijking met separate 
toediening van beide geneesmiddelen. Gecombineerde behandeling met beide 
geneesmiddelen gaf een verbetering van de nachtelijke SaC^ in vergelijk met 
enkelvoudige behandeling met beide geneesmiddelen. 
• Of MPA het effect van ACET op de centrale C02 gevoeligheid moduleert kon noch 
ontkend noch bevestigd worden Echter, uitgaande van de bevindingen welke in dit 
proefschrift beschreven zijn, gecombineerd met de gegevens uit de literatuur is het 
aannemelijk dat de beide geneesmiddelen onafhankelijk van elkaar werken op de 
regeling van de ademhaling. 
8.3. De effecten van lage dosis acetazolamide op de ventilatoire C02 respons 
curve in de genarcotiseerde kat. 
In hoofdstuk 2 wordt een dosis respons studie van intraveneuze toediening van ACET 
beschreven, in intacte katten en in katten met gedenerveerde perifere chemoreceptoren, op 
de gradiënt tussen de arteriële en eind expiratoire PC02 
Een lage dosering ACET (4 mg.kg"1) veroorzaakt een toename van de ventilatie van ongeveer 
65% bij een PaC02 van 4.5 kPa, zonder een gradiënt te veroorzaken tussen de arteriële en 
eind-expiratoire PC02 (P(a-ET)C02. Dit betekent dat het C02 transport 
nog niet belemmerd wordt door het compleet remmen van het erytrocyten carbo anhydrase. 
In de eerste twee uur na toediening veroorzaakte deze lage dosering een lichte daling van het 
standaard bicarbonaat van respectievelijk 1.8 en 1.7 mmol.L1 in respectievelijk intacte katten 
(n=7) (p<0.05) en in katten met gedenerveerde perifere chemoreceptoren (n=7) (p>0.05). 
Doseringen hoger dan 4 mg. kg"1 veroorzaakten een significante P(a-FT)C02 gradiënt. 
Aansluitend werd in zowel katten met gedenerveerde perifere chemoreceptoren als in intacte 
katten het effect van 4 mg.kg1 ACET op de centrale en zowel centrale als perifere 
chemoreflexen bestudeerd. 
In dit hoofdstuk, als ook in de andere dierexperimentele studies, werd de "dynamische emd-
expiratoire koolzuur sturings" techniek (DEF-techniek) gebruikt. Deze techniek maakt het 
mogelijk een scheiding aan te brengen tussen de bijdrage van de perifere en centrale 
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chemoreflex lussen door ventilatoire responsen te analyseren die verkregen worden door 
stapvormige verandenngen aan te brengen in de PBTC02 
Zoals te zien is in tabel 1 veroorzaakte een dosis van 4 mg kg 1 ACET in katten met 
gedenerveerde penfere chemoreceptoren een stijging in ventilatie van 64% bij een 
normocapmsche waarde voor katten met een PaC02 = 4 5 kPa Er werd een daling van de C02 
gevoeligheid van de centrale chemoreflex (Sc) waargenomen van 0 56 L mm1 kPa1 Het 
intercept op de PaC02-as, ofwel het apneupunt (B) daalde met 0 3 kPa In intacte katten 
veroorzaakte dezelfde dosis een stijging in ventilatie van 66% bij een PaC02=4 5 kPa De C0 2 
gevoeligheid van de penfere chemoreflex (Sp) daalde met 0 09 L mm1 kPa1 Sc en Β namen 
af met respectievelijk 0 68 L mm1 kPa1 en 1 0 kPa De laatste bevindingen waren met 
significant verschillend van de bevindingen die werden gevonden m katten met gedenerveerde 
penfere chemoreceptoren Het effect van ACET op de penfere chemoreflex wordt waarschijnlijk 
veroorzaakt door een direct effect op de penfere chemoreceptoren ("glomuslichaampjes") De 
effecten van het geneesmiddel op Sc en Β worden waarschijnlijk met veroorzaakt door een 
direct effect op het centrale zenuwstelsel, omdat uit literatuur gegevens blijkt dat ACET de 
bloed-liquor bamere vnjwel met passeert Er wordt bediscussieerd dat het effect van ACET op 
Sc en Β mogelijk berust op een effect van dit geneesmiddel op de cerebrale bloedvaten Dit 
resulteert m een veranderde relatie tussen de artenele PC02 en de PC02 van het 
hersenweefsel 
8.4. Het effect van lage dosis acetazolamide op de ventilatoire C 0 2 respons 
tijdens hypoxie in de genarcotiseerde kat 
Hypoxie komt vaak voor bij patiënten met een ernstig COPD Dit was de reden om het acute 
effect van ACET (4 mg kg1) op de ventilatoire C02 respons te bestuderen m zeven 
genarcotiseerde katten onder hypoxische omstandigheden (hoofdstuk 3) Na toediening van 
een bolus van 4 mg kg1 ACET werd een transiente initiële daling van de ventilatie 
waargenomen Dit wijst op een direct effect op de penfere chemoreflex, omdat tijdens hypoxie 
de bijdrage van de penfere chemoreflex aan de ventilatie groter is dan tijdens normoxie In de 
daaropvolgende stabiele situatie veroorzaakte ACET een stijging van de ventilatie Zoals te 
zien is in tabel 1 verlaagde het geneesmiddel de C02 gevoeligheid van de penfere (Sp) en 
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centrale (Sc) chemoreflex met respectievelijk 0.11 en 0.34 L.min'1.kPa"1. Het apneupunt Β (x-
intercept van de ventilatoire C02 respons curve) daalde met 1.93 kPa (alle parameters p<0.01). 
Het netto resultaat was een stimulatie van de ventilatie met ongeveer 50% bij een P E T C 0 2 van 
4 kPa. Er wordt bediscussieerd dat de effecten van ACET tijdens de stabiele situatie 
waarschijnlijk worden veroorzaakt door een direct effect op de perifere chemoreceptoren als 
ook een indirect centraal effect op de regeling van de cerebrale blood doorstroming, zoals werd 
beschreven in hoofdstuk 2. 
8.5. Medroxyprogesteron acetaat in combinatie met acetazolamide stimuleert 
de ademhaling in katten. 
In hoofdstuk 4 worden de effecten beschreven op de ventilatoire C0 2 respons curve van MPA, 
en MPA gevolgd door ACET, in acht genarcotiseerde vrouwtjeskatten, die 1 maand voor de 
studie een ovariohysterectomie hadden ondergaan. De katten werden voorbehandeld met 17 
ß-estradiol (E2) om een stabiele en vergelijkbare endocriene status in alle proefdieren te 
verkrijgen. Een standaard dosis van 10 Mg.kg"1 E2 is nodig om een facilitatie van de ventilatie 
door progesteron bij proefdieren te bewerkstelligen. 
In tabel 1 zijn de effecten van 0.4 Mg.kg1 MPA en van 4 mg.kg1 ACET op de ventilatoire 
parameters samengevat. Na infusie van 0.4 Mg.kg'1 MPA nam de ventilatie toe met 35% bij een 
PaC02 van 4.5 kPa. Sp daalde met 0.09 L.min"1.kPa-1 en Sc daalde met 0.13 Lmin"1.kPa"1. Er 
werd een linksverschuiving van het apneupunt waargenomen (een daling in Β met 0 38 kPa 
(alle parameters ρ < 0.01)). 
Daaropvolgende toediening van ACET liet een toename in de ventilatie zien van in totaal 116% 
(MPA+ACET) bij een PaC02 van 4.5 kPa. Sp en Sc daalden verder met respectievelijk 0.04 en 
0.18 L.min"1.kPa"1. Het apneupunt daalde verder met 1.18 kPa (alle parameters ρ < 0.01). De 
bovenstaande resultaten impliceren een meer dan verdubbeling van de ventilatie bij een 
PaC02 van 4.5 kPa, vergeleken met monotherapie met een van beide geneesmiddelen Omdat 
met beide behandelingen de ventilatoire C0 2 gevoeligheid daalde wordt geconcludeerd, dat 
het stimulerende effect op de ventilatie veroorzaakt wordt door een daling van het apneupunt. 
Gecombineerde toediening van MPA en ACET leidt tot een grotere toename in ventilatie dan 
separate behandeling met een van beide geneesmiddelen. 
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dierexpenmentele studies 
(Hoofdstuk) 
nonmoxie (8 3 ) 
intacte katten 
katten met gedenerveerde 
perifere chemoreceptoren 
hypoxie (8 4 ) 
normoxie (8 5 ) 
controle 
ACET 
controle 
ACET 
controle 
ACET 
controle 
MPA 
MPA+ACET 
VE*» 
(% control) 
100 
166 
100 
164 
100 
150**1 
100 
135 
216 
Sp 
(L mm 1 kPa 
0 28 ± 0 18 
0 1 9 ± 0 1 2 
-
-
0 22 ± 0 08 
0 11 ± 0 03 
0 22 ± 0 09 
0 13 ± 0 06 
0 09 ± 0 06 
Samenvatting en 
Sc 
') (L mm 1 kPa1) 
1 52 ± 0 55 
0 84 ± 0 21 
1 52 ± 0 42 
0 96 ± 0 32 
0 74 ± 0 32 
0 40 ± 0 10 
1 01 ± 0 38 
0 88 ± 0 32 
0 70 ± 0 49 
conclusies 
Β 
(kPa) 
4 0 ± 0 5 
3 0 ± 0 6 
4 5 ± 0 5 
4 2 ± 0 7 
2 88 ± 0 97 
0 95 ± 0 92 
4 02 ± 0 27 
3 64 ± 0 42 
2 46 ± 1 50 
Tabel 1 Samenvatting van de data verkregen door analyse van de ventilatoire C02 responsen uit de 
velschillende dierexpenmentele studies *' PaC02=4 5 (kPa), **' PaC02=4 0 (kPa) Sp, Sc and Β data 
zijn weergegeven als gemiddelde ± SD 
8.6. Vergelijking van acetazolamide met medroxyprogesteron als respiratoire 
stimulantia in hypercapnische COPD patiënten. 
In hoofdstuk 5 werden de effecten van ACET (2 dd 250 mg) en MPA (2 dd 30 mg) bestudeerd 
bij 12 hypercapnische patiënten met een stabiel COPD (gemiddelde FEV, 33 ± 4% voorspeld 
(gemiddelde ± sem)) op de dag en nachtelijke bloedgas waarden en het effect op de 
hypercapnische en hypoxische ventilatoire en Po ι responsen in een "cross-over" studie 
Zoals te zien is in tabel 2 daalde de PaC02 overdag met 0 7 kPa tijdens ACET behandeling 
en met 0 6 kPa tijdens MPA behandeling De PaOj overdag verbeterde met ACET met 1 3 kPa, 
terwijl geen significante verandering werd waargenomen met MPA De gemiddelde nachtelijke 
PETCO2 daalde met beide behandelingen met 0 9 kPa gedurende ACET en met 1 0 kPa 
gedurende MPA behandeling Het percentage van de tijd dat de nachtelijke Sa02 lager was 
dan 90%, werd met ACET gereduceerd met 50%, (alle parameters p<0 05) Gedurende MPA 
behandeling werden er geen verandenngen gevonden op de nachtelijke parameters 
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De toename m rust ventilatie was alleen significant met MPA behandeling 1 2 L mm1 De 
helling van de hypercapnische ventilatore respons veranderde met gedurende ACET en MPA 
behandeling De hypoxische ventilatoire respons nam toe met 0 2 L mm1 % 1 tijdens ACET 
behandeling en met 0 1 L mm1 %1 gedurende MPA behandeling De hypoxische Po ι respons 
verbeterde met ACET behandeling met 0 013 kPa %1, (alle parameters p<0 05) 
Deze studie laat zien dat ACET en MPA beiden een gunstig effect hebben op de bloedgas 
waarden overdag en 's nachts m hypercapnische COPD patiënten Echter, de effecten van 
ACET zijn evidenter, vooral op de nachtelijke saturatie 
8.7. Gecombineerde behandeling van acetazolamide met medroxyprogesteron 
bij COPD patiënten. 
In hoofdstuk 6 wordt de laatste humane studie beschreven, waann de effecten zijn bestudeerd 
van een twee weken durende behandeling met MPA (2 dd 30 mg) of ACET (2 dd 250 mg) 
gevolgd door een twee weken durende behandeling met beide geneesmiddelen (MPA-ACET) 
In 17 stabiele patiënten met een ernstig COPD (FEV., 34 ± 4% voorspeld) zijn de effecten 
bestudeerd op de ventilatoire en bloedgas parameters overdag en 's nachts m een 
dubbelblinde gecontroleerde vorm 
Met de enkelvoudige behandeling van ACET, MPA daalde de gemiddelde PaC02 overdag 
significant met respectievelijk 0 4 en 0 7 kPa De gemiddelde Pa02 overdag verbeterde met 
beide geneesmiddelen met respectievelijk 0 6 en 1 0 kPa 
Zoals te zien is m tabel 2 daalde de gemiddelde PaC02 overdag met gecombineerde therapie 
met MPA-ACET met 1 2 kPa De ventilatie nam toe met gecombineerde behandeling met 1 9 
L mm1 
De hypercapnische en hypoxische ventilatoire responsen namen significant toe met MPA-
ACET behandeling met respectievelijk 2 1 L mm1 kPa1 en met 0 27 L mm1 %1 
De Po ι respons op hypoxie nam toe bij de combinatie therapie met 0 02 kPa % 1 De 
nachtelijke PETC02 daalde significant MPA-ACET behandeling met 1 4 kPa Met de combinatie 
van MPA-ACET nam de gemiddelde nachtelijke Sa02 toe met 4 7% 
We concludeerden dat, onder hypercapnische condities, gecombineerde behandeling met 
ACET en MPA een grotere verbetenng m bloedgas waarden overdag en 's nachts gaf dan 
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separate behandeling met een van beide geneesmiddelen. De toename in ventilatie die nodig 
is om een overschot in C02 af te blazen gedurende hypercapnie is gering (ongeveer 2 L.min1 
bij onze patiënten). De combinatie van MPA-ACET behandeling in hypercapnische COPD 
patiënten lijkt effectief te zijn gedurende een korte periode. Of chronische behandeling met 
beide geneesmiddelen als monotherapie of in combinatie met elkaar de levensverwachting 
en/of kwaliteit verbetert moet verder bestudeerd worden. 
behandeling 
humane studies (Hoofdstuk) enkelvoudige (8.6.) gecombineerd (8.7.) 
V E (L min1) 
PaC02 (KPa) 
Pa02(KPa) 
nacht PETC02 (KPa) 
% tijd nacht. SaO2<90% (%) 
SHCVR (L mm·1 kPa1) 
SHVR (L.min1 %1) 
SHPoi(kPa.%1) 
placebo 
9.6 ±0.7 
6.3 ±0.1 
8.7 ±0.3 
5.6 ±0.3 
34.9 ±10.7 
4 3 ± 0 6 
-0.2 ± 0.05 
-0.007 ± 0.002 
ACET 
f 0 0 ± 0 6 
5.6 ± 0.2 
10.0 ±0.4 
4.7 ±0.3 
16.3 ±7.5 
41±06 
-0.4 ±0.1 
-0.02 ± 0.003 
MPA 
10.8 ±0.8 
5.7 ±0.2 
93±04 
46 ±0.1 
23S±115 
52±09 
-0.3 ± 0 1 
-0 01 ±0 003 
placebo 
9.3 ±0.5 
6.5 ± 0.2 
7.9 ±0.3 
5.5 ± 0.2 
61.8 ±9.9 
3.7 ±0.6 
-0.13 ±0.03 
-0.01 ± 0.00 
MPA+ACET 
11.2 ±0.8 
5.3 ±0.2 
9.6 ±0.4 
4.1 ±0.2 
42.0 ±10.4 
5.8 ±1.0 
-0.40 ± 0.07 
-0.03 ± 0.01 
Tabel 2. Selectie van data uit de humane studies, beschreven in hoofdstuk 8.6 en 8.7 welke significant 
veranderden. (Data genoteerd in schumschnn veranderden niet significant t.o.v. placebo). Data zijn 
weergegeven als gemiddelde ± sem. 
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Stellingen 
behorende bij het proefschrift 
Ventilatory stimulation bij acetazolamide and medroxyprogesterone acetate 
A study in cats and COPD patients 
M. Wagenaar 
15 januari 2003 
1 Intraveneuze toediening van 4 mg.kg"1 acetazolamide geeft nog geen significante 
gradient tussen de arteriele en de end-tidal PC02. (dit proefschrift) 
2 Het gebruik van bepaalde respiratoire stimulantia bij COPD patiënten met een 
hypercapnie kan op korte termijn leiden tot een normocapnie (dit proefschrift) 
3 Of het gebruik van carbo-anhydrase remmers en progesteron een positief effect 
heeft op de lange termijn overleving bij COPD patiënten zal nog bewezen moeten 
worden 
4 Het is maar goed dat er patiënten zijn Anders zou dit proefschrift niet tot stand zijn 
gekomen. 
5 Het uitvoeren van een hypoxische ventilatoire respons manoeuvre kan ook bij 
gezonde proefpersonen een adembenemende inspanning zijn (eigen waarneming) 
6 Een slecht-nieuwsgesprek kan zeer aangrijpend zijn voor de patient èn voor de arts. 
7 Het routinematig maken van een röntgenopname van de thorax in expiratiestand bij 
het vermoeden van een pneumothorax is naast het maken van een 
inspiratieopname met gerechtvaardigd. (Schramel F, Wagenaar M, Sutedja T, Golding R. 
Postmus P. Ned Tijdschr Geneeskd, 1995) 
8 Bij patiënten met een achalasie van de oesophagus is periodiek endoscopisch 
onderzoek geïndiceerd 
9 Indien binnen een politieke partij het dualisme ontaardt in voortdurende 
incompatibilité d'humeur, is deze ten dode opgeschreven. 
10 Een medisch wetenschappelijk proefschrift is vaak onleesbaar voor de met-medisch 
wetenschapper. 



